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Abstract
Technologies such as micro-expression arrays and high-throughput sequenc-
ing assays have accelerated research of genetic transcription in biological cells.
Furthermore, many links between the gene expression levels and the pheno-
typic characteristics of cells have been discovered. Our current understanding
of transcriptomics as an intermediate regulatory layer between genomics and
proteomics raises hope that we will soon be able to decipher many more cel-
lular mechanisms through the exploration of gene transcription.
However, although large amounts of expression data are measured, only lim-
ited information can be extracted. One general problem is the large set of
considered genomic features. Expression levels are often analyzed individually
because of limited computational resources and unknown statistical dependen-
cies among the features. This leads to multiple testing issues or can lead to
overfitting models, commonly referred to as the “curse of dimensionality.”
Another problem can arise from ignorance of measurement uncertainty. In
particular, approaches that consider statistical significance can suffer from
underestimating uncertainty for weakly expressed genes and consequently re-
quire subjective manual measures to produce consistent results (e.g., domain-
specific gene filters).
In this thesis, we lay out a theoretical foundation for a Bayesian interpretation
of gene expression data based on subtle assumptions. Expression measure-
ments are related to latent information (e.g., the transcriptome composition),
which we formulate as a probability distribution that represents the uncer-
tainty over the composition of the original sample.
Instead of analyzing univariate gene expression levels, we use the multivari-
ate transcriptome composition space. To realize computational feasibility,
we develop a scalable dimensional reduction that aims to produce the best
approximation that can be used with the computational resources available.
To enable the deconvolution of gene expression, we describe subtissue specific
probability distributions of expression profiles. We demonstrate the suitabil-
ity of our approach with two deconvolution applications: first, we infer the
composition of immune cells, and second we reconstruct tumor-specific ex-
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Chapter 1
Introduction
The central subjects of this thesis are biological cells and the expression of their genomic
features. The expression of genomic features or genes is represented by the abundance of
Ribonucleic acid (RNA) molecules, which are associated with a specified group, within
given cells. A group of RNA, which constitutes a genomic feature, is described through
the locations on the deoxyribonucleic acid (DNA) molecules specific to the biological cells
under consideration. A location is characterized by the annotation of a reference DNA
sequence and it is assumed to be the template for RNA synthesis within the cell. Some
groups within a specified nucleotide chain interval of the DNA are referred to as genes,
corresponding RNA molecules as gene transcripts. The sum of all of the RNA within
a cell is called the transcriptome. The transcriptome is the only direct product of the
DNA. Consequently, the abundance or presence of different transcripts is directly related
to the cell’s activity, and is a reliable indicator for the cell type and its characteristics.
The transcriptome is commonly assessed via RNA sequencing (RNA-seq) experiments,
which read the nucleotide sequence of transcripts in the sample. Modern high through-
put sequencing technologies allow parallel sequencing of millions of DNA/RNA-fragments
[27]. The results can then be used to quantify the expression of constituent transcripts
and to estimate the transcriptome composition of the sequenced cells. While single-cell
sequencing techniques are available, they have limited accuracy for expression estimates
[52]. In addition, many measurements use tissue samples, which contain a bulk of poten-
tially different cells. In bulk sequencing, the transcriptome composition for specific cell
types can be occluded by other cells in the same sample. However, some applications
(e.g., to characterize tumor cells [65]) seek the expression of one specific cell type. Addi-
tionally, the composition of cell types within a sample can have clinical relevance, such
as regarding the immune cell infiltration of tumors [22, 40] or other tissues.
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1.1 State of the Art and Motivation
Many of the current software tools for analyzing differential expression of genomic fea-
tures in RNA-seq data (e.g., DESeq2 [73], voom [68], and EdgeR [98]) focus on univari-
ate expression changes. Only very limited knowledge of the multivariate genome-wide
expression pattern (also referred to as expression profile) is used to improve predictions.
Attempts have been made to incorporate some unused information, (e.g., pairwise co-
expression) by combining sets of genes to meta-genes [134] and examining them with
established statistics. Further inferences are complicated by very high dimensionality,
multiple testing problems, noise, and processing batch effects in the data. Hence, it is
difficult to deduce reliable multivariate models and to incorporate non-linear dependen-
cies.
Expression variance is primarily assessed across a set of samples but sample-specific
measurement uncertainty is often ignored. Few approaches attempt to model the vari-
ability caused by measurement inaccuracy and make assumptions that imply complex
models that are infeasible for many applications [135].
Recent results in medicine have revealed the importance of tissue composition, espe-
cially regarding immune cell infiltration of tumor tissue [45, 30]. Therefore, we aspire to
quantify the constituent subtissues. To reconstruct such information (e.g., from gene ex-
pression profiles from bulk RNA-seq) specialized computational algorithms are required.
However, to carry out such deconvolution with univariate genomic markers, each of the
constituent subtissues must express specific genes exclusively [120, 124]. One such de-
convolution method is implemented in the MCP-counter [13]. However, especially in
mixtures with tumor cells, the required exclusivity is not guaranteed. Furthermore, the
expression of individual genes can fluctuate among cells of the same type. In addition,
calculating the deconvolution from too few features can diminish the accuracy of the
result.
The expression levels for a single sample in an instance of time and for n genomic
features can be given through a vector x ∈ Rn. If the dynamics are not considered, then
any type of tissue or cell can be fully characterized through a probability density function
(PDF) f : Rn → R+. The PDF prescribes an expression pattern distribution (EPD) or,
in other words, the probability of the observed expression pattern x of the given tissue
or cell type to be within any chosen set S ⊂ Rn.
Numerous deconvolution approaches incorporate a single average expression pattern
per subtissue and employ least square regression techniques [74, 122, 4, 106, 96, 43, 44,
138, 124, 94]. These procedures consequently either assume an approximate univariate
normal PDF for subtissue-specific raw expression patterns or no variability at all. How-
ever, the EPD is not well-approximated with a normal distribution in linear space [10].
In addition, the heterogeneity in specific subtissues and biological variability (e.g. due
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to the cell-cycle or cell differentiation) cannot be described fully without consideration
of the coupling or co-expression of genes in the characterizing PDF [92]. Furthermore,
some of the heuristics that have been employed imply profound assumptions. Notably,
the simplex recovery approach in CAM [124] requires near “noise-free” expression mea-
surements, expression patterns that are linearly independent between different subtissue
types (orthogonality assumption), and samples that are heterogeneous in mixture but
homogenous in phenotype. These assumptions pose a rather coarse simplification and
leave room for improvements. For example, Abbas et al. [3] have shown that expres-
sion patterns have strong correlations between cell types. This directly contradicts the
orthogonality assumption and can make the regression approach ambiguous.
Other deconvolution tools include CIBERSORT [83], CIBERSORTx [84], MySort [23],
and ImmuCC [24]. These approaches use support vector regression but also characterize
each subtissue through a single average expression pattern that cannot encode subtissue-
specific variability.
Bayesian approaches have also been used for the deconvolution task. Prominent ex-
amples are DSection [38] and BayICE [112]. Both also assume univariate, normally
distributed subtissue-specific raw expression patterns and normally distributed measure-
ment errors in linear space. To investigate the resulting posterior distribution for latent
variables, such as sample composition and subtissue-specific expression levels, these tools
employ a computationally costly hybrid Gibbs and Metropolis-Hastings sampler. These
samplers do not use gradient information of the posterior distribution and require many
samples to produce reasonable estimates.
The Bayesian expression deconvolution approach TEMT [71] requires RNA-seq results
from a purified non-tumor sample in addition to the mixed sample and deconvolutes tu-
mor from non-tumor expression. It considers the RNA-seq experiment as a random
experiment and it takes detailed sequencing information into account, such as read posi-
tions within the transcripts and the read length distribution. This results in a parameter
rich model that is investigated with a computationally cheap maximum a posteriori esti-
mation. However, this model is hard to generalize to allow for more than two subtissues
without losing feasibility. Furthermore, the maximum a posteriori estimate reveals rather
limited information about the predicted values. The estimate is sensitive to the parame-
ter transformation and hence prone to bias [82]. Additionally, TEMT hinges on the size
and quality of the pure samples and it implicitly assumes a fixed expression profile for
the non-tumor subtissue. The allowed deviation from these expression patterns must be
attributed to the modeled measurement uncertainty of the RNA-seq experiment.
Other approaches adopt a linear regression scheme to recover tissue specific expres-
sion patterns from mixed samples [108, 84, 123, 124]. These approaches require multiple
samples that contain the tissue of interest in different fractions. The number of required
samples ranges from two in UNDO [123] to four to five fold more then cell or subtissue
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types in CIBERSORTx [84]. If patient specific tumor expressions are to be deconvoluted,
then all of the samples must derive from the same patient. However, all of these methods
assume a fixed expression pattern per tissue type in all samples. This is a strong assump-
tion that we aspire to renounce. UNDO requires known exclusively expressed marker
genes for each tissue type. The other methods need the actual cell-type composition per
sample as an input. Additionally, running multiple RNA-seq experiments per patient is
not always cost efficient.
Figure 1.1: A convolution of two images.
These methods either estimate the sample composition if the subtissue-specific gene
expression patterns are exactly known or reconstruct one expression pattern per subtissue
from multiple samples if the compositions are known. However, we argue that sample
composition and the expression pattern per subtissue can be recovered from only a single
sample if the subtissues are characterized by adequate EPDs. Considering the image in
figure 1.1, most viewers can easily recognize that two images of two different animals were
superposed onto one another. Furthermore, both animals can be identified effortlessly
as a dog and a cat, and we can recognize their respective breed. We can also attribute
distinctive features of the coat patterns to the animals. This is possible with only a single
image and is due to the viewers experience of what cats and dogs can look like. Another
example for such effortless human deconvolution is the famous “cocktail-party effect”
[25] that allows a human listener to understand a single voice from a sample of multiple
superimposed speech samples. We argue that our task of gene expression deconvolution is
very much alike recognizing and characterizing animals from overlaid images or isolating
single voices from a crowd, and it just as well should be possible with only a single sample
and good EPDs of the subtissues. However, just as deconvoluting the image one pixel at
a time without looking at neighboring pixels or isolating a voice from a single sound is
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almost impossible, we believe that reconstructing subtissue-specific expression patterns
without considering the co-expression between genes will never be ideal.
CDSeq [57] and BayesPrism [26] both pursue a single sample deconvolution, and they
respectively model subtissue-specific EPDs with a Dirichlet and a multinomial distribu-
tion, which do not allow modeling co-expression or gene specific variance. Characterizing
a heterogeneous class of subtissues, such as tumor cells, is not possible with such a pa-
rameterization. Additionally, CDSeq employs a costly Gibbs sampling for inference and
BayesPrism outputs only a maximum a posteriori estimation.
In summary, a lot of work has focused on the selection of individual marker genes
instead of considering EPDs that can incorporate statistical dependencies between all
genes. Other efforts are directed to ease or improve computation of established models,
which that come with complicating superposed constrains, such as positivity. Moreover,
few authors consider the effects of the parametrization on the results or fully discuss
implicit assumptions of their models. The diversity of the reviewed approaches shows that
a generally applicable and agreed upon interpretation is yet to be found. Moreover, the
few single sample deconvolution methods that are available lack a detailed formulation
of the subtissue-specific EPDs, which is essential in particular to reconstruct the gene
expressions of tumors.
We argue that resolving these issues (i.e., using multivariate EPDs per subtissue)
should improve the computational deconvolution and may supply a toolset for RNA-seq
data interpretation that enhances downstream applications, such as the detection of dif-
ferential expression in subtissues or survival analysis based on tumor-specific expression.
We further argue that incorporating only very agreeable assumptions and ensuring broad
applicability may facilitate the development of a generally agreeable interpretation of
bulk RNA-seq data.
1.2 Scope of this Thesis
We will ascertain how and to what degree of certainty latent information (e.g., tissue
composition and cell type-specific expression patterns) can be deduced from bulk RNA-
seq experiments. We carefully select assumptions to develop a theoretical basis upon
which we build concrete applications that demonstrate the utility of the results.
We choose assumptions that can easily be agreed upon while being sufficiently instruc-
tive to imply a comprehensible and computationally feasible inference scheme. By making
fewer assumptions, we have to consider more possibilities for the connection between data
and the latent information. With mathematical reasoning and inferential statistics, we
are able to develop computational algorithms that can infer the desired latent informa-
tion considering thousands of genomic features. The computational model includes a
probabilistic description of tissue-specific expression pattern distributions (EPDs). This
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features the description of multivariate co-expression of genomic features and allows a
broad variability to account for subtissue heterogeneity, phenotypic diversity, and differ-
ent sample treatments.
Our approach enables (i) the inference of subtissue-specific EPDs from cohorts of
heterogeneous samples, (ii) the deconvolution of single samples when tissue-specific EPDs
are known, and (iii) the reconstruction of tissue-specific expression patterns, while always
propagating uncertainty information about the results. We implemented the model with a
computational efficient Automatic Differentiation Variational Inference (ADVI) scheme.
To demonstrate the utility of the inference scheme, we implemented two applications,
applied them to the respective example data, and then evaluated the quality of the
result.
First, we infer the immune cell composition for individual samples of colorectal and
breast cancer. Therefore, cell type-specific EPDs are constructed with publicly avail-
able expression data of purified human immune cells. The distributions are incorporated
into an Bayesian network to deduce the probability distributions of the tissue composi-
tions. We apply the scheme with ADVI on datasets provided through a Sage Bionetworks
DREAM challenge and compare the result with the attached true cell-type composition.
This first application will be referred to as inference of cell composition.
Second, we reconstruct tumor-specific expression patterns from heterogeneous tissue
samples the prostate carcinoma without prior knowledge of tumor- or non-tumor specific
EPDs. We incorporated pathological estimates of the sample compositions and used the
complete dataset to define a probability distribution of all latent variables, including
parameters of the tissue-specific EPDs. This application is unprecedented because tumor
expression deconvolution has not yet been performed before with single samples per
patient let alone without prior knowledge about the tumor-specific EPD. To evaluate the
deconvolution, we use the reconstructed tumor-specific expression values in a biomarker
discovery study. The result of the study using deconvoluted and original expression
values is then compared in an independent testing cohort. This second application will
be referred to as deconvolution of expression patterns.
This thesis has seven major parts. After introducing some general concepts in chapter 2
and 3, we discuss the employed probability distributions in chapter 4. These probability
distributions will serve as building blocks in the inference scheme. However, before we
put them together, we simplify the data and distributions by a dimensional reduction in
chapter 5. Chapter 6 gives an overview of the data acquisition, treatment, and charac-
terization. In chapter 7, the final inference schemes are presented. Finally, chapter 8 will




To avoid ambiguity, we define the following notations to hold throughout the thesis (unless
stated otherwise).
x .. vector x ∈ Rn with the elements x = (x1, . . . , xn).
1 .. one vector 1 = (1, . . . , 1)T ∈ Rn. The dimension n depends on the context.
Note that |1|2 =
√
n.
·̄ .. sum. For example x̄ = ∑︁ni=1 xi
⟨·, ·⟩ .. scalar product. For example, ⟨x,y⟩ = ∑︁i xiyi or ⟨f, h⟩ = ∫︁ f(x) · h(x)dx for
scalar valued functions.
| · |p .. p norm. For example, |x|p = p
√︂∑︁n
i=1 |xi|p or f : A → R then |f |p =
p
√︂∫︁
A |f(x)|pdp. Note that |x|1 = x̄ if all elements of x are positive.
| · | .. the absolute value for scalars, the number of elements for sets and the deter-
minant for matrices.
B(·, ·) .. beta function.
R .. set of real numbers.
R+ .. set of positive real numbers without 0.
Ra×b .. set of real valued matrices with a ∈ N rows and b ∈ N columns.
Ok .. Stiefel manifold, or the set of matrices that consist out of k orthonormal row
vectors Ok ⊂ Rk×n where n depends on the context.
(·)i,j .. matrix index. For example, (A)i,j = aij.
A .. a real valued matrix in Rn×m. Also written as (aij) = A, where aij = (A)i,j,
and is often used as the collection of columns annotated with the lower case
counterpart ai.
I .. the identity matrix I =
⎛⎜⎜⎜⎝
1 · · · 0
... . . . ...
0 · · · 1
⎞⎟⎟⎟⎠.
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·T .. matrix transpose. For example, (AT )i,j = (A)j,i.





· · · dfm
dx1... . . . ...
dfm
dx1




diag(·) .. diagonal matrix to the given vector. For example, for x ∈ Rn it is
diag(x) =
⎛⎜⎜⎜⎝
x1 · · · 0
... . . . ...
0 · · · xn
⎞⎟⎟⎟⎠
.
P[·] .. probability. For example, for a random variable x ∈ Ω the probability for x
to be in a set S ⊂ Ω is P[x ∈ S].
f(·) .. the probability density function. For example, for a random variable x ∈ Ω
and a subset s ∈ Ω it holds that
∫︁
S f(x)dx = P[x ∈ S].
E[·] .. expected value. For example, for a random variable x ∈ Ω: E[x] =
∫︁
Ω yf(y)dy.
V[·] .. variance. For example, for a random variable x ∈ Ω: V[x] =
∫︁
Ω(y − E[x])2dy.
· ◦ · .. function composition. For example, g ◦ f(x) = g(f(x)).
Cat(p) .. is the categorical distribution with probability pi for category i.
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2.2 Abbreviations
To aid the reader, we list the abbreviations, and also reference the section and page on
which they are introduced.
BCR .. biochemical recurrence (5.1.4 p. 47).
CI .. confidence interval (4.1 p. 16).
DoD .. death of disease (5.1.4 p. 47).
DR .. dimensional reduction (5 p. 43).
ELBO .. evidence lower bound (3.5.2 p. 14).
EPD .. expression pattern distribution (1.1 p. 2).
FDR .. false discovery rate (5.1.1 p. 45).
FFPE .. formalin-fixed paraffin-embedded (6.3 p. 82).
ID .. internal distortion (5.1.2 p. 46).
PCA .. principal component analysis (3.2 p. 11).
PDF .. probability density function (1.1 p. 2).
SDE .. systematic differential expression (5.1.1 p. 45).
TCC .. tumor cell content (4.2 p. 18).
TPM .. transcripts per kilobase million (6.2 p. 79).
VST .. variance stabilizing transformation (4.3.4 p. 32).
Chapter 3
Methods
3.1 The Convolution Assumption
The transcriptome composition within a tissue sample with a vector p ∈ ∆n−1 where
pi ∈ [0, 1] amounts to the fraction of transcript of group i. The elements of ∆n−1 =
{x ∈ Rn|xi ≥ 0, |x|1 = 1} are positive partitions of one and they code the expression of
n distinct genomic features. We will infer p from RNA-seq experiments in section 4.3.
Our primary assumption is that the given tissue sample can be subdivided into samples
of specific cell types and that the total p can be decomposed into a weighted sum of
tissue specific transcriptome compositions xt ∈ ∆n−1 such that the weights correlate
linearly to the respective transcriptomic mass of the subtissue. This assumption has
been experimentally justified [108].
Assumption 1 (Transcriptome Composition). A biological tissue sample has a tran-
scriptome composition p ∈ ∆n−1 that can be decomposed into a linear combination of
subtissue specific transcriptome compositions (xt)t∈T = X with
p = Xα (3.1)
where α ∈ ∆T −1, T = {1, . . . , T} is the set of subtissues that the sample consists of and
αt amounts to the share of transcripts coming from the subtissue t.
Please note that the subtissue expression patterns xt can be sample-specific. Many
other models assume a constant subtissue specific average expression pattern across all
samples and they only add a sample specific error term to the right-hand side of equation
(3.1) [9]. In contrast, we deliberately refrain from such a simplification. Instead, we
assume subtissue-specific EPDs to infer the sample composition. Furthermore, in contrast
to other approaches, we do not assume p to be the measured raw or normalized expression
values but rather we define a probability distribution of p that depends on the observed
values.
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3.2 Principal Component Analysis
Throughout this study we will often resort to Principal Component Analysis (PCA),
which is a means for a partial singular value composition of the estimated covariance
matrix for some data. By providing eigenvector wk and an eigenvalue for large eigenvalues
first, PCA often serves as a dimensional reduction (DR) technique by projecting the data
to the fist few eigenvectors, which are also referred to as principal components. This
calculation is efficient because it does not need to estimate the full covariance matrix but
instead computes the components through the iterative optimization
wk = arg max
∥w∥2=1
wTXTk Xkw
where X0 is the dataset and Xk+1 = Xk(I − wkwTk ). The data is commonly centered
with X ′ = X − b, such that the row-wise mean is 0, before calculating the wk. The
result is a whitening matrix W with the columns λ−1k wk, where λk is the kth eigenvalue.
The transformed data Y = (X − b)W has the mean 0, a covariance matrix I and
a possible lower dimensionality depending on how many columns of W were calculated.
This transformation is also referred to as whitening transformation or multivariate stan-
dardization.
If the dataset X is approximately normally distributed, then the DR comes with the
additional benefit of probabilistic independence of its components [53].
3.3 Expression Patterns
When we refer to an expression pattern or expression profile in the course of this work,
we mean a feature expression vector p ∈ Rn that can change another expression vector
x ∈ Rn in a prescribed way µ : Rn × Rn × I → Rn, where I ⊂ R is the intensity of
the expression pattern impact. In the simplest case of an additive effect we could write
µ(x,p, η) = x + ηp. We usually model expressions as partitions of one x,p ∈ ∆n−1 and
in that case, an additive expression pattern is prescribed with I = [0, 1] and
µ(x,p, η) = (1 − η)x + ηp. (3.2)
However, additive expression patterns are not always a good abstraction of an effect
on the transcriptome. Natural effects on the transcriptome often manifest in a relative
instead of an additive change in gene expression. Additionally, some effects come with
an inhibition of expression in certain genes. This inhibition cannot be modeled directly
with (3.2) or involves negative expression values that cannot be interpreted directly as
mass or amount of the respective transcripts.
In section 4.3.3, we introduce the τ−1 ◦ log transformation on ∆n−1. This diffeomor-
phism will allow us to model the relative expression x with exp ◦τ◦ : On−1 → ∆n−1 in
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logarithmic space, where On−1 = {z ∈ Rn|∑︁ni=1 zi = 0}. In this context, we prescribe
the effect of an expression pattern p ∈ On−1 with
µ(x,p, η) = exp ◦τ
[︂
τ−1 ◦ log(x) + ηp
]︂
= x · diag ◦ exp(ηp) · λ(x,p, ν)
(3.3)
where λ(x,p, ν) = |x·diag ◦ exp(ηp)|−11 is a scalar normalizing factor. This multiplicative
expression pattern can model relative and inhibitory expressional effects.
Note that the results of a PCA wk after the τ−1◦log transformation can be interpreted
as multiplicative expression patterns. This will also be discussed in section 5.5. In other
words the variance of a given expression pattern within a group of samples is equivalent to
certain pairwise correlation or co-expression between the participating genomic features.
Due to this duality, some studies resort to the language of graph theory and model co-
expression as edges between feature expressions that act as nodes (s. section 4.7.4).
However, to argue about the theory of this work, it is easier to write about expression
patterns instead of fuzzy co-expression clusters of a network, which are the equivalent
concept in graph theory language.
Also note that an expression vector x can be decomposed into some finite combinations
of expression patterns. These are either linear combinations of additive effects or, in the
case of multiplicative expression patterns (3.3), they are a linear combination before the
application of the diffeomorphism exp ◦τ . We will make use of this fact for dimensional
reduction in chapter 5.
3.4 Bayes’ Theorem
Our core method is to exploit the probabilistic coupling of hidden quantities with ob-
served measurements (e.g., the RNA-seq result) to infer knowledge about what cannot
be measured directly (e.g., the cell type composition). The tool that is used to describe
this knowledge is the conditional PDF f(a|b), which defines a probability for the hidden
value a to be within any selected set when we already know the measured value b. This
conditional PDF is linked to the coupled PDF of a and b through
f(a|b) · f(b) = f(a, b) = f(b|a) · f(a).
f(a) and f(b) are the marginal PDF, which describes the probability for one value to be
in a selected set if the other is unknown. The symmetry of the equation in a and b gives
rise to Bayes’ theorem for PDFs:
f(a|b) = f(b|a) · f(a)
f(b)
Given that the data b is fixed for a given analysis, the constant f(b) is completely deter-
mined by the fact that the integral of the PDF f(a|b) over all possible values of a has to
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be 1. What is left to elaborate is f(a), the PDF for values a if we have made no measure-
ment, and f(b|a) the PDF for observations b if we know the hidden value a. Note that
f(b|a) = f(b) if a and b are independent, and that the theorem can be applied repeatedly
if more variables are involved. Formulating these terms for many dependent variables
will be covered in chapter 4 and the repeated application of Bayes’ theorem will allow us
to combine these intermediate dependencies into the complete model in chapter 7.
3.5 Inference Algorithms
To apply the results of Bayes’ theorem on large datasets, we have to resort to compu-
tation inference algorithms. A Bayesian model implies a PDF over a space of unknown
parameters f : Ω → R+. Each line in a Bayesian model description has the form a ∼ D(b)
and induces a PDF f(a|b), which is the parametrized probability density function of the
distribution D. If a is known, then Bayes’ theorem can be applied to attain f(b|a) (as we
do in multiple sections of this work). The line-wise implied distributions are independent
and hence aggregated through multiplication. This allows to evaluate f for the complete
parameter set. However, the form of f usually does not allow to conclude interesting
properties, such as the expected value or variance algebraically. In addition, because the




ϑ · f(ϑ)dϑ or V[θ] = E[(θ − E[θ])2] =
∫︂
Ω
(ϑ − E[θ])2 · f(ϑ)dϑ
is difficult. The next sections describe computational efficient techniques to make these
estimates as efficiently as possible. Such techniques can be aided with an algebraically
simple form of log ◦f and knowledge of the derivative δ log ◦f
δθ
, which will be prepared
throughout chapter 4 and 5.
3.5.1 Inference Through Sampling









through an adequately large sample S that follows the distribution f .
The well-known Markov chain Monte Carlo (MCMC) method simulates a Markov
chain that is designed to produce states that follow the distribution of f . The state








for any symmetric proposal probability density g : Ω × Ω → R+ \ {0}; that is, g(θ2|θ1) =
g(θ1|θ2). Note that adaptations for asymmetric g are possible but not discussed here and
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removing the 0 from the domain of g ensures ergodicity of the Markov chain. There must
be an implementation to draw a proposal sample θ2 ∼ G(θ1) with the PDF g(θ2|θ1). This
proposal is then accepted as the next state with the probability min [f(θ2)/f(θ1), 1]. The
rate at which new proposals are accepted as the next state of the Markov chain is called
the acceptance rate.
A basic choice for g is a multivariate normal distribution, with a covariance matrix
that can be adjusted for the scale and dependency between different parameters of the
model. These adjustments are essential for the efficiency of the process. While large
distances between θ1 and θ2 are desirable to quickly explore Ω, f(θ2)f(θ1) tends to become
very small and therefore reduces the acceptance rate, which slows down the sampling.
The key to efficiency is that g should have a high enough probability for distant states
to be likely to be accepted.
A popular option for g is a simulation of θ1 as a particle in an energy potential log ◦f
with a randomly chosen momentum φ ∼ N (0, I). This simulation can use the potential
derivative δ log ◦f
δθ
and the well-established leapfrog integrator to efficiently approximate
Hamilton dynamics. Because we know from the Boltzmann distribution that particles
in an energy potential log ◦f attain the distribution f , this simulation is very likely to
propose a state with high acceptance probability, even if it is far away.
To propose states that are as far away as possible, the No-Turn-Sampler [48] (NUTS)
implementation continues the Hamilton dynamics simulation until the particle trajectory
begins to loop towards its origin θ1 and proposes the distant state.
Nevertheless, sampling methods for estimations of (3.4) remain computationally de-
manding. Many evaluations of log ◦f and its derivative are required to produce a sample
and many samples are needed to represent a high-dimensional f .
3.5.2 Variational Inference
A cheap alternative to the sampling-based inference is introduced through the Automatic
Differentiation Variational Inference (ADVI) [67]. If f(θ|X) is the posterior distribution
of the parameters θ and the data X, then ADVI computes the parameters ϕ ∈ Φ for a
normal distribution of the parameters f(θ|ϕ) such that
ϕ = arg min
ϕ∗∈Φ
KL[f(θ|ϕ∗)∥f(θ|X)] (3.6)
where KL is the Kullback-Leibler-Divergenz. To allow for the distribution of parame-
ters to be modeled with a normal distribution, transformations of the parameter space
are devised that ensure approximately normality for parameters of the respective dis-
tribution. For example, the Dirichlet distributed composition vector α of our model is
transformed with a so-called stick-breaking transformation η : ∆n → Rn. A new stick-
breaking transformation is introduced by τ−1 ◦ log in this thesis and is implemented in
section 8.1.3.1.
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To solve (3.6), ADVI uses the Evidence Lower Bound (ELBO):
ELBO(ϕ∗) = Ef(θ|ϕ∗)[log ◦f(θ, X)] − Ef(θ|ϕ∗)[log ◦f(θ,ϕ∗)] (3.7)
which is known to differ from the KL (3.6) by a constant that depends only on the data
[133]. Hence, ELBO can be optimized instead of KL:
ϕ = arg min
ϕ∗∈Φ
ELBO(ϕ∗).
Note that (3.7) has the form of (3.4), so it can be approximated with a sampling
based inference algorithm. However, instead of running the inference until the sample
distribution converges against the posterior, only a single sample from f(θ|ϕ∗) is drawn
to allow a very rough estimate of (3.7) using the NUTS sampling algorithm.
However, for an efficient optimization, we require the gradient ∇ϕ∗ELBO(ϕ∗) or
an estimate thereof. To retain the form (3.4) for the gradient, the random variable
is reparametrized. Before applying the derivative, we know that if x ∼ N (0, 1), then
xb + a ∼ N (a, b). We use this transformation for ϑ ∼ N (0, I) such that ζ(ϑ,ϕ∗) = θ,
where θ is distributed according to f(θ|ϕ∗). This allows us to do a substitution in (3.7)
ELBO(ϕ∗) = Eϑ[log ◦f(ζ(ϑ,ϕ∗), X) · λ] − Eϑ[log ◦f(ζ(ϑ,ϕ∗),ϕ∗) · λ]
where ϑ ∼ N (0, I) and λ = | det ◦Dζ−1|. Now the gradient has the form
∇ϕ∗ELBO(ϕ∗) = Eϑ[∇ϕ∗F (ϑ,ϕ∗, X)]
for some F , which may be reviewed in [67]. Hence ELBO(ϕ∗) and ∇ϕ∗ELBO(ϕ∗) can be
estimated with samples from N (0, I).
The estimated gradient is used for a gradient descent optimization of (3.6). To stabilize
the very rough estimate of ∇ϕ∗ELBO(ϕ∗), a sliding average with previous results is
calculated using a stochastic optimizer. The optimizer combines the NUTS sample to
refine the estimate similarly of (3.4) and puts weights on the samples to reduce the
impact of earlier samples as they come from an early and less accurate approximation
of the distribution. In this thesis, we resort to the adagrad [36] or adam [62] optimizer,
depending on the application.
Note that many parameterizations of f(θ|ϕ) are possible and that common implemen-
tations feature a univariate and a multivariate normal distribution. We choose the more
popular univariate parametrization because we can assume approximate independence of
most parameters after our DR and it is computationally much cheaper.
Assumption 2 (ADVI Inference). For inference by univariate ADVI, we can adopt
its assumptions, particularly Gaussianity of the parameter posterior after the specific
transformation and statistical independence of the transformed parameters.
Chapter 4
Prior and Conditional Probabilities
Assumption 1 states that different types of cells contribute to the measured RNA ex-
pression vector in different shares. The goal of this work is to recover the constituent
expression vectors xt of the contributing cell types T and the cell type composition α
from one single sample. The problem of recovering the exact expression vector of each
cell type is under-defined and (even though we will add knowledge and make additional
assumptions) a unique solution will stay elusive, at the very least due to the measurement
uncertainty. Therefore, only a probabilistic solution can be pursued.
In this chapter, we find mathematical formulations for relevant knowledge in the form
of probability density functions (PDF). These distributions will serve as building blocks
of our inference scheme.
4.1 Mixture Coefficients
As formulated in assumption 1, we assume that the measured RNA expression is a linear
combination of vectors X weighted with the mixture coefficients α ∈ ∆n−1 ⊂ Rn. In
section 4.2, we will establish a prior for the deconvolution of expression patterns when
pathological estimates for the composition are known. In this section, we want to establish
a prior distribution of α for the inference of cell composition and based on prior knowledge
about the composition of the specific tissue type.
Although we could simply assume a very uninformative prior, experience shows that
the frequency of occurrence for most cell types within specific tissues only varies within
a rather narrow range. This prior information can be vital or the interpretation of
ambiguous samples and it can improve inference accuracy across all cell types.
The knowledge about tissue compositions is typically given by confidence intervals
(CIs) on the percentage for any given cell type. It may seem natural to formulate the
uncertainty of percentage for each cell type with a normal distribution. The combined
prior probability density for a given mixture α would then be given by the normalized
product of all of thee involved normal distributions, which is positive on the whole Rn.
16
4.1. MIXTURE COEFFICIENTS 17
However, this violates the important assumption α ∈ ∆n−1 or the fact that all of the
entries must be positive and add to one. The Dirichlet distribution is a very natural
way to formulate a distribution on ∆n−1. Hence, to employ the prior knowledge, we may
translate CIs to coefficients of the Dirichlet distribution.
Please note, that we lack knowledge about the tissue compositions for the example
application in this thesis. Hence, the inference presented in this section is not applied.
Assumption 3 (Mixture Prior). Prior to the RNA-seq data, we assume the mixing
coefficients to be Dirichlet distributed α ∼ Dirichlet(a), where a, listed in A.4, depends
on the tissue source; if the source is unknown, then a = 1.
To find a parameter set a for a given tissue type, we use the connection of the
parameter to the implied CIs. If α ∼ Dirichlet(a), then αi ∼ B(ai, |a|1 − ai) is the
marginal distribution. Consequently, the probability for ai to be within an interval [li, ui]
is given through the regularized incomplete beta function Iz:
pi := P(αi ∈ [li, ui]) = Iui(ai, |a|1 − ai) − Ili(ai, |a|1 − ai)
We could optimize the equation in a such that its value becomes close to 0.95, which is
the probability of lying within the 95 percent CI. However, in the spirit of the Bayesian
inference that is pursued here, we will instead employ a more descriptive approach. We
assume an uncertainty to the given CIs by allowing the percentage of the marginal dis-
tribution to be slightly off. To deduce a reasonable uncertainty, we assume a minimal
number of observations:
Assumption 4 (Mixture Data Uncertainty). The given CIs of the cell type compositions
for a specific tissue are supported by at least 100 independent observations.
While the true number of observations may be much higher, we would rather under-
estimate the certainty of the given data than introduce a bias towards inaccurate values
through the resulting prior. If the 95 % CI is supported by 100 observations, then 95
were within the CI. The test of whether an observation is within the CI is a Bernoulli ex-
periment, so the PDF to observe M samples within the CI is given through the binomial
distribution with
M ∼ Binomial(100, pi)
and M was observed to be 95. Assumption 4 together with assumption 8 yields a Bayesian
network, from which we can deduce that
pi ∼ Beta(95 + 1, 5 + 1).
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The resulting standard deviation of pi is ≈ 2.32% and the complete Bayesian model for
a mixture coefficient of T ∈ N different cell types is
m ∼ Poisson(λ) λ ∈ N (4.1)
a′ ∼ Multinomial(1,m) 1 ∈ RT (4.2)
a = a′ + 1 (4.3)
pi = Iui(ai, |a|1 − ai) − Ili(ai, |a|1 − ai) i ∈ {1, . . . , T} (4.4)
Mi ∼ Binomial(100, pi) i ∈ {1, . . . , T} (4.5)
where Mi = 95 is given through the data. λ is the expected resolution of the composition.
Choosing a large λ induces a more informative prior Dirichlet(a). The correct value of
m depends on how fine grained the given CIs are. To give a good estimate for its prior
expected value λ = E(m), we could use the fractions given by the lower bound of the
CIs and choose λ such that the smallest fraction can be represented by a partition of




The construed model implies a distribution of a and we could achieve the most ac-
curate results in subsequent analysis by incorporating this model. However, this adds
to the computational cost and complicates the analysis. Therefore, it may be beneficial
to calculate an estimated â ≈ E(a) using any computational inference method and then
use this fixed value in the larger model. This flattens the hierarchical model for the prior
distribution of the mixture to a mere Dirichlet distribution with coefficient â.
However, we could not include this inference into our example application in section
8.1. Because we have no reliable data for the decomposition of the specific tissue samples
(breast and colorectal cancer) we resort to α = 1 instead. Consequently, this section is
a purely theoretical result. For the deconvolution of expression patterns in section 8.2,
we use another prior for the coefficient that is induced by the pathological estimate and
is explained in section 4.2.
4.2 Distribution of Tumor Cell Content
One application evolves around the composition into only two subtissues: tumor and
tumor-free tissue. In that case, we model the tissue composition α = (α, 1 − α), where
α is the Tumor Cell Content (TCC).
This section investigates prior information about α based on the estimate given by
the pathologist and prior to any transcript quantification. On one hand the pathological
estimates are en essential information for our example application to learn tumor spe-
cific EPDs based on mixed samples. On the other hand the estimates are known to lack
accuracy [109] and assuming a wrong TCC too rigorously can throw of our inference.
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Hence, it is necessary to include the pathological estimates with some degree of uncer-
tainty and allow the model to deviate if the molecular data contradicts the pathology.
We use a probabilistic model of how the pathological estimates are conducted and apply
Bayes theorem to retrieve the latent information of the true TCC based on the estimated.
Specifically, we approximate the process of determining the TCC of a given sample by
discretizing the sample into chunks.
Assumption 5 (Tumor Quantification). The quantification of tumor tissue by the pathol-
ogist in a given sample is a repeated Bernoulli experiment of classifying small chunks of
the sample as either part of a tumor or tumor-free tissue.
n denotes the number of chunks that the sample is split into and pα denotes the chance
to be categorized as a tumor chunk. Hence, the distribution of the measured tumor cell
content α̂ is






pnα̂α (1 − pα)n(1−α̂).
(4.6)
The expected value is pα and its variance
V(α̂) = pα(1 − pα)
n
. (4.7)
The probability of pα depends on the true ratio of tumor cells α ∈ [0, 1]. The probability
pt for a chunk that consists of tumor cells to be categorized as a tumor cell chunk and
the probability pf for a tumor free chunk to be categorized as a tumor free chunk:
pα(α, pt, pf ) = αpt + (1 − α)(1 − pf )
= α(pt + pf − 1) + 1 − pf
(4.8)
The likelihood of the true TCC α for an estimated tumor content α̂ is hence given by
fc(α|α̂, pt, pf , n) = fd(α̂|α, pt, pf , n)λ(α̂, pt, pf , n)
with the normalizing factor
λ(α̂, pt, pf , n) =
(︃∫︂ 1
α=0
f(α̂|α, pt, pf , n)
)︃−1
=





−1 + pf + pt
−





−1 + pf + pt
⎞⎠−1 .
Where Bz(a, b) =
∫︁ z
0 u
a−1(1 − u)b−1du is the well-known incomplete beta function. This
leaves us with a prior distribution of α that incorporates the pathological estimate α̂,
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which we can use in the later inference. If we assume the pathologist to be perfect, that
is pt = pf = 1, than the prior becomes a beta distribution of α.
Note that Bayes’ theorem and (4.6) give rise to the beta distribution
pα ∼ B(nα̂ + 1, n(1 − α̂) + 1). (4.9)
The classification accuracy pt, pf and the resolution of the quantification process n
remain to bee determined. Because we only have single estimates per sample, we cannot
infer these parameters without involving additional data. Hence, for the scope of this
work, we only assume rough estimates. To determine a reasonable parameter n per
cohort, we compare the fractions {α̂j, j ∈ samples} reported to the possible fractions i/n.
To quantify how well a chosen n can reproduce this set of fractions, we quantify how
close the set {n · α̂j, j ∈ samples} is to a set of integers. We accept the smallest n such
that given tolerance t is not overstepped:







|n · α̂j − i|
)︃
(4.10)
Assumption 6 (Tumor Quantification Accuracy). We assume pt and pf , which are the
probabilities to correctly identify a chunk of tumor and tumor-free tissue, respectively, to
be 95%. The parameter n is the smallest that can closely reproduce the reported tumor
fractions and is given by n = n(0.1), as in equation (4.10).
4.2.1 Optimal Tumor Cell Content Drawing
While the formulation of a prior distribution was the main goal of our investigation, it
also reveals a way to correct given TCC estimates α̂ under consideration of sub-optimal
categorization accuracies pt, pf and resolution n. We could use the maximum likelihood
estimate of the inferred probability density function:
α̃ := arg max
α∈[0,1]
fc(α|α̂) = arg max
α∈[0,1]
fd(α̂|α)
or we use a more stable estimate by minimize the error squares of the resulting distribution
fd(α̂|α) towards the estimated α̂:
α̃ := arg min
α∈[0,1]
E([α̂− α]2).
There is a closed form for a unique solution discussed in A.1.
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4.3 Transcriptome Composition Distribution
In this section, we will discuss how we can infer a probabilistic description of the transcript
composition p ∈ ∆n−1 from an RNA-seq experiment. We will also construct a specific log-
transformation of the transcript composition vector, which will allow us to sample freely
without breaking any constraints in the later inference process. It will also let us make
the assumption of normality thanks to a more normal distribution of the transformed
values.
4.3.1 Sequencing Read Distribution
A basic assumption about reads in RNA-seq is that their abundance is closely linked to
the abundance of the genomic features that they originate from. From a statistical point
of view, each of the genomic features makes up a category that a read can be assigned to
and all of the distributions of these categories can be formulated in terms of a categorical
distribution. This leads to:
Assumption 7 (Bernoulli). In a single RNA-seq experiment, the probability of one read
to originate from a genomic feature k is given by






and the vector p = (p1, ..., pn) completely describes the distribution. p is fixed for a given
sample and it does not change during the experiment.
Without loss of generality, we can assume that ∑︁ni=1 pi = 1 because we can always
construct a category k = n+ 1 of remaining reads with pk = 1 −
∑︁n
i=1 pi.
The vector p represents the discovery rates of the constituent transcripts. This quan-
tity is closely linked to the true transcriptome composition of the sequenced sample,
and will be referred to as such. To be more precise, p is not only influenced by the
transcriptome composition but is also influenced by technical variables, such as sample
treatment, RNA-read length distribution, and uncertainty of the assignment of reads to
a transcript. However, their effect is implicitly modeled through the cell and tissue type
EPD, as discussed in section 4.4.
Note that other studies came to very similar conclusions to model read count distri-
butions but they are not well accepted because biological variance cannot be modeled
well with this parametrization [89].
Other approaches, such as TEMT [71], take RNA-seq experiment specific read length
distributions and the read positions within a transcript into account to correct p with
the effective transcript length and read distribution bias to bring it closer to the true
transcriptome composition. However, this complicates the model, relies on data that
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is not always available and does not entirely relieve the corrected p from the effects of
varying read lengths, read distribution, or other technical variables. To retain feasibil-
ity, modeling p as the transcript discovery rate instead and accounting for all technical
variability in the cell or tissue type EPDs is more applicable for our scenario.
Notably, TEMT considers the RNA-srgeq experiment with a specific order of reads,
although this order is usually irrelevant. However, generalizing for unordered reads would
only introduce constant factors of binomial coefficients, which would have no impact on
the result of the tool.
Assumption 7 directly implies a multinomial distribution of the RNA-seq experiment
result x = (x1, ..., xn) with
∑︁n
i=1 xi = m. x is the distribution of m reads onto n genomic
features or categories.
f(x|p) = n!




Given the data x, we can apply Bayes theorem to infer a distribution of the transcript
mixture p and model its uncertainty.
f(p|x) = f(x|p)f(p)
f(x) . (4.11)
Because p is bound to the n-simplex, a proper prior f(p) can be expressed with the






By letting α = 1, the function becomes uniform on the finite simplex, which we assume
for the prior of p.
Assumption 8 (Uniformity). Prior to any observation, we assume p ∼ Dirichlet(1) for
the transcriptome composition p.
One could argue that this prior is not as uninformative as possible because it is only
uniform for the chosen parameterization. However, the assumption seems reasonable: it
gives all possible mixtures an equal possibility and it simplifies the resulting posterior
distribution.
Moreover, not all of the possible mixtures of transcripts have equal probability. For
example, we already know that the expression of genes in one sample across the genome
is quite heterogeneous and a completely equal mixture of all transcripts seems less likely
than any combination involving very-highly and very-lowly expressed features. However,
these priors depend on the type of the sequenced sample and the set of genomic features
considered in the experiment. Making these distinctions is not within the scope of this
work.
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Considering (4.11), we further note that f(x) and all other factors in the equation












and hence p ∼ Dirichlet(x + 1).





= xk + 1
n+ |x|1
. (4.12)
This illuminates the common practice to use y = log(x + 1) to analyze gene expression
data in log scale. The quantity |x|1 is equivalent to the sequencing depth and therefore
log(n + |x|1) is similar among the samples. While that was mostly done to avoid the
undefined log(0) for features that received no reads, this result puts it on the sound bases
of two reasonable assumptions.
This result, however, does not support adding 1 to the counts after normalizing for
sequencing depth. This in fact leads to heavy distortions and poor results.
It is also revealed through (4.12) that a feature that has no reads in x has an expected
probability of 1
n+|x|1 , which will be discovered with the next read.
While log(E[p]) yields interesting results, because the distribution of p is quite skewed,
the mean E is sometimes far apart from the population median and can therefore be
misleading. It might be beneficial to calculate E[log(p)] because the distribution of log(p)
tends to be more symmetric. This can be done either by sampling p ∼ Dirichlet(x + 1)
and calculating the sample mean after applying the logarithm or it can be calculated
analytically with







where ψ is the digamma function ψ(x) = d
dx
ln(Γ(x)). As demonstrated in the appendix
A.2 and depicted in figure A.1, ψ(k) and log(k) behave very similarly. Because the
difference is bound by 1
k
for k ≥ 1 and the relative variance of small values in p is high,
log(E[p]) proves to be a useful approximation of E[log(p)]. This is further supported
by the similarity of the results in figure 4.1. However, the log(E[p]) might lack some
variance, as indicated in figure 4.2a. It is as yet unclear if this variance is beneficial to
further inferences.
One drawback of E[log(p)] is that there is no p′ ∈ ∆n−1, such that log(p′) = E[log(p)].
This point will be further discussed in section 4.3.3.
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(a) PCA of E[log(p)]. (b) PCA of log(E[p]).
(c) PCA of 20, 000 samples p ∼ Dirichlet(x+
1).
(d) PCA of τ−1 ◦ log(E[p]) as in equation
(4.16).
Figure 4.1: PCAs of different transformations of the count data in logarithmic scale, as
discussed in section 4.3.1 and 4.3.3. The axis are labeled with the component number
and the share of variance that it explains. This can be compared to PCAs of normalized
expression data in figure A.2. The cohorts are described in section A.5.3.
If a single estimate of the transcriptome composition for a given RNA-seq result is
required, then we choose log(E[p]) or E[log(p)] over the maximum likelihood estimate
(MLE) of the induced transcriptome composition distribution. While the expected value
minimizes the expected error squares to the true transcriptome composition in the re-






which resamples the common CPM normalization to a factor of one million. Note that
log(MLE[p]) ̸= MLE[log(p)] and we are not aware of a closed form of MLE[log(p)].
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E[log(p)] log(E[p]) p ~ Dir(x + 1) tau log(E[p])
(a) Comparing PCA component variances of
the four datasets shown in figure 4.1. The
curves for E[log(p)] and τ ◦ log(E[p]) are al-
most identical.








(b) Variance of the first 1000 components
of an incremental PCA on the logarithm of
20000 samples of p ∼ Dirichlet(x + 1),x ∼
Uniform(X). The vertical line marks the
number of actual samples in X and an eigen-
value gap between the larger variances among
actual samples and the smaller variances at-
tributed to measurement uncertainty.
Figure 4.2: Variances of PCA components or sorted eigenvalues of the covariance matrix
for the data.
Furthermore, the analytic variance of p is given by
V[pi] =




i=1[xi + 1] = n+ |x|1. The relative quantity
V[pi]
E[pi]
= (xΣ − xi − 1) · c
for some constant c shows that it is negative proportional to the count xi and is therefore
is larger in features of small counts.
4.3.1.1 Empirical Plausibility Investigation
Figure 4.2b already reveals a gap between the observed variance and the technical vari-
ance estimated by the Dirichlet distribution, which agrees with the assumption that the
uncertainty of the RNA-seq result is smaller than the biological variance that, which we
aim to assess.
To further demonstrate the plausibility of the inferred theoretical transcriptome com-
position distribution, we compare it to a set of technical sequencing replicates from
ELSA. The ELSA cohort consists of one sample that was prepared and sequenced three
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times with the Illumina HiSeq Sequencer. The variance within the cohort is a combi-
nation of variance due to the library preparation and the the sequencing process. The
total number of reads that were assigned to a genomic feature in the three samples of the
ELSA cohort is approximately 3.6 · 106, 3.8 · 106 and 4.2 · 106.
Our theoretical result describes the variance due to the sequencing process, which
we assume to be multinomially distributed. Given that we cannot explain the variance
due to the sequencing library preparation process, we expect the variance of ELSA to be
slightly above the theoretical variance.
To make an empirical comparison between ELSA and our theoretical result, we sim-
ulated the sequencing process with our deduced distribution. To do so, we combined
all ELSA samples to deduce a good estimate of the transcriptome composition. Please
note that it is not vital to know the true transcriptome composition of the ELSA sample
to produce a simulation cohort with comparable variance. We summed the three read
count vectors of the ELSA cohort and then calculated the expected value of the induced









where XELSA is the set of read count vectors of the ELSA cohort. To simulate a cohort
of similar sequencing depth, we used the average read count m ≈ 3.8 · 106 as parameter
in the multinomial distribution. Our simulation cohort is a set of 1000 samples from
Multinomial(pELA,m). We refer to the simulated cohort as Seq-Err. This cohort is
an empirical representation of the theoretical RNA-seq result distribution. To put the
difference between ELSA and Seq-Err into perspective, we also includ the UT1 cohort
into the comparison that also exhibits biological variance. A cohort description can be
found in appendix A.5.3.
We want to compare the variance within Seq-Err to the variance within ELSA. How-
ever, because only three samples are provided, the per gene variance estimate for the
ELSA cohort is very unstable. To compensate for the lack of samples, we combine many
measured features into statistically independent meta-features, which are more stable
then single gene expression measurements. To avoid bias through the construction of the
meta-features, we use the PCA transformation that we obtained earlier in figure 4.1d.
This PCA was calculated without any influence from the ELSA cohort. We use the ex-
pected log transcriptome composition E[log(p)] for all of the expression vectors and we
then apply the predetermined PCA transformation. Consequently, a component repre-
sents a more stable meta-feature that is expected to have statistical independence from
the other meta-features. Some of the resulting projections are depicted in figure 4.3a.
The variance of the RNA-seq simulation Seq-Err may not be confused with the tran-
scriptome composition uncertainty. To illustrate the difference, we generated the set
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Trans-Uncert by drawing 1000 samples from Dirichlet(x + 1). This set represents the
transcriptome composition uncertainty induced by an expression vector x that we selected
at random from the ELSA cohort.
Figure 4.3b shows an unbiased variance estimate for the cohorts and for each com-
ponent. As expected, the variance in the ELSA cohort seems to be slightly above the
theoretical variance and far below the high variance due to biological differences in UT1.
In particular, the first few components of the PCA are affected by the variance introduced
through the RNA-seq library preparation step. Because the components selection was
not influenced by the ELSA cohort, a very similar variability must also be present in the
cohorts used in figure 4.1.
In figure 4.3c, we investigate the variance estimates independently of the PCA. We
calculated the gene-wise unbiased variance estimates within each cohort of the E[log(p)]
values. To stabilize the estimator, we took the arithmetic mean over the 17.487 genes,
which represent the 30 % highest expressed features in the ELSA cohort. Unfortunately,
a large portion of counted genes are not expressed in the analyzed samples. These genes
distort the variance estimate towards lower values, especially when the total number
of reads is low. Consequently, we excluded the 70 % of the genes which are weakest
expressed pELSA. To illustrate the effect of sequencing depth on the variances, we re-
calculated Seq-Err and Trans-Uncert for different total read counts. For Seq-Err, “read
count” corresponds to the parameter m. To use the same “read count” in Trans-Uncert,
we chose an x from the respective Seq-Err cohort at random. Seq-Err exhibits the
distortion towards lower variance by weakly expressed genes for very low read counts. In
contrast, Trans-Uncert is strictly increasing for decreasing read counts.
The results show that the theoretically expected variability in the RNA-seq results
is close to the observed variability in the ELSA cohort of technical replicates. This
is contrasted by the resulting transcriptome composition uncertainty. In particular, if
weakly expressed genes are included, as in figure 4.3b or for low total read counts in
figure 4.3c, then the resulting uncertainty surpasses the variability of repeated RNA-
seq experiments. This also illustrates how the variability of weakly expressed genes is
underestimated if the theoretically inferred uncertainty is not acknowledged and hence
the significance of differential expression for weakly expressed features is overestimated.
This is a common issue for differential expression analysis and is often addressed by
removing weakly expressed genes through a subjectively chosen expression threshold, as
we did for figure 4.3c.
Our investigation does not allow a rigorous conclusion but it does demonstrate the
plausibility of our inference of transcriptome composition based on RNA-seq results. It
also may motivate new statistical methods to calculate the significance of differential ex-
pression in weakly expressed genes. We also show that the random effect from the library
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preparation cannot be explained with the inferred distribution. Because a mechanistic de-
scription of the random effects involved in the process seems intractable, the distribution
may only be deduced from empirical samples. We formulate the cell-type characteris-
tics of specific cells through EPDs in section 4.4, and we infer specific parameterizations
in section 5.4.5 and 8.2.5. Because the characterizations come from the empirically ob-
served distribution of samples, they also cover the variance due to the library preparation.
Hence, we do not ignore this source of uncertainty in the inference.
(a) We applied the PCA from figure 4.1d on the new cohorts and we show the selected compo-
nents. The explained variance percentages in the axis labels come from the original data. We
use the log of the transcriptome compositions in Trans-Uncert and the E[log(p)] analogously to
figure 4.1a for all other cohorts.
(b) We applied the PCA from figure 4.1d on
the new cohorts and we show the unbiased
variance estimates along each component for
each cohort. “UT1 and others” is the collec-
tion of all cohorts used to calculate the PCA
transformation in figure 4.1d.
(c) Mean unbiased variance estimates for mul-
tiple cohorts across the 30 % (17.487) highest
expressed genes in the ELSA cohort. “read
count” is the number of reads per sample as-
signed to a genomic feature. Seq-Err and
Seq-Uncert was generated for different read
counts.
Figure 4.3: Visualizations of the ELSA cohort, which is a set of three technical replicates;
UT1, comes from RNA-seq of different prostate biopsies; Seq-Err, is a set of 1000
samples from the multinomial distribution induced by a single transcriptome composition
vector; and Seq-Uncert, is a set of 1000 samples from the Dirichlet distribution implied
by a single RNA-seq gene count vector.
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4.3.2 Dirichlet and Normality
In section 4.3.1, we relate the result of the RNA-seq experiment x to the feature expression
p in the sequenced sample. When we formalize EPDs, we want to characterize different
types of tissues or cells through distributions of p. For a complete characterization of
cell types, it is vital to incorporate the different inter-feature-relations or co-expression
of genes. The first order of statistical dependency is quantified in covariance. The dis-
tribution that incorporates this covariance, and no additional higher moments is the
multivariate normal distribution. However, this distribution is unsuitable for modeling
p, most obviously because of the constraint p ∈ ∆n−1. In addition, because a single
observation x implies a distribution of p, which is so unlike a normal distribution, it is
inconceivable how any cell characteristic could result in a normal distribution of p.
In the next chapter, we will transform the space of compositions such that an approx-
imation by multivariate normal distributions becomes much more tangible.
4.3.3 The τ−1 ◦ log Transformation
It is often preferential to evaluate expression data in the log scale. The skewedness of the
distribution on the canonical scale makes it difficult to do any statistics that requires an
approximate normal distribution.
The Dirichlet distribution is defined on the n−1 simplex ∆n−1 ⊂ Rn. Likewise to the
log normal distribution, we could simply apply the logarithm to the random variables and
infer a density distribution on log(∆n−1). This set is a curved manifold with a strictly
positive Gaussian curvature. However, there is no normal distribution corresponding to
random variables on such a geometry. Therefore, we need another change of coordinates
to flatten the manifold.
We made the observation, that log(∆n−1) can be expressed as a function on the n− 1
dimensional hyper-plane orthogonal to 1. Let On−1 := {z ∈ Rn|z̄ = 0} be this hyper-
plane containing 0 and τ : Rn → Rn with
τ(z) := z − 1 log (| exp(z)|1) + 1z̄.
A depiction for the case n = 2 is shown in figure 4.4.
We want to use the composition exp ◦τ as a substitution in the Dirichlet PDF. There-
fore, we need to keep track of the deformation we apply on the coordinate space. The
proofs for most of the following lemma can be found in appendix B.
Lemma 1. τ maps On−1 into the logarithm of the n− 1 simplex: τ(On−1) = log(∆n−1).
It can be looked up in the proof of this lemma that for y ∈ log(∆n−1)
τ−1(y) = y − 1ȳ/n. (4.14)








Figure 4.4: Depiction of the point set ∆1, subsets of O1 and log(∆1) within the range of
the plot, mapping vectors of τ for a few points in O1, and mapping vectors of τ−1 ◦ log
for a few points in ∆1.
Lemma 2. exp ◦τ : On−1 → ∆n−1 is a diffeomorphism.
In the proof, it becomes apparent that this is the well-known softmax function, which
is often applied in the context of artificial neural networks. Therefore, we can rely on a
repertoire of results and good implementations.
Lemma 3. The determinant of the Jacobian of exp ◦τ is |D exp ◦τ |(z) = n exp[(1−n)z]| exp(z)|n1 .
The result of lemma 3 could be used for the coordinate transformation within Rn.
However, the Dirichlet distribution has only n − 1 degrees of freedom and the value of
one feature is entirely determined by the sum of all other features pi = 1 −
∑︁
j ̸=i pj.
Hence, we need to apply a diffeomorphism on the first n − 1 features only. If we set
zn := −
∑︁n−1
i=1 zi, then z ∈ On−1 and p := exp ◦τ(z) ∈ ∆n−1, hence pn = 1 −
∑︁n−1
i=1 pi.
Now let z′ := z1,...,n−1 and
exp ◦τ ′(z′) := exp ◦τ(z)1,...,n−1 =
exp(z′)
| exp(z′)|1 + exp(−z′)
then exp ◦τ ′ is a diffeomorphism from Rn−1 to ∆n−11,...,n−1, the n− 1 free parameters of the
Dirichlet distribution.
Lemma 4. The determinant of the Jacobin matrix of exp ◦τ ′ is
|D exp ◦τ ′|(z′) = n(exp (−z′) + | exp(z′)|1)n
.
Reintroducing z ∈ On−1 yields |D exp ◦τ ′|(z) = n| exp(z)|−n1 , which coincides with
|D exp ◦τ |(z) on On−1. This will allow us to formulate a probability density function
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flog D : On−1 → R+ that is equivalent in probability to the Dirichlet probability density
function fDirichlet. This means that for every S ⊂ ∆n−1 ⊂ Rn, it holds that







We substitute q = exp ◦τ(y) and calculate
P(p ∈ S) =
∫︂
τ−1◦log(S)










exp(⟨z,x⟩ − |x|1 log(| exp(z)|1))n









Hence, the equivalent to the Dirichlet distribution for z ∈ On−1 is
flog D(z|x + 1) =
n exp⟨z,x⟩
B(x + 1)| exp(z)|n+|x|11
. (4.15)
This will allow us to freely select a sample from a subspace spanning On−1. We
will define an appropriate base to span this sampling space as needed. Then, all of
the constraints on p = exp ◦τ(z) of the Dirichlet distribution are fulfilled through the
choice of the coordinate system. One example for such a base is provided through the
Helmert matrix H ∈ Rn×(n−1). The orthonormal columns of H span On−1. Note that
H ◦ τ−1 ◦ log = H ◦ log which is the known isometric logratio transformation [37]. The
isometric logratio transformation retains a lot of metric properties and is predominantly
used to investigate ∆n−1 in statistical applications.
To shed some light on the transformation, we applied a PCA on values of
τ−1 ◦ log(Ex[p]) = log(x + 1) −
1
n
| log(x + 1)|1 (4.16)
where x ∈ Nn is a raw gene count vector and depicted the result in figure 4.1d. The
components are tangential to On−1 because all of the mapped data points are in the
hyper-plane. The components of the cohort-wise distributions show superior statistical
independence. This hints towards enhanced normality of the transformed data (s. section
3.2) and reduces redundancy between the components. Further investigation will follow
in section 5.1.4.
Note that our implementation of the diffeomorphism τ−1 ◦ log and its inverse exp ◦τ
was accepted to the Python package PyMC3 [102] as a tool to enhance statistical inves-
tigations involving the Dirichlet distribution: https://github.com/pymc-devs/pymc3/
pull/4129
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4.3.4 Variance Stabilization
It is well-known that the expression counts xl ∈ Nn obtained through RNA-seq for a set
of different tissues l ∈ L do not follow a gene-wise normal distribution xl ≁ N (µ,σ)
and hence, many statistical methods cannot be applied or suffer from inaccuracies. The
common tools for differential expression analysis such as RNA seq data such as DESeq2
[73], voom [68] and, EdgeR [98], can address this issue through application of a transfor-
mation ρ : Nn×Ω → Rn such that ρ(x,θ) ∼ N (µ,1) approximately. ρ is called a variance
stabilizing transformation (VST). For example, DESeq2 [73] applies [34], which assumes
a negative binomial distribution with gene expression mean dependent parametrization.
Differential expressions between selected groups are conserved by shifting the group spe-
cific expression mean to the overall gene mean before inferring θ.
The parameter set θ ∈ Ω has to be inferred cohort-specifically and the transforma-
tion is only valid for samples of the same cohort. This complicates multi-cohort stud-
ies and the technique cannot be applied on single or very few samples. Additionally,
an inverse transformation is generally not supplied, the differential is hard to calcu-
late and measurement uncertainties cannot be propagated. We argue that the τ−1 ◦ log
transformation already produces approximately normally distributed expression vectors
τ−1 ◦ log(Ex[p]) ∼ N (µ,Σ) without the shortcomings listed earlier. Evidence is presented
in figure 4.1d and through demonstration PCA suitability in section 5.1.4.
Note that in section 5.4.4.1 we perform a difference preserving transformation ρ that
is very similar to DESeq, which results in group specific distribution ρ(x,θ) ∼ N(µ, I)
through PCA. In contrast to DESeq2 we also stabilize the covariance. However, the
parameters inferred by PCA can be cohort specific. This is counteracted in following
sections by intensive dimensional reduction and the inclusion of many datasets.
4.4 Cell and Tissue-Type-Specific Expression
Pattern Distributions
An essential part of the Bayesian modeling that we pursue is a parametrization of the
EPDs within a given group of cells or tissue types g : Ω → R+, where Ω is the space of
possible expression patterns, commonly either Rn, ∆n−1, On−1 or a subspace of On−1.
For a random variable x that is distributed according to that EPD, we write x ∼ T . We
refer to g and T as the cell or tissue type characterization or EPD.
For the example application of inference of cell decomposition we settle with a mul-
tivariate normal distribution after an appropriate transformation of the expression data
(s. section 5.4). However, for the deconvolution of expression expression patterns in
tumor cells the EPDs of subtissues can be rather heterogeneous. For the latter applica-
tion we must allow the parametrization of T to be fairly general and capable to model
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key features of the distribution. In this section, we discuss three different approaches to
such a parametrization. All investigated methods have their shortcomings and an ideal
approach is yet to be found. We will resort to the Gaussian mixtures presented last.
However, we also discuss the alternatives and respective theoretical results we developed
in an attempt to find a more suiting parametrization of EPDs.
4.4.1 Method of Moments and Factor Analysis
A general way to parametrize a distribution function is through its moments [16]. Al-
though we investigate this approach in this section, it was not included into the example
applications of this work. We present it nevertheless because it is an important iteration
in our endeavor to parametrize EPDs.
We want to use the first moments µg and the second central moments Σg to reconstruct
the distribution g : Rn−1 → R+ on the expression data after the τ−1 ◦ log transformation.
The moment vector is (µg,Σg, 0, ...) defines a multivariate normal distribution with mean
µg and covariance matrix Σg. While it is easy to estimate the mean from the data µ̂g
and an estimate Σ̂g does not have full rank. When the number of samples smaller then
the number of features and all of the data points are contained in an N − 1 dimensional
hyper-plane in the feature space and the rank of Σ̂g is at most N−1. However, we assume
at least a technical noise with amplitude σtech ∈ R+,n−1, such that
Σg = diag(σtech) + Σg,bio
where Σg,bio is the covariance matrix of biological effects. An estimate σ̂tech and Σ̂g,bio
has to be inferred from Σ̂g.
Probabilistic PCA (PPCA) [114, 80] does a feature selection but assumes spherical
noise σtech = 1 ·λ, λ ∈ R+. The of the features selection is a eigenvector decomposition of
Σ̂bio that spans a subspace that should contain most of the biologically induced variance.
4.4.1.1 Tumor Free Cells
To infer Σg for a specific cell type, pure samples are required. In the case of tumor-
free cells, control samples can be used to directly apply PPCA and obtain a normal
distribution f̂ o ≈ fo. The assumption for a sample expression vector x ∈ Rn is




where t0 ∈ Rk is the strength of biological effects and k the number of features selected
by PPCA.
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4.4.1.2 Tumor Cells
Because tumor cell samples are regularly cell mixtures of tumor and tumor-free cells, the
model assumption is
x = α(µft + Σ
1/2
ft




The mean for the distribution of mixed cells is µm = αµft + (1 − α)µfo for some
α ∈ [0, 1] hence
µ̂ft =
µ̂ − (1 − α)µ̂fo
α
where µ̂m is the sample mean of the data.
We do not assume to have any information on α. To reliably remove the effect of
tumor-free cells, we project the data to the subspace orthogonal to Σ̂fo,bio and apply
PPCA to obtain an estimate for Σ̂ft,bio ≈ α2Σft,bio that is orthogonal to Σ̂fo,bio.
This allows for “deconvolution” by projection into the sub-spaces defined by the eigen-
vectors of Σ̂fo,bio and Σ̂ft,bio. To eliminate the effects of α the data can be projected to
the unit sphere around their corresponding means. We can then use spherical harmonics
as a basis to do regression on the sphere for any phenotypic property that we expect to
depend on tumor cell expression patterns.
Unfortunately, this approach comes with many implicit assumptions and turned out
not to be accurate enough. To attain reliable EPDs of tumor and tumor free tissues
in high dimensionality, too many purified samples are needed and the assumption that
Σfo,bio is approximately orthogonal to Σft,bio is too rough and does generally not hold.
4.4.2 Characteristic Function
Another general parametrization of g arises through a parametric description of its charac-
teristic function. However, as we will conclude at the end of this section, this parametriza-
tion is unsuitable for our application.
















The CF is also called moment generating function because the moments of f are the
coefficients of the CFs Taylor series.
A sample estimate of φ is given by the sample estimate of the expected value
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This converges against the delta distribution for r → ∞. This distribution perfectly
explains the data but it is extremely non-flat and therefore does not generalize to new
observations. However, by limiting r to a smaller value, we can directly control the
flatness of the result. The respective integral can be solved algebraically:










, for x = x′
Jn/2(r||x′−x||2)
||x′−x||n/22
, for x ̸= x′
It remains to choose r optimally. To measure how well the resulting distributions gen-
eralizes to new observations, we do a leave-one-out cross-validation. The leave-one-out







We could use either the likelihood or Kullback Leibler divergence as a measure of good-





However, this function is very non-flat and therefore hard to optimize numerically. A



































The risk estimate becomes
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(a) Data and marginal
histograms.
(b) A Gaussian kernel density
function estimation.
(c) The density function estima-
tion using the characteristic func-
tion.
Figure 4.5: Data drawn from a Gaussian mixture with probability density function esti-
mation with Gaussian kernels and the characteristic function.
(a) Data and marginal
histograms.
(b) A Gaussian kernel density
function estimation.
(c) The density function estima-
tion using the characteristic func-
tion.
Figure 4.6: Data drawn from a Gaussian mixture along a subspace and probability density
function estimation with Gaussian kernels and the characteristic function.







which can be minimized numerically. While the presented derivation has been developed
within this study, similar investigations and a more mature theory can be found in the
field of reproducing kernel Hilbert spaces [15].
Empirical investigations have revealed that sample estimations of g through the pre-
sented approach would not always be strictly positive and hence require additional mod-
ifications to be valid. Additionally, this approach implicitly aims to model a PDF by
a composition of oscillations in intensity. This yields wavy patterns in the inherently
suboptimal approximation, which cannot be expected to generalize well to additional
samples. Such an approximation may be more suitable for PDFs that are expected to
express repeating patterns along some vector. Some empirical results are depicted in
figures 4.5 and 4.6.
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4.4.3 Gaussian Mixture Model
Another way to model the approximation of a general distribution g is by a combination





for some L ∈ N, p ∈ RL, µ1, . . . , µL ∈ Rn and Σ1, . . . ,ΣL ∈ Rn×n. f(·|·,Σl) is a
Gaussian kernel that corresponds to a reproducing kernel Hilbert space D. Fining a good
parametrization of the Gaussian mixture to approximate g often amounts to finding an
optimum f ∗ of the empirical risk R : D × Ωm → R:
f ∗ = arg min
f∈D
R(f,X, g(X)) + ∥f∥
where X ∈ Rn×m is the dataset and ∥ · ∥ is some norm on D.
The represented theorem states that if g ∈ D, then f ∗ is known to take the form of
ĝ in (4.17) e.i. g can be fully described with a Gaussian mixture. Since D is dense in
L2(Rn) [95], we know we can approximate any conceivable EPD arbitrary well if we let
L to be large enough. Empirical results also show that the approximation with Gaussian
kernels outperforms other methods in many applications [79].
We will resort to this method in later phases of this work to approximate arbitrary
cell or tissue type EPDs. Choosing this parametrization guarantees the multimodality
of the parameter likelihood function. Because any order of kernels produces the same
distribution, every local maximum in the likelihood exists L! times. This issues is also
addressed in 8.2.1.
4.5 Prior Covariance Matrix Distribution
Throughout this work, many probability distributions are modeled as multivariate normal
distributions N (µ,Σ) with µ ∈ Rm and the covariance matrix Σ ∈ Rm×m. However, the
parameter Σ which models the uncertainty of the corresponding random variable may
itself be subject to uncertainty. Hence this parameter poses a random variable in the
inference process. For most computational inference, we must be able to draw samples
according to its distribution.
While defining a prior distribution on a random matrix can be as simple as defining a
prior for each entry, the entries, Σ cannot be arbitrary and must obey certain constrains
to constitute a valid covariance matrix; that is, that Σ must be symmetric and positive
semi-definite or xT Σx ≥ 0 for all x ∈ Rm. Although a prior on each entry would imply a
prior on the subset of symmetric positive semi-definite matrices, the implied information
may be rather unexpected and direct sampling from it is not possible. Furthermore,
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projecting a sample to the subset is no solution because it implies a different distribution
with undesired biases.
A natural choice is the inverted Wishart distribution, which is conjugate to the normal
distribution. However, its heavy tails make inference by sampling inefficient. Addition-
ally, the prior links variance to correlation and hence is not rotationally invariant. This
introduces some arbitrariness, specifically after the coordinate transformations we pursue.
The onion method [70] is the most celebrated method to define a weakly informative
prior on covariance matrices that is suitable for inference through sampling. We use the
Cholesky decomposition of symmetric positive semi-definite matrices Σ′ = LTL together
with the Lewandowski-Kurowicka-Joe (LKJ) distribution to sample the triangle matrix
L. Because this alone yields a correlation matrix, we define a prior for the standard
deviations σ ∈ Rk that we use to rescale Σ = diag(σ)Σ′ diag(σ). The LKJ distribution
has one free parameter η ∈ R+ that regulates the tendency towards the identity matrix,
where η = 1 results in a uniform distribution. We write Σ ∼ JKLCov(η,σ).
This distribution is implemented in the PyMC3 python module that we use in the
inference process.
4.6 Bayesian Survival Analysis
Our work with transciptomics often aims to relate differences in the expression levels to
characteristics of the phenotype, potentially in a probabilistic manner. One characteristic
of interest, specifically in oncology, may be the hazardousness of a tumor, which is usually
expressed in terms of event rates. Many possible event rates for a given patient or sample
can be measured and compared directly to other patients that have been observed for
the same period of time. However, in survival analysis, the event of interest is “death of
disease” (DoD). Therefore, after the first event occurs, the event rate cannot be observed
any further. Consequently, we cannot observe for an arbitrary time, and hence cannot
create a cohort with events and in which all patients have been observed for an equal
period. In other words, survival analysis suffers from censored data. This requires specific
statistical methods to relate any measurement to the event rate.
To make use of a dataset, the patients are organized in overlapping batches. For each
observed event i, we collect all patients that were also alive at the time of the event ti
and combine them into a batch Bti .
Assuming that we model a parametrized hazard function h : Ω ×R× Ψ → R+, where
x ∈ Ω is the patient characteristic, t ∈ R is time, σ ∈ Ψ is a parameter set, and h(x, t,σ)
is the event rate at time t for the patients with the characteristic x. Now the PDF f for
the occurrence of an event at time t for patient i is
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which involves h explicitly.
It has been suggested to model h entirely, such as through approximation with a
step function as investigated by [54]. However, this requires a very high dimensional
parametrization Ψ that may even result in degenerate inference because there is no data
for some intervals in the step function. Instead, we use the categorical PDF for the
patients at event times, which is also used in the classical Cox-regression. As stated by





and hence j ∼ Cat(pti). Because we do not have data for all possible values of t,
the distribution is only investigated at event times ti. Making the proportional hazard
assumption h(x, t,σ) = h0(t)g(x,σ) simplifies (4.18) such that h0(t) cancels out and
therefore no time dependency of h has to be modeled to infer σ. This makes computation
much cheaper, while allowing for a large class of possible hazard function h. This leads
us to make the following assumption for our application of the survival analysis:
Assumption 9 (Proportional Hazard). If xi is the transcriptome composition of patient
i, then the transcriptome based hazard rate for this patient takes the form h(xi, t,σ) =
h0(t)g(xi,σ) where the base hazard h0 : R → R+ and σ is the same for all patients.
To incorporate this result in the inference process, we include a distribution





for each event time ti and the corresponding observations.
In the typical application of Cox-Hazard-Regression, we customarily assume
g(x,σ) = exp⟨x,σ⟩ (4.20)
the exponent of the scalar product. This is equivalent to projecting the transcriptome
composition x onto a line defined by σ before taking the strictly monotone exponential.
While other parametrizations of g are possible, we often resort to (4.20) because more
complicated models are difficult to infer with the amount of available data. If the form
(4.20) is assumed, then we use a prior distribution σ ∼ N (0,1) for the inference.
Note that the conventional Cox regression amounts to maximizing the likelihood func-






where E is the set of all events and g as in (4.20).
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4.7 Demarcation from Existing Methods
Some of the chosen modeling parameters seemingly contradict some established modeling
practices for RNA-seq data. This section aims to clarify apperent deviations.
4.7.1 Negative Binomial Distribution
How to model feature expression variability in RNA-seq most adequately is a long-
standing problem. Empirical observations strongly suggest assuming a negative bino-
mial distribution (NBD), as demonstrated in [34]. This has been adopted by several
software tools to evaluate the differential expression of individual features between two
or more groups [98, 73]. The calculated variance of expression within one group in-
cludes not only the uncertainty of the measurement but also the biological variability
of the feature that can be distinguished [14]. Because we model measurement uncer-
tainty separately from biological variability, we cannot apply the same argument to our
case. We argued mechanistically in 4.3.1 to use a binomial distribution (BD) for the
measurement uncertainty and thus a Dirichlet distribution for the underlying feature
expression, and we can argue for BD and NBD to be equivalent in our case: because
n = k ( the number of successes) + r (the number of failures) we can write






So the NBD is equivalent to the BD in every term except the binomial coefficient. To










)︂ = 1 − k
n
So the ratio differs from one only by k
n
, which becomes very small when k ≪ n. In our
schema, n stands for the total amount of obtained reads and k for the number of reads
assigned to the feature of interest. Given the large number of features, k is commonly a
lot smaller than n, and we can deduce NBD ≈ BD.
Both, NBD and BD, model the amount of successes in a repeated Bernoulli exper-
iment. The difference between the tow stems from the fact that in NBD we stop the
Bernoulli experiments after a set amount of failures. This assumption translates to an
RNA-seq experiment in which the sequencing depth n is the result of a random process.
While this is true for a set of multiple samples, we do not want to take this effect into
account when we study a single sample with a particular given sequencing depth.
These arguments suggest favoring the BD to model sample specific measurement
uncertainty in RNA-seq. However, it has no implication for modeling variability within
a collection of samples and it does not contradict current applications of the NBD to
measure the significance of differential expression in RNA-seq.
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4.7.2 Steady State Assumption
We do not assume to find our expression data in a dynamic equilibrium nor do we intend
to explain the dynamics of the transcriptome. Our data comes from single tissue samples
from different patients of different composition and different characteristic states. We
model the cell and tissue type characteristics (s. section 4.4) with a PDF that explains the
probability for the state of the transcriptome for any sample of the same type. This PDF
includes a probability for a sample to be of a distinct subtype, as well as the probability
for different transcriptomic states (e.g., a different phase of cell differentiation, a different
time in the circadian rhythm or different treatment).
The high heterogeneity within the defined sample types complicates the PDF and
hence the inference process. We do not strictly require homogeneity of the sample type.
However, it remains advantageous to keep it pure and in a comparable state (e.g., through
equal treatment).
4.7.3 Partial Correlation
Partial correlation coefficients for sets of features aim to quantify direct dependencies
between pairs after accounting for co-expression with any other potential interaction
partner within the set. This is done by fitting linear models of the potential interaction
partners to the expression of the two features of interest. The correlation of the residuals
is termed a partial correlation.
Partial correlation effectively identifies direct interaction partners in generated data
from ordinary differential equation models of small regulatory networks [66]. However,
this method comes at a high computational cost because many combinations of potential
interaction groups have to be evaluated for it to be exhaustive. This approach also relies
on the uniqueness of the signals because a single redundancy would not leave residual
information for a partial correlation with other interaction partners. The effectiveness
has only been demonstrated when there are measurements for all interaction partners but
there are many interaction partners in the proteome, genome, and epigenome that are
not measured in RNA-seq. The robustness of this method against random noise is also
questionable. There are numerous potential interaction partners and a high probability to
find one that is highly correlated just by chance. Only one such feature would deteriorate
the partial correlation to any other partner.
We aim to model our knowledge of feature expression with multivariate probability
density functions and hence include feature dependencies. Consequently, there is no need
to evaluate the directness of these dependencies or the causality behind it. Dependent
probabilities solely resemble the observed co-occurrence under given conditions.
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4.7.4 Interaction Networks
Some studies use the language of graph theory to argue about expression interactions,
such as [104] or [134]. This language is extremely powerful when used to study networks
of nodes with pairwise connections. Some theories even extend to hyper-edges connecting
more than two nodes. However, in this work we do not put the theory to use and instead
we work with continuous values and attempt to refrain from discretizations. Instead of
nodes, we speak of expression values for a given feature; instead of a edges, we speak of
pairwise correlations; and instead of clusters as a set of nodes, we speak of vectors, giving




The transcriptomic expression state of an entity is described by abundances of the differ-
ent genomic features. This could be the relative abundance of a certain transcript or the
combined abundance of all of the transcripts of a certain gene. The amount of distinct
genomic features n can be well above 105. Generally, to model the transcriptome proba-
bilistically we have to define a PDF in this n-dimensional space. If the dimensions of this
space are not probabilistically independent, then it becomes computationally difficult to
model a PDF. The number of parameters in a multivariate distributions increases along
O(n2) or faster; for example, in a multivariate normal distribution we can model pairwise
linear dependencies with the covariance matrix Σ ∈ Rn×n, which has up to n+n22 degrees
of freedom. Modeling this number of parameters is not only infeasible but also not very
beneficial because the majority of feature pairs do not share a unique dependency that
needs to be modeled. Instead, the expected interaction matrix is rather sparse and genes
co-express not just pairwise but in larger functional groups. It should also be possible
to compress this information without a substantial loss of information, e.g., by model-
ing transcriptome composition employing a few expression patterns of distinct functional
groups and their co-expression. Many approaches simplify the data crudely by combining
genes in disjoint sets (e.g. gene clustering algorithm) and enforce positivity of expression
through optimization constraints (e.g. in positive matrix factorization). In contrast we
model a continuous impact from each functional group on all genes by multiplicative ex-
pression patterns through the exp ◦τ transformation and comply to positivity implicitly.
In this chapter, we will deduce compressions through dimensional reduction (DR).
We start in section 5.1 with a DR that can generally be applied on transcription data
without losing too much information and which we can use in the example application
deconvolution of expression patterns. In section 4.3, we introduce a PDF of the tran-
scription composition based on the RNA-seq measurement. Section 5.2 is dedicated to
translate this PDF to a PDF of the compressed transcriptome compositions. Section
5.3 incorporates the multivariate normal cell type specific EPDs to deduce PDFs of the
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compressed transcriptome compositions for the individual cell types that make up the
RNA-seq sample. The following section 5.4 specializes the DR for the inference of cell
compositions. Subsequently, we reconcile the attained formulation of the DR with our no-
tion of expression patterns and functional groups of genes in section 5.5. Finally, section
5.6 considers other compression techniques before we close the chapter in the conclusion
in section 5.7.
5.1 DR for Deconvolution of Expression Patterns
A dimensional reduction (DR) is a transformation ϕ : Rn → Rk with k < n and a
ϕ−1 s.t. ϕ ◦ ϕ−1 is the identity. Note that the same does not hold true for ϕ−1 ◦ ϕ. We
consider such a DR suitable for a dataset X ⊂ Rn if ϕ−1 ◦ϕ(x) is equivalent to x for the
inference under consideration.
PCAS is common schema for DR. With PCA, we can find the linear transformation
ϕk(x) = A(x − b), ϕ−1k (y) = ATy + b, b ∈ Rn, A ∈ Rk×n ist orthogonal (5.1)
for some k < n that minimizes the error squares ∑︁x∈X ||x−ϕ−1k ◦ϕk(x)||2. Because the er-
ror squares can often be associated with information loss, PCA usually provides a suitable
linear DR even for small chosen dimensionalities k. Likewise, the PCA transformation
provides an optimal compression among all whitening transformations [60].
However, for RNA-seq data the information loss is not equivalent to the error suqres.
Because highly expressed genes show a larger total variance without any phenotypical
impact [34], we can tolerate larger error squares in these dimensions than those of rather
weakly expressed genes. A direct PCA would quickly become unsuitable for small dimen-
sionalities k because it poorly approximates weakly expressed genes when considered to
infer phenotypic properties.
We aim to uitilize the power of PCA after stabilizing the variance. Several approaches
have been performed to find an optimal version of the variance stabilizing transformations
(s. section 4.3.4). It has, however, often been a stable proxy to use the logarithm as
such a transformation. This heuristic has been confirmed in studies such as [10], which
modeled transcript expression by log-normal distributions. In some cases, the distribution
function included a switching mechanism for weakly expressed genes to give the sometimes
occurring 0 a non-zero probability. However, this crutch is not necessary for our schema
because we use the Dirichlet distribution where an abundance of exactly 0 is only a zero
set that has no relevance for the inference. We can avoid problems arising from the
discrete nature of the transcript count data by using the relative transcript abundance
p ∈ ∆n−1 as inferred in section 4.3.1, which is always strictly positive in each entry.
We argued in section 4.3.3 that τ−1 ◦ log(p) is scaled such that its distribution across
measurements and biological replicates is approximately normal. This theory would allow
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us to apply PCA for a given dimensionality as a near-optimal DR. It is, however, unclear
if this is indeed the case and we cannot safely make such an assumption. Consequently,
we choose a less descriptive approach by:
Assumption 10 (Suitability). A DR (ϕ, ϕ−1) is suitable for a cohort X if no system-
atically differential expression (SDE) can be detected between ϕ−1 ◦ ϕ(X) and X,
and the internal distortion (ID) is “low enough”.
This premise allows us the application of any DR and test retrospectively for its
suitability, which ensures by definition an untainted inference. As we will see in the
definitions for SDE and ID, we rely on results of DESeq2 [73] and fdrtool [111] for to
determine SDE and ID. Hence, the assumptions being made in the inferences of the two
software packages are made implicitly for our cause. To avoid obscuring this fact, we
hereby state explicitly:
Assumption 11 (Implied Assumptions). All assumptions of DESeq2 and fdrtool can be
adopted to decide suitability.
As indicated by “low enough,” we have no objective threshold for ID and neither
do we have an entirely objective measure. We therefore rely mostly on SDE to decide
suitability and we hope to convince the reader with the somewhat subjective assessment
that follows.
5.1.1 Systematically Differential Expression
In this section we define Systematically Differential Expression (SDE) and investigate
it in our data. Intuitively, we want SDE to resample a reconstruction bias that results
from applying and reversing a DR. SDE stands for an information loss that has biological
relevance. However, the classical approach to calculate bias with error squares does
not accurately represent biologicaly relevant bias. Instead, we want to rely on more
sophisticated measures to quantify SDE. A gold standard to detect SDE has not yet
been established but many tools have been shown to provide reliable probabilities for
differences in expression to occur by chance. An individual genomic feature is said to be
SDE if its p-value is smaller than expected. In typical applications, one has to specify
a threshold below which all of the features will be classified as significantly differentially
expressed. This heuristic inherently produces false positives and false negatives because
the PDFs of p-values for differentially expressed and not differentially expressed features
have support on the whole interval.
We do not need to be as specific because we are not interested in individual features.
Only a bias towards smaller p-values is sufficient to detect the existence of SDE features. If
the 0-hypothesis is correct, then the p-value distribution of not SDE features is uniform.
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To expose the presence of SDE features, we only need to decide whether the p-value
distribution deviates from a uniform distribution towards smaller values.
Two things are critical for SDE detection: a sound 0-hypothesis to calculate correct
p-values and an accurate detection of p-value distribution deviations. We use DESeq2
[73] to infer reliable p-values and fdrtool [110, 111] to detect aberrations from uniformity.
The amount of SDE features is estimated by one minus the maximal tail based FDR of
fdrtool. The tail based FDR at a given p-value is the proportion of features that follow
the 0-hypothesis among all those with a smaller p-value. We call this quantity 1 − η.
5.1.2 Internal Distortion
Similarly, to how SDE quantifies bias through DR in a biologically meaningful way we
aim to quantify variance through DR with Internal Distortion (ID). One inter-sample
relationship that we deem important is the differential expression between two distinct
groups in the same cohort. Once again, we decided to employ DESeq2 for a quantification.
DESeq2 bases estimates of significance for differential expression on the Wald statistic,
which is approximately normally distributed under the 0-hypothesis. This characteristic
enables numerous tests that rely on approximate normal distribution of the random
variable. We compare the differential expression in the original data with that in the
dimensional reduced data by Pearson correlation of the Wald statistic across all features.
Definition 1. We define ID of a DR (ϕ, ϕ−1) and a dataset X to be
ID(X,ϕ−1, ϕ) := 1 − ρ(DE(X),DE ◦ ϕ−1 ◦ ϕ(X))
where DE(X)i is the Wald statistic of differential expression of all features between two
groups of samples in X measured by DESeq2, and ρ is the Pearson correlation. The two
groups should differ in a characteristic that should be preserved.
Now we can use assumption 11, which implies a normal distribution of the Wald
statistic under the 0-hypothesis, to statistically evaluate ID. However, this quantity is
not fully objective because (i) it relies on the choice of grouping the samples and (ii)
we cannot define an objectively correct threshold below which we could call ID “small
enough.” The quantity is only an indication for better or worse DR.
5.1.3 Choosing a DR
As discussed earlier, the logarithm has a variance stabilizing effect on the transcript
abundance vector p. It has also been argued that sample characteristics can be modeled
by log-normal distributions of the abundances. It seems therefore natural to apply a PCA
on log(p) with the functions ϕk and ϕ−1k .
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Because p is not uniquely defined by x ∈ X, we tested four different approximations,
as depicted in figure 4.1. We chose method (d) to apply PCA on γ(X) where
γ(x) :=
(︂




τ−1(log(x + 1) − log |x + 1|1), |x|1
)︂
as prescribed in equation (4.12) and τ−1 as in (4.14). Hence, γ : Rn → On−1 × N+. The
second value of the image tuple represents the sequencing depth, and the functions ϕk
and ϕ−1k only operate on the first argument. We keep the sequencing depth to store the
measurement accuracy of x. This quantity is not explicitly part of our inference model
and instead the uncertainty is modeled by the variance of the resulting distribution. For
now, we use |x|1 as an abstraction to recover x from E[p] through γ−1.
5.1.4 Testing the DR
To test suitability, we compare X with rk(X) = γ−1 ◦ ϕ−1k ◦ ϕk ◦ γ(X) where ϕk is as in
equation (5.1). The inverse to γ is
γ−1(z,m) = round (exp ◦τ(y)(m+ n) − 1) .
To analyse SDE, we calculated ϕk for dimensionality k ∈ {1, . . . , 732} by PCA on
the whole dataset γ(X). The dimensional reduction rk was applied cohort-wise to ensure
that we could use DESeq2 to evaluate a differential expression, as this does not work well
across several cohorts. We then used fdrtool to calculate 1−ηk, the estimated proportion
of SDE features and we plot the result against the number of components k in figure 5.1.














Figure 5.1: The proportion of differentially expressed features between X and rk(X)
against the number of used components k. The values stay constant for numbers of
components above 300. The cohorts are described in A.5.3.
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This empirical study revealed that virtually no SDE can be detected for k = 220
or above. Only in cohort UT1 did a small set of genes stay persistently differentially
expressed for all dimensionalities up to 732. Because theoretically no information is lost
when k equals the sample size - 1, we contribute this differential expression to a small
numerical inaccuracies that we cannot avoid.
To calculate the ID, we defined two groups of samples per cohort that preferably
exhibit a subtle and relevant contrast. Based on the availability of the clinical data, we
split the cohorts into high and low hazard groups. The high hazard groups are the samples
of patients for which a clinical event occurred. For UKD1 and UKD4, long follow-ups
are available and we used DoD as the clinical event and for the other cohorts we used
“biochemical recurrence” (BCR) as an indicator for a high hazard.
The results of the empirical ID analysis on all cohorts can be seen in figure 5.2.
We plotted a solid horizontal line to mark an ID of 0.1. It appears that the ID for the
selected grouping quickly shrinks in the first 100 components for all cohorts and continues
to decrease until we reach the lossless DR k = 732. However, at k = 275, which is marked
by a dotted line, the ID seems acceptably low and only in UT1 does it still exceed the
value 0.1; therefore, we selected this value as an ideal cutoff.























Figure 5.2: The ID as defined in definition 1 within each cohort against the number of
used components k. The cohorts are described in A.5.3.
Choosing the DR (ϕ275 ◦τ−1 ◦ log, exp ◦τ ◦ϕ−1275) is an approximately 200 fold reduction
in dimensionality. Deducing its suitability signifies that no more than 275 independent
values are required to fully characterize a given sample and it suffices to define an EPD
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over these 275 values to fully characterize any cell or tissue-type. However, it may be
necessary to choose an even smaller value for k to ensure feasibility of some applications.
While a reduction below k = 275 may imply some loss of information, operating at lower
dimensions could still retains the most pronounced differences between the samples and
can yield meaningful results. It may even be possible to find more accurate measures
of information loss to justify further reduction without meaningful deficits for the subse-
quent application. However, for our example application, the deconvolution of expression
patterns, we cannot guarantee that a reduction below 275 dimensions with the presented
method will yield ideal results.
5.2 Transformed Density Functions
Section 4.3.3 defines flog D(z|x+ 1), so we can use On−1 as the parameter-space in which
we can impose a normal distribution as a prior for expression patterns. Now, section
5.1.4 selected ϕk as a DR of On−1, where
ϕk(z) = A′(z − b).










such that A ∈ Rn×n is orthogonal. The first term 1/
√︂
(n) is a unit vector orthogonal to
On−1 and B is orthonormal. Therefore, ϕ : Rn → Rn with
ϕ′(z) = A(z − b)
is a diffeomorphism of Rn and ϕ′2,...,n is a diffeomorphism of On−1. Note that |Dϕ′2,...,n| =
|A2,...,n| amounts to the product of the eigenvalues of the PCA transformation, which are
either 1 if the PCA is not whitening or the standard deviation per component in the
whitening case. This allows us to do the coordinate transformation
flog DA(y) := flog D(A−1y)|A2,...,n|.
To define an accurate PDF on the k-dimensional space, we would have to integrate the





where Ω′ is the n − k dimensional subspace orthogonal to the base spanned by A′ and
1/
√
n. However, this integral is unsolved and we have to rely on the following assumption:
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Assumption 12 (Approximation). The marginalized PDF f ′k is well approximated by a
slice of the original PDF:
fk(y′) := flog D(A′−1y′)λ ≈ f ′k(y′)
for some constant λ.
The approximation is justified by the choice of the subspace spanned A′ through
PCA, which minimizes the likelihood for a sample to deviate too far from the subspace.
However, the resulting fk is not a proper prior.
5.3 Probability Distribution of Mixtures in DR Space
This section contains the main theoretical result and the only theorem of this thesis.
It combines the described priors and the conditional probabilities with the dimensional
reduction to conclude a single PDF of the resulting parametrization after an RNA-seq
experiment. This dictates the conditional PDF of the tumor content and the tissue-
specific expression patterns before tissue-specific EPDs are involved.
The feature composition of a cell type i is given by qi ∈ ∆n−1, which is a partition of
one. The DR discussed earlier (ϕk ◦ τ−1 ◦ log, exp ◦τ ◦ ϕ−1k ) links qi to a representation
q′i ∈ Ok with
q′i := ϕk ◦ τ−1 ◦ log(qi).
A bulk RNA-seq sample can be partitioned into T different cell types with different
feature compositions. The partition sizes α ∈ ∆T −1 are also a partition of one and the
individual values αi correspond to the total RNA mass of cell type i and by assumption
1 to the percentage of the sample consisting of this type. The feature composition of the





The respective DR representations q′i can be used to approximate q in the logarithm
expression space On−1, as discussed in 4.3.3, with
q′ ≈ ϖ(α,Q′) := τ−1 ◦ log
[︂
exp ◦τ ◦ ϕ−1k (Q′)α
]︂
. (5.2)
This approximation is justified by section 5.1.4. It is a numerical inconvenience to cal-
culate the log of a sum of exponents. However, the small number of considered tissue
types T prevents escalating roundoff errors, the positivity averts loss of significance and
the small range ∆n−1 of the inner function avoids integer overflow. Therefore, it is not
disconcerting to do this calculation here.
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By Bayes theorem the combined PDF is the product of EPDs of the individual tissue
types f times the likelihood of the mixing result, given the observation as discussed in








where |Dϕk| is an abuse of notation because ϕk is not a diffeomorphism but can be made
so as explained in section 4.3.3 and can be approximated by the product of eigenvalues
of the affine transformation. Given that we will not care about constant factors of the
likelihood in the inference process, this term can be ignored. Θ is the collection of tissue
characterizations θi and is modeled separately.
The likelihood flog D in this equation is somewhat over-parametrized because ϖ is not
injective. However, such an over parametrization has been found to be beneficial for the
objective of finding a global likelihood maximum for non-convex problems [132].
To improve the convergence of the inference process, we require the derivativesDα log ◦f
and DQ′ log ◦f for the log-likelihood. The derivatives of the log-EPDs depend on their
parametrization. Because the derivative of the log-EPDs is only included by addition,
it can be calculated independently. Here we focus only on flog D. Let w(α,Q′) =
exp ◦τ ◦ ϕ−1k (Q′)α be the reconstructed mixed expression, then the log-likelihood is
L := log ◦flog D(ϖ(α,Q′)|x) = log(n) + xTϖ(α,Q′) − log ◦B(x + 1) (5.3)






=xTϖ(α,Q′) + |x|1 · 1T log(w) + c(x, n). (5.5)
One can tell from (5.3) that maximizing the likelihood involves maximizing a scalar
product of the observed count and the log-composition of the inferred transcriptome
composition, while minimizing the ratio between the arithmetic and the geometric mean
of the respective expression vector w. The scalar product becomes larger when the two
vectors tend to agree and therefore match our intuition as a sample that is closer to the
observation should be more likely. Additionally, in (5.4) the ratio in the log acts as a
penalty that is always positive (AM-GM inequality) and gets closer to 0 the closer the
values in w are to one another. Hence, it poses a regulatory effect that is inherited from
the prior and takes an interpretable form in this representation of the likelihood. All of
the other terms are constant in the parameters and do not play a role in the optimization
or sampling process.
5.3.1 Likelihood Gradient
When calculating the derivative, we have to keep the constrained |α|1 = 1 in mind. To
keep the calculation tractable, we specialize on the case M = 2; hence, α = (α, 1−α)T =
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(αt, αf )T , w(α, qt, qf ) = αtqt +αfqf and Q′ = (q′t, q′f ) where t and f stands from tumor
and tumor free, respectively.
qs := exp ◦τ ◦ ϕ−1k (q′s) =
exp ◦ϕ−1k (q′s)












































































Formally stating a central theoretical result of this thesis:
Theorem 5. If assumptions 1, 7, 8, 10, 11, and 12 hold, then the conditional PDF of the
tissue type composition α ∈ ∆2 and the tissue type specific expression pattern description
q′i ∈ Ok for tissue i is given by equation (5.5) and its derivatives are given by equations
(5.10) and (5.13).
Note that the deduced PDF ignores any tissue specific EPDs and is hence not yet
suitable for a deconvolution application. To allow a deconvolution, EPDs have to be
defined on the DR parametrization of expression patterns Ok, and appended through
multiplication. This is done implicitly in chapter 7.
The proof of this theorem is omitted because it is a straight-forward calculation in-
volving the supplied lemmata.
5.3.3 Implementation
We implemented the result in several ways. The implementation used in the exam-
ple applications is rather implicit. Through PyMC3 [102], only the elementary priors
and conditional PDFs have to be defined and the software automatically combines the
PDFs and their respective derivatives in a global PDF. Additionally, we implemented
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two dedicated Theano [113] operations with their respective derivatives. One version is
implemented for evaluation by the CPU using NumPy [46] and is available in the tumor-
deconv code repo [86] in the file logDect_cpu.py and another version for evaluation on
GPUs using PyCuda [63] in the file logDect_gpu.py. These operations can conveniently
be used in a model defined for PyMC3 because Theano is its native backend.
5.4 DR for Inference of Cell Composition
Some applications of RNA-seq deconvolution do not require the reconstruction of ex-
pression patterns of the constituent parts. One example is the Tumor Deconvolution
DREAM Challenge [101]. The goal of the challenge is to reconstruct the mixing coef-
ficient α ∈ RM (as in assumption 1) of M different cell types that make up the tumor
surrounding tissue. The actual expression patterns of the different cell types are not of
interest. Therefore, the DR can retain much less information. The challenge comes with
strong restrictions on computational resources, hence the pressure to reduce the dimen-
sionality is high. Specifically, a maximum of 20 CPU-minutes and 1 GB of memory can
be used for the deconvolution of a single sample.
The limited resources also prompt us to use the simplest EPD parameterization that
allows us to include co-expression information: The multivariate normal distribution.
Hence, we have the additional requirement on the DR, that the distribution of training
data after the transformation should by approximately normally distributed.
5.4.1 Problem Formalization
The result of a deconvolution is a probability density f(α,X|x) (s. assumption 1). In
the context of the DREAM challenge, the only information of interest is E[α]. A lossy
DR comes with a loss of information, which in turn increases V[α] and therefore the
expected prediction error ∥E[α] − α′∥2, where α′ is the true composition of the sample.
We therefore want to decrease the dimensionality while keeping V[α] as small as possible.
To evaluate V[α], we inspect the distribution across all of the model parameters.
f(y,α,X) = f(y|α,X) · f(α) · f(X)
= f(α|y,X) · f(y,X)
y is the measured expression vector of a given sample and since the distribution of
α and X are independent f(α,X) = f(α) · f(X). Due to assumption 3, f(α) is a





f(y|α,X) · f(X) · c
f(y) dX
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is the distribution of α given y after marginalizing out X. What makes this expression
hard to assess is the fact that:
f(y|α,X) = fMultinomial(y|Xα + 1).
As we have seen in section 4, this expression would result in a Dirichlet distribution of
Xα and hence a linearly distorted Dirichlet distribution for α. One could construct a
sequence of probability distributions on the cell type characteristics (X) fk : Rn×N → R+
such that it converges to a delta distribution for k → ∞ that has positive probability
only for the mean cell type characteristics X̄. In other words, such that the expression
pattern of each cell type is known and has no variance.
The integral would disappear in the limit and the variance of α would solely be due







where λ(X̄) is a normalizing constant. Because α ∈ ∆N the mapping X̄· : RN → Rn is
an embedding of the small simplex into a high dimensional one and the variance of f̄ is
only determined by the shape of the Dirichlet distribution within the embedded simplex.
It is intuitively clear that a small embedding cuts out a rather flat area of the Dirichlet
distribution, which hence comes with a larger variance. Hence, more distinct columns of
X̄ (i.e. expression patterns of the different cell types) reduce V[α]. This motivates the
main idea of the following sections: The DR should retain the distance between columns
of X̄ although they are described probabilistically by EPDs. However, it becomes in-
creasingly complicated to accurately quantify V[α], and therefore the suitability of the
DR, even for the simplified case we constructed here. So for reasons of practicability, we
will have to make a leap of faith.
5.4.2 Naive PCA
We demonstrate in appendix A.3 that expression data is not well-approximated with PCA
if not processed accordingly. However, using the τ−1◦log(E[p]) transformation yields more
suitable results, as shown in figure 4.1d. Thus, we apply the same transformation and
PCA on the deconvolution training data (s. section 6.1) shown in figure 5.3. However,
the first components are not related expression patterns that help to distinguish different
cell types but rather some larger effects that have an impact on all cell types. In general,
the discovered principal components produce rather fragmented groups of cell types and
their values do not seem to form a normal distribution within one cell type. Hence,
this DR would complicate the formalization of EPDs and does not ideally ensure stark
differences between distinct cell types. We subsequently turn to optimizing the DR to
retain the information that we are interested in, see sections 5.4.3 and 5.4.4.
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(a) PC 1 and 2. (b) PC 3 and 4.
(c) PC 5 and 6. (d) PC 7 and 8.
Figure 5.3: PCA on tumor immune cell training data after transformation through τ−1 ◦
log(E[p]) as in equation (4.16).
5.4.3 Whitening
Given that in machine learning it is often the goal to reveal effects independently of their
size, it is a common practice to whiten the data. In other words, to scale it to the stan-
dard normal distribution centered around 0 and with unit standard deviation. Because we
are interested in multivariate effects, we cannot do the standardization univariately but
instead have to rescale multidimensionally by assessing the complete covariance matrix
Σ ∈ R(n−1)×(n−1). There are two issues that we have to address to realize this rescaling.
Firstly, if we have less samples N than spatial dimension n, then the empirical approxi-
mation Σ̂ will not be of full rank and a rescaling A with AΣ̂AT = I would be impossible.
The second issue is computational infeasibility: because n is typically very large, the
required singular value composition of Σ̂ tends to be infeasible. We resolved these issues
by inflating the covariance matrix with the technical variance that we inferred in 4.3.1
and we apply an incremental PCA to ensure feasibility. A similar technique has been
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applied to the tumor data in figure 4.2b.
5.4.3.1 Covariance Inflation
According to the theoretical result in section 4.3.1, each RNA-seq sample implies a dis-
tribution of transcript compositions with a full rank covariance matrix. To respect this
variance in the incremental PCA approach, we draw a total of 100,000 samples from these
distributions per iteration and we do so uniformly across all of samples. This not only
ensures a full rank covariance in each iteration but also drowns variances that are too
small to be distinguished from technical noise. Hence, there is a regularizing effect on
the result that makes it more stable against random noise.
5.4.4 DR Through Optimization
We aim to find an affine transformation that whitens the data. But instead of reducing all
variance to 1 and removing all covariances ubiquitously, we want to be more specific and
preserve any effects that we deem to be relevant. To justify this approach, we have to keep
the goal of the procedure in mind: a DR that retains information relevant to distinguish
different cell types. One solution is to maximize the distance between different cell type






where k ∈ N is the chosen number of dimensions to reduce to and DX are all pairwise
differences of the expression patterns xi − xj between samples i, j of different cell types.
However, this is computationally costly due to the pairwise distance calculation of all
samples and does not ensure a high contrast between the resulting cell characteristics
(e.g. columns of X̄ in 5.4.1). Specifically, we will abstract the cell-type specific EPDs
with multivariate normal distributions and the pairwise distance between samples of these
abstracted EPDs may not be optimized.
A more direct way would be to maximize some measure of statistical distance d








Several established measures d come to mind: The Kullback-Leibler divergence, the more
general Rényi divergence, or the Jensen–Shannon divergence, all of which mostly quantify
informational differences, intuitively do not ensure a high distinguishability, and most im-
portantly are not symmetric. The Lévy–Prokhorov metric is very costly to compute. We
exclude these metrics for the mentioned reasons. Other metrics under consideration are
the Bhattacharyya distance, which measures the amount of overlap, similar to ⟨f iA, f
j
A⟩;
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and the Wasserstein metric, which measures the minimal transport required to transfer
one point distribution to another. Both have an analytic form for pairs of multivariate
normal distributions and can hence be calculated cheaply.
Note that for normally distributed random variables X ∼ N (µ,Σ), the mapped
variable Y = AX is also normally distributed with Y ∼ N (Aµ, AΣAT ). Plugging that




∥Aµi − Aµj∥22 + trace
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which is the negative sum of 2-Wasserstein distance squares for normal distributions that










det Σi det Σj
⎞⎠ ,
(5.15)
where ΣA = A(Σi+Σj)A
T
2 is the negative sum of the Bhattacharyya distances for normal
distributions [69].
Now we define a starting point for the iterative optimization A0 and implement it.
5.4.4.1 Starting Point
To initialize the optimization, we want to choose an A0 ∈ Ok that is already reasonable.
Because all EPDs are multivariate normal distributions, they are complete characterized
by their means and variances. It is also intuitively clear that for two normal distributions
to occupy distinct areas of the parameter space, it is foremost the mean that needs to
differ. In the extreme case where all variances are spherical, BΣiBT = λI, the stochastic
distances become purely determined by the means. This can be seen in equation (5.14)
and (5.15). Hence, we first look for an information preserving transformation B ∈ Rl×n
that aims to rescale the per cell type covariance matrix accordingly. Consequently, we
apply the incremental PCA descried in 5.4.3.1 but we temporarily shift the samples by
subtracting their cell type specific mean x′i = xi − µt. The transformation matrix B
resulting from the incremental PCA stretches the space such that the total covariance
matrix approximates I. Because we draw an equal amount of samples of each cell type
and the cell type specific means are shifted to 0, the cell type specific covariance matrices
Σi must add up to I. This can be seen from the sample estimate of the covariation








where M is the number of samples, T the number of cell types and λ = M−T(M−1)T . Hence,
the resulting average covariance across cell types is λI or in other words the expected
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covariance of a given EPD is λI. Consequently, the result is the linear transformation of
the data, which makes the expected cell type specific variances spherical.
Due to memory and time restrictions, we could not perform the incremental PCA in
full rank. As we saw in section 5.1.4, k = 275 is already information preserving for the
tumor cohorts. For the new application, we chose k = 1000 which is generously larger
and can still be handled by the compute system at hand.
We use the resulting B = BoBd, where Bo ∈ O1000 is the orthogonal projection and
Bd ∈ R1000×1000 is a diagonal matrix with the multiplicative inverse of the PCA inferred
standard deviations to transform the cell type specific means:
µ′i := Bµi.
We then applied another PCA directly on the set of transformed means (µi)i∈T and
use the resulting transformation A0 ∈ OT −1 as starting point for the optimization.
A visualization of the coarse grain dataset after the DR A0B is depicted in figure 5.4.
Please note that A0B is not an orthogonal projection but instead a linear distortion that
partially standardizes the cell specific covariance matrices.
5.4.4.2 The Optimization Process
We implemented the cost functions (5.14) and (5.15) in tensorflow [2] and used pymanopt
[115] to do a gradient descent optimization along the Stiefel manifold Ok on a GPU with
the starting point A0. The input EPDs are defined with the pre-transformed mean µ′i
and the covariance
Σ′i := BΣiB = cov[XB,XB].
We stopped the optimization when the change in g per iteration went below 10−10.
Both resulting transformations from the Wasserstein distance AWasserstein and the Bhat-
tacharyya distance ABhattacharyya are depicted in figure 5.4.
Please note that the resulting transformations optimize the statistical distances of
the estimated data distributions only after the whitening through B. In particular the
Wasserstein distance is sensitive to such a distortion because if it is equivalent to the
accumulated distance, then the data would need to be transported to map one distribution
to another. However, not whitening the data numerically drowns important statistical
differences in the much larger batch effect and yields worse results, as can be seen in A.6,
where we chose B = Bo. Meanwhile, the Bhattacharyya distance dB is invariant under
linear rescaling, due to its definition














for any square matrix C of full rank. Rescaling the domain of p yields q′(x) = q(Cx)∥C∥2
and hence dB(p, q) = dB(p′, q′). However, the results are not equivalent to A.6, which may
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be attributed to the different starting points and different scaling. The scale of a given
component effects the relative numerical condition of the multiplication operations, and
hence its impact on the optimization. In both results of the appendix A.6, the transformed
data is distributed less normally and hence is less suitable to be approximated with normal
distributions. So we resorted to the results after pre-whitening.
5.4.5 Results
(a) C 1 & 2 for A0. (b) C 1 & 2 for AWasserstein. (c) C 1 & 2 for ABhattacharyya.
(d) C 3 & 4 for A0. (e) C 3 & 4 for AWasserstein. (f) C 3 & 4 for ABhattacharyya.
(g) C 5 & 6 for A0. (h) C 5 & 6 for AWasserstein. (i) C 5 & 6 for ABhattacharyya.
(j) C 6 & 7 for A0. (k) C 6 & 7 for AWasserstein. (l) C 6 & 7 for ABhattacharyya.
Figure 5.4: Projections to components (C) after DRs (A(·)B0 ◦τ−1 ◦ log, exp ◦τ ◦B−10 AT(·)).
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(a) Confusion matrix for A0. (b) Confusion matrix for AWasserstein.
(c) Confusion matrix for ABhattacharyya.
(d) Henze-Zirkler statistic after DR.
Figure 5.5: Confusion matrix for classification through cell type EPD after the DR
(A(·)B0 ◦τ−1 ◦ log, exp ◦τ ◦B−10 AT(·)) against the labels given in the data and Henze-Zirkler
statistic.
The results are shown in figure 5.4. The optimization for the Wasserstein distance
stopped after just 199 iterations and for the Bhattacharyya distance stopped after 385
iterations. As may be expected from the choice of A0, the optimization for pairwise
Wasserstein distance does not change the transformation substentially. Meanwhile, the
Bhattacharyya optimization distorts the result much more and the two-dimensional pro-
jections presented in the figures do not reveal an obvious separation of the cell types.
To decide which transformation to use, we devised an approach to evaluate the classi-
fication accuracy of the resulting cell type EPDs. While classifying a sample of cells of a
single type is not the goal of the final algorithm, it serves as an easy method to calculate
a proxy for the deconvolution and it is an objective measure for the quality of the DR. If
the cell type of a sample cannot be inferred after DR, then we supposedly will not infer
any composition of mixed samples correctly. To classify a sample x, we evaluated the
cell-type-specific EPD:
class(x) = arg max
t∈T
ft(ABx|ABµt, ABΣtB−1AT ),
where B−1 = B−1d BTo . In other words, we do a maximum likelihood estimate for to which
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cell type a given sample belongs. The result can be compared with the cell type labeled
to the sample and gives rise to the confusion matrix in figure 5.5. Despite the low sample
count for specific cell types, the covariance matrix ABΣtB−1AT rarely becomes singular,
due to the dimensional reducing A. However, if necessary, the issue of singular covariance
in any dimensionality can be avoided through the same Dirichlet resampling approach
used to whiten the data in 5.4.3.
Rather than improving the classification accuracy, the optimization seems to dete-
riorate it. We could explain this with the numerical condition of the process because
we calculate large nested sums due to the Stiefel Manifold restriction. However, it is
also very likely to be an artifact of overfitting. The algorithm optimizes the stochastic
distance between the estimated normal distributions without taking into account how
normally distributed the actual data is. This leads to some components being selected
along which the data is highly non-normally distributed and the tail area contains more
samples than the inferred normal distribution would predict. This could lead to the
higher misclassification rate that we see in figure 5.5.
Additionally, the Henze-Zirkler statistic in figure 5.5d indicates that a transformation
with the optimized DR yields a data distribution that is less accurately described with a
multivariate normal distribution. Notably, after none of the transformation, the cell type
specific expression patterns could be classified as multivariate normally distributed by
the Henze-Zirkler test. This suggests that optimizing the statistical distance of the de-
duced normal distributions does not perfectly optimize the statistical distance of the true
distribution and another parameterization of the distribution may be needed. However,
the good classification accuracies allow us to settle with this approximation.
As a consequence of this result, we opted to use the starting point A0 in the DR
(A0B ◦ τ−1 ◦ log, exp ◦τ ◦B−1AT0 ) for the deconvolution algorithm because it is not only
the best performing method in the classification test but also the cheapest to acquire.
5.5 Interpretation of DR
All of the DRs that we constructed are of the form (A ◦ τ−1 ◦ log, exp ◦τ ◦ A−1) where
A ∈ Rk×n. The k rows of A could be interpreted as k functional groups, each coming
with one weight per genomic feature that describes the impact the features have on
the function groups. Meanwhile, the rows of A−1 ∈ Rn×k are expression patterns that
describe the impact functional groups have on the gene expressions. In the special case
were A is orthogonal, the functional groups are independent and A−1 = AT . Hence, the
matrix A translates any gene expression pattern into activity of functional groups and
back. While the matrix multiplication is a linear operation, it is done after the τ−1 ◦ log
transformation on the counts. So the effect of the functional groups is not modeled
additively but instead the gene-wise expression pattern is the product of multiplicative
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effects from the functional groups. For example, the expression of gene i may be impacted
by the functional groups j and l: xi = aijyk + ailyl where y ∈ Rk is the activity of groups
in the sample and a(··) are the entries of A. However, this is the expression of feature i
in log-space. The linear expression of i is
exp ◦τ(xi) = exp(aijyj) · exp(ailyl) · λ
with a normalizing factor λ coming from τ . Hence, a negative value of (for example)
aijyj results in a factor smaller 1 for the expression of feature i. Negative expressions are
impossible by design and the effects from functional groups on the gene expression are
multiplicative. For example, if the activity of group j is yj = 3 and its impact on feature
i is aij = −0.1, then its effect exp(aijyj) ≈ 12 will half the expression of feature i.
In the previous sections, we selected the matrix A with different aspects in mind. It
may be insightful to inspect the coefficients of A to study the relevance of specific genes
for the DR at hand.
5.6 Comparison to Other DRs
A DR in our context requires the ability to compress and reconstruct the original form
of the data, while minimal information is lost. This requires knowledge about redundan-
cies within the original data and therefore dependencies between the individual features.
Dependencies can be expressed by predicting the value of a given feature by a function
of all of thee other features. While these functions could have many forms, it is often
only feasible to restrict the search for the best fit to linear functions. All of the linear
dependencies between the features are encoded in the covariance matrix of the centered
data. This is the reason why most DR methods operate on this matrix. If one is inter-
ested in a nonlinear dependency, it is often best to transform the raw data such that the
dependencies of interest becomes linear and then apply one’s favorite linear DR.
In this section, we discuss different DR methods and how they relate to our approach.
5.6.1 Weighted Correlation Network Analysis
The weighted correlation network analysis (WGCNA) [134] tends to view genomic
features as vertices and co-expression as edges with flow capacities in a network. Edge
capacities are absolute values of expression correlation between the two connecting feature
vertices. The capacities are then scaled in hopes of producing scale freeness, which is
a property that is often observed in naturally growing networks. Formally stated, this
means
P(degree = k) = c · k−γ, c, γ ∈ R+ (5.16)
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where P(degree = k) is the probability, that a uniformly randomly selected node of the
network has degree k and γ ≥ 2. This optimization is done in one of two ways. The
binary way is to select a cut off value for the edge capacities and setting them to 0 or 1
if they are below or above the cut off value, respectively. In contrast, the favored way
is to apply a whole numbered exponent β to the edge capacities. Because the equation
(5.16) induces a linear dependency log(P(degree = k)) ∼ log(k), it also implies a Pearson
correlation of 1 between the log(P) and log(k). Therefore, the algorithm optimizes the
exponent for this Pearson correlation. The resulting matrix with the absolute Pearson
correlation coefficients with the exponent β will serve as adjacency matrix A.
However, we argue that there is an error in this logic. While equation (5.16) implies
the Pearson correlation, it cannot be deduced that Pearson correlation always implies
equation (5.16). Instead, the lack of Pearson correlation implies the lack of scale freeness.
In fact, we argue that the perused optimization fails to produce scale freeness of the
resulting network in many cases. To illustrate this point, we present empirical evidence
in the following subsection.
It is stated in [134] that the degree of a node i in a network with continuous edge
capacities is ki(p) =
∑︁
j ̸=i |aij|p. Therefore, equation (5.16) becomes continuous in k.
Because P(degree = k) = 0 for continuous degree, we only require
P(degree ≥ k) =
∫︂ ∞
k
c · x−γdx = c · k
1−γ
γ − 1 .
Analogous to [134], this can be converted to a linear function of log(k):
log(P(degree ≥ k)) = log(c) − log(γ − 1) + (1 − γ) log(k). (5.17)
Hence, scale freeness implies a higher absolute Pearson correlation between log(k) and
log(P(degree ≥ k)).
To investigate the scalefreeness of our data after different normalizations and transfor-
mations, we calculated the Pearson correlation between both sides of the equation (5.17)
across 1000 values of k between the smallest degree or at most 1 and largest degree or
at least 2 of our network for the UKDP cohort (a cohort description can be found in
the appendix A.5.3.4). We did this for evenly spaced values of k (linspace set) similar
to the WGCNA package and values of k that are spaced evenly on the logarithmic scale
(logscale set) because the correlation coefficient is calculated for values log(k) and the
range is covered more even with the latter set. We repeated this process for exponents
β = {1, . . . , 50} and we plot the results in figure 5.6.
The WGCNA method continues by transforming the adjacency matrix A = (aij) to
the so-called topological overlap of two nodes W = (ωij) by
ωij =
lij + aij
min{ki, kj} + 1 − aij
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Figure 5.6: Absolute value of the Pearson correlations as measure of scalefreeness for
cohort UKDP as described in section 5.6.1.
where lij =
∑︁n
k=1 aikakj and ki =
∑︁n
k=1 aik. To ensure feasibility, this is done for disjoint
submatrices. The resulting dissimilarity matrix (1 − wij) is then used for hierarchical
clustering to assign features to distinct sets, which are referred to as modules. These
modules are viewed as rather independent from external features. The values of the
included features are combined by a weighted average through PCA and doped eigengene.
The DR is the mapping from the original feature expressions to the set of resulting
eigengene values.
We argue that the our DR has some similarity to the modules of the WGCNA method.
In particular, the matrix W in WGCNA aims to measure the connection between two
feature through the capacity of paths (the nominator) connecting the two relative to
the total capacity of paths flowing out of the node (the denominator). A very similar
measure can be calculated if the edge capacities A are interpreted as rates of a flow
between nodes. If the mass on the nodes is distributed by x0 ∈ Rn and the flow is A
units per time, then the mass distribution after time t will be x(t) = x0 · exp(At) [8].
Note that this does not necessarily obey mass conservation and it can involve negative
flow. Negative flow can be interpreted as the consumption of a given feature depending
on the abundance of another feature. This system has stable mass distributions xi, which
means λi(t)xi = xi exp(At) for a scalar λi : R → R. Hence, xi is an eigenvector of exp(At)
and therefore an eigenvector of A. xi is a distribution that only depends on itself and
its propagation through time does not depend on any other pattern in the state of x.
Thus, it could be viewed as an independent eigengene of the system. If A is chosen to be
the covariance matrix, as in our DR, then the components of the PCA are membership
functions for the eigengenes of such a system.
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The so-obtained membership functions take values between −1 and 1, and therefore
do not supply unique assignment of the features to the components. It is, however,
possible to project these membership functions to form a partition of unity with sharp
transitions between components [99, 127] and produce stets that can be compared to the
modules of the WGCNA method.
In summary, we find that the justification for the rather complicated WGCNA al-
gorithm is not very strong. Although adjusting the covariance matrix elements with
exponents and calculating the topological overlap to conclude disjoint sets of genes seems
intuitively appealing, it lacks strong arguments to be beneficial. Additionally, the results
are sensitive to the choice of sub-matrices before calculating the topological overlap, and
hence contain undesirable computational artifacts. Furthermore, suitability, as we de-
fined it, cannot be produced by the WGCNA DR. Because the result is always a discrete
assignment of genes to modules and some genes do not get assigned to any module, the
theoretical reconstruction of expression will always introduce SDE and ID for moduleless
genes. Genes within one module cannot retain any differential expression among one
another and necessarily produce ID. Because of this and the fact that our PCA approach
is simpler and yet performant, we opted against WGCNA.
5.6.2 t-Distributed Stochastic Neighbor Embedding
The t-distributed stochastic neighbor embedding (t-SNE) is a dimensional reduction
technique that aims to visualize high-dimensional data and was first proposed in [75]. It
finds a low-dimension representation of the data that preserves certain distance relations
between point pairs through optimization. It does not, however, produce a transformation
that can be applied to new data points. The only way to embed a new point k into a pre-
constructed low dimensional representation is to optimize its representation in the terms







This calculation requires all of the pairwise distances to the original training data in the
original space pik and the dimensional reduced space qik. Hence, the complete training
data becomes part of the transformation, which is computationally very costly, may not be
differentiable or even continues and has no well-defined inverse. While the transformation
produces very nice visualizations for fixed datasets, it cannot be used in our application
because it requires a quick back and forth transformation between the dimensionally
reduced and the original high dimensions space.
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5.6.3 Diffusion Map
The DR by diffusion maps was introduced by [28]. It uses a proximity measure between












The DR is given by the first k eigenvectors of P t for some t ∈ R+.
Similarly to t-SNE, the DR does not define a diffeomorphism of complete space Ω and
including a new sample in the DR requires the complete dataset and a recalculation of
all eigenvectors. It is theoretically possible to generalize the discrete transition matrix P
into a continuous transition operator with eigenfunctions ϕl : Ω → R that would define
the required diffeomorphism. However, this generalization is not within the scope of this
thesis.
5.6.4 Non-negative Matrix Factorization
If the popular squared error cost function is used, then the objective of Non-negative
Matrix Factorization (NMF) is equivalent to that of PCA, as explained in section 3.2
with the additional constraint that all entries in the transforming matrix W are positive
and there is no centering of the data. This constraint makes sense when we model additive
effects on the expression of genes. No matter how strong a given effect is, it could never
make any expression negative. In contrast, we ensure positivity by the design of our DR,
as explained in section 5.5.
The main reasons why we do not use NMF in our context are as follows:
• It models additive absolute effects on the gene expression (s. section 3.3); that is,
to assume the absolute difference in expression is more meaningful then the relative
difference, which is rarely the case.
• We model the transcriptome as a partition of one because of assumption 1. Modeling
the expression after NMF makes it difficult to fulfill this constraint.
• NFM always requires a numerical optimization with constraints. After the τ−1 ◦ log
transformation, we can apply PCA directly without producing negative expression
values and obtain a DR with positivity much cheaper.
One may argue that the process of finding our DRs involved expensive resampling with
the Dirichlet distribution. However, the PCA does not require this additional processing
and the NMF would profit from this resampling in a similar fashion. Consequently, it is
only fair to compare NMF to PCA directly without the resampling step.
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5.7 Conclusion
In this chapter, we attempted to construct a DR with the least assumption that we could
make. All of the DR methods that we reviewed either make more assumptions, directly
contradict the ones that we are making or do not produce a transformation that we can
invert or apply on new data.
We demonstrated in section 5.1.4 that our DR retains most of the information that
we deem to be relevant. DRs that do not come with an inverse transformation cannot be
tested for on this conservation of information.
Our DR is given through a diffeomorphism, which allows us to transform any PDF
on the gene expression space such that it is given on the reduced space Rk. Additionally,
the transformed PDF has support over the complete Rk. This means that we do not
have to test for any constrains during the later inference process. This makes inference
techniques such as automatic differentiation variational inference applicable. None of the
other DR methods that we reviewed share these essential properties.
Chapter 6
Data for Example Application
In this chapter we will present the data we used for the two example applications. Section
6.1 covers the training data for the inference of cell composition and section 6.3 describes
the prostate carcinoma data on which we applied the deconvolution of expression patterns.
6.1 Immune Cell Data
One part of the deconvolution deals with the tumor composition of immune cells. In
particular, in the course of the Tumor Deconvolution DREAM Challenge [101], we had
to acquire as much publicly available data as possible to learn about typical immune cell
expression patterns. The challenge rules contained two schematics of immune cell type
classes, which had to be deconvoluted. One coarse grain set of seven different, rather
large classes of immune cells that ought to be differentiated and a fine grain list of 14
different cell types. Both set of distinctions are depicted in A.5.1.
The authors of the challenge planned for the competitors to obtain much of their
training data from publicly available expression data of purified immune cells. To give
us a head start, they provided us with an extensive list of potentially beneficial datasets.
It is left to the competitors to obtain, sanitize and combine the data as part of the
challenge.
6.1.1 Provided List of Publicly Available Data
The organizers of the challenge provided a list of studies that potentially featured pub-
lished expression data of specific immune cells. The list is the result of an extensive text
mining in the Simple Omnibus Format in Text (SOFT) files on the Gene Expression
Omnibus (GEO) [12] platform. The authors created a set of regular expressions, which
was matched against multiple data fields of the SOFT files in the GEO database. A
sample that was related with a match and the corresponding study was included in the
list, together with the used regular expression, the associated cell type and the text that
matched the regular expression. This was done for expression microarray and RNA-seq
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(a) The RNA-seq samples. (b) The expression microarray samples.
Figure 6.1: The samples extracted from DREAM challenge GEO dataset list.
data separately. The expression microarray list features 49,319 samples and the RNA-seq
lists 63,640 samples. If a sample is associated with a single cell sequencing experiment,
then it often consists of thousands of different expression vectors with one expression
vector per individually sequenced cell of the same tissue sample.
The provided list associates the tissue samples to cell types that do not necessary
match the cell type groups that ought to be deconvoluted. We then associated the
reported types with the deconvolution classes based on our biological knowledge. The
resulting mapping is documented in A.1.
6.1.2 Obtaining the Publicly Available RNA-seq Data
The RNA-seq data that is hosted by GEO is only partially standardized. While most
of the study and sample description is orderly documented in the SOFT files, the result
of the RNA-seq experiment or the processed expression data is only supplied through
supplementary files and in any format.
We downloaded all of the supplementary files of all of the listed studies. To standardize
the format, we wrote a parsing script in R that recognized the output formats of some well
known software such as HTSeq and other feature counting tools and converted them into
R dataframes. Because the sample names are not standardized, we started to implement
heuristics that would link many naming schemes to entries in the SOFT file and henceforth
to an entry in the list provided by the challenge organizers. We than started to write
study specific parsing routines for the largest studies first and resolved data- or sample-
name parsing problems. In some cases, these specific parsers could be generalized to parse
other studies that adopted a similar format. However, some naming schemes had to be
hardcoded manually. For example, in GSE100576 the sample name WT To 1 stands for
wild type total RNA replicate 1, which could be linked to sample title Total RNA, HSV-1
8h p.i., Rep 1 in the SOFT file after reading in the study summary that all samples are
wild types. A statistic of extractions is depicted in figure 6.1a.
To later unify the data, we also had to map the genomic features for which the
expression was measured to a unified set of features. The DREAM challenge announced
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the two different sets of expression features that they would use for the validation of
submitted deconvolution tools. The first set are the well-defined Ensembl stable gene
IDs [100], without a version tags. The second set are the HUGO gene symbols [17]. We
opted for the latter for the following reasons:
1. A large portion of the publicly available data supplies expression data natively on
this feature set.
2. The responsible HUGO Gene Nomenclature Committee (HGNC) supplies an ex-
tensive mapping definition, which relates most of the existing IDs or naming con-
ventions to an approved HUGO symbol.
3. The main benefit of Ensembl IDs is that they are stable in genomic location. This
stability ensures that the expression of a specific ID relates to the same ID in any
version of the genome. Nevertheless, we can make use of this advantage. If Ensembl
IDs are provided, then we would prefer them over potentially provided gene names
and translate them to HUGO symbol based on the latest published mapping by the
HGNC. In this way, we ensure location stability up to the point of our translation.
4. Using gene symbols makes communication with biology experts much easier, and
allows consultations and quick sanity checks of intermediate results of the deconvo-
lution tool without additional translations. This advantage should not be underes-
timated.
We mapped all o the supplied features to HUGO gene symbols according to the HGNC
mapping provided on their website and only based on the feature names. This results in
an n-to-n mapping with multiple ambiguities. To provide a single expression value for
each HUGO symbol, we summed the expression of all of the features that were mapped
to the same HUGO symbol and logged the following ambiguities per HUGO symbol and
dataset:
1. Number of features in the dataset mapping to the same HUGO symbol.
2. Minimum number of missing expression values for a feature in the dataset that was
mapped to the HUGO symbol.
3. Maximum number of HUGO symbols that a mapped feature was mapped to.
4. Number of samples for which no expression could be calculated after the mapping
(number of NAs).
A dataset is the collection of all of the expression vectors of a study that were associated
with a cell type set, which ought to be deconvoluted as listed in A.5.1. This was done
for the coarse and fine grain challenge. The logged ambiguities will be used later on in a
quality score that we used to unify the data.
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6.1.3 Obtaining the Publicly Available Expression Microarray
Data
The format of expression microarray hosted by GEO is standardized through the SOFT
format. However, different microarray platforms measure expression of different probes
or genomic regions. We used the R package GEOquery to download the study specific
expression data and import it with the expression matrix, phenotypic and genomic fea-
ture data into a convenient R object. To map any set of expression microarray features,
we employed the GEOmetadb R package to query the appropriate Bioconductor Anno-
tationDbi [90] package from the GEO metadata for the, respectively, used microarray
platform. Any required AnnotationDbi packages were installed on the fly and used to
map any set of features to HUGO gene symbols. Similarly to the RNA-seq case, we kept
track of the same n-to-n mapping ambiguities, even now here we have an n-to-1-mapping
that simply results in less ambiguities.
Mapping sample names is not an issue for the microarray datasets due to the stan-
dardized format.
The resulting extraction statistics are depicted in 6.1b.
6.1.4 Data Sanitization
As announced by the challenge organizers, sanitization of the supplied training data will
most likely enhance the training result and is hence part of the challenge. While we will
later employ some automatic sanitization based on the expression patterns, the first step
of our sanitization is a coarse evaluation of the cell expression data quality. The text
mining approach to collect the datasets was highly sensitive and we could rarely find
any publicly available dataset that was not covered by the list. However, the list also
features many studies that published expression data of only strongly modified immune
cells or only mention an immune cell type in the description while supplying only vaguely
related results. In most scenarios, it is indispensable to read the publication related to the
GEO dataset when using the data for any study. In our case, however, the sheer amount
of datasets and related studies make this common approach infeasible. Nevertheless,
superficial manual filtering of the data to remove the coarsest outliers should be beneficial.
Consequently, we focused on the data description, which can be found in the SOFT file
associated with the study. The SOFT file comes with a study abstract, descriptions of
the sample, data processing and other sample characteristics that help us to understand
what kind of sample was analyzed. This information could be condensed into a few tags
that are relevant for the applicability of the data for the study at hand and potentially for
other studies to follow. To reduce the hurdles that come with such a tagging approach,
we developed a small interactive software tool that automates as much of the process as
possible.
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6.1.4.1 A Tagging Tool
To speed up the process of tagging all of the training samples, we developed a software
tool that we refer to as geotag [88]. There are a view characteristics that we deem to
be relevant to decide whether to include a certain sample in one of our studies. The
tool should allow us to note these characteristics quickly with as little user interaction
as possible. It should also be simple to open the relevant SOFT file, display the relevant
section and allow easy navigation to read additional details. Because the tool requires
access to around 100 GB of SOFT files, it should run on a headless server that has
sufficient resources. Other desired features that are not strictly required but help to
improve the process are:
1. Allow to display any custom data table with custom columns that help to tag a
samples/rows.
2. Filter data rows based on regular expressions.
3. Custom sorting and organization of columns.
4. Tag-based line coloring for better overview and feedback to prevent mistakes.
5. Allow adjustment of tag definitions.
6. Allow creation of new tags that are shared between all users.
7. Search the data table with regular expressions.
8. Self-contained help to show the user all features without the need to read a manual.
9. Undo/redo ability.
10. Automatic backups that do not accumulate indefinitely.
11. Select, show and tag multiple samples/rows simultaneously.
12. Allow to make notes per sample/row.
13. Quick and easy navigation.
14. Log all tag relevant user interactions.
15. Save the results automatically and in a human readable format.
16. Save last state upon exit to allow the work to continue where it was left off upon
restart.
17. Allow the user to modify the sample list to attach additional columns.
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We resorted to the Python 3 Curses module to implement an Ncurses based user
interface conveniently in Python. Because curses runs on the command line, we also made
use of the tmux software to display and organize the opened SOFT files with the paging
tool less and within the same window. While a web-browser based user interface certainly
was an option, it is likely that it would have required more work to produce the graphical
interface and to piece software together that would allow the desired interactivity.
The resulting tool has all of the required and proposed features. It saves the tags as
yaml files on a per user basis. The tag definitions are distributed through a central tag
yaml file and backed up in the per user tag files. The current state of the program is
saved as a serialized Python dictionary object that can be ignored and overwritten upon
user choice to allow a restart upon corruption of the file through a software error or after
an update of the tool. We also log all tagging processes and reorganization steps of the
data table incrementally in a text log file together with the date and time of the action.
This may help to troubleshoot incomprehensible results.
The tool was distributed within our working group, such that most members could
participate in the tagging process.
6.1.4.2 Tagging Results
During the tagging process, multiple tag classes were established to track relevant in-
formation of each sample (e.g. the quality of annotation, patient health status and
treatment). Although this information will help to select datasets for other studies, they
do not play a role in this work. Here, we focused on the two predefined tags, which are
a note and the quality of the sample with respect to the application. Because we want
to learn typical expression patterns of the annotated cell type, a potentially modified
cell should be tagged with lower quality then a pure native sample. The tagging tool
allowed us to give the tag quality an integer value between 0 and 9. Before we started to
assign values to the samples, we agreed on some predefined values, as shown in table 6.1.
Note that not all of the values are predefined but instead were used to tag intermediate
samples. For example, slightly stressed samples would receive a 7 instead of a 6, and pure
samples that may not be isolated at utmost care may received an 8 a 9.
Over the course of a week, many samples were tagged and the sample list was extended
with additional columns that list text mining results from the SOFT files (e.g. sample
title or sample characteristics). This further sped up the tagging process. Because we
mostly tagged independent from one another, we decided to go through the samples at
a random order. Consequently, many samples were tagged as at least ones and when
the coverage reached a substantial share of the data the same samples became tagged by
multiple users, which allowed us to validate the consistency (s. figure 6.2c) and improve
the tag quality by aggregating the tags across all users. The most common discrepancy
that occurred was when someone who was not a user recognized a certain flaw of the
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quality value description
0 unrelated or no data
1 bad sample
2 bad annotation but potentially useful data
3 mixture of different cell types
4 modified cells (e.g. knock-down or spike-in)
6 stressed cells
9 perfectly pure and unmodified cells
Table 6.1: Predefined quality values to be tagged accordingly.
tagged dataset. This led us to aggregate the values by taking the smallest quality value
that someone assigned to it. Only the following samples were corrected to a higher quality
value manually:
• Some samples marked as GCB (germinal center B-cells) were tagged very low prob-
ably due to the unexpected naming.
• Studies GSE73502, GSE73765, GSE87849 and GSE9482 were tagged very low en-
tirely because cells were heavily modified but some wild type samples included as
a control were overlooked.
The complete results of the tagging project are summarized in figure 6.2.
6.1.4.3 Automatic Sanitization
In some cases, data hosted on GEO can be labeled incorrectly or the treatment of the
samples can differ so drastically that the measured expression patterns cannot be used.
However, because we extracted data from many studies, we can compare the measure-
ments and identify notable inconsistencies. We use the confusion matrix in figure 5.5 to
mark a sample inconsistent if its classification does not match its original label. Based
on this information, we can remove samples before relearning the cell type characteristic.
However, this approach introduces a bias towards lower variance in the cell-type char-
acteristic and an overly extensive removal of inconsistent samples could deteriorate the
deconvolution. To limit this bias, we only exclude complete studies that contain more
inconsistent than consistent samples. Most notably, we excluded
• GSE79706 (56 samples), mostly labeled as monocytes and classified as macrophages.
• GSE41914 (96 samples), all labeled as NK-Cells and classified differently.
• GSE116672 (6865 samples), all its samples are classified as monocytes and a spe-
cialized viscRNA-sequencing protocol was used.
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(a) The number of quality tags given by to
one sample by different team members.
(b) The distribution of the mean quality
tagged per sample.
(c) A histogram on the standard deviation of
quality tags per sample.
(d) The distribution of the minimal quality
values tagged per sample.
Figure 6.2: Descriptive statistics of the quality values tagged to the immune cell samples
from the GEO database by our team.
• GSE66360 (99 samples), where most labeled endothelial cells are classified as CD4-
T-cells.
• GSE31312 (496 samples), where most labeled GC-B-cells are classified as endothelial
cells.
We also attempted to use classification based on clusters after a t-SNE dimensional
reduction to remove wrongly labeled data. However, t-SNE did not work well for the
heterogeneous data, even after initialization with PCA. A sample t-SNE visualization is
depicted in appendix A.5.2.
6.1.5 Data Unification
Because our approach of deconvolution aims to incorporate any multivariate relations of
gene expressions, it is vital for the training data to report the expression of all genomic
features that are included into our model. Therefore, samples that do not report all of
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the required features have to be excluded and we have to be careful about which set of
features we require for our study. We want to retain as many features as possible, and
especially highly relevant genes, while we have to be attentive not to exclude too many
samples through the selection. However, it is not critical to make an optimal choice here.
The selection of considered datasets, as well of the selection of measured features per
dataset, is subject to many random processes. We cannot make any requirements of the
completness of the selections. Instead, the algorithm can only attempt to do as well as
possible given the available data. Choosing a suboptimal selection of features will lessen
the power of the later inference. However, if the selection is ”just good enough”, then it
allows us to retain a couple of thousand features and few hundred samples per cell type,
and then the selection will suffice to demonstrate the application of the deconvolution
algorithm. However, deducing an optimal data unification process is not within the scope
of this thesis.
6.1.5.1 Feature Mapping
As discussed in sections 6.1.2 and 6.1.3, we mapped all o the measured features to the
set of HUGO genes, aggregated the expression values per gene and kept track of any
ambiguities of the mapping. The captured ambiguity information will be relevant in the
next section.
6.1.5.2 Feature Selection
It appears to be sensible to maximize the Shannon entropy of the data resulting from the
feature selection. The Shannon entropy is strongly related to the concept of information
content and it is used to quantify data [107]. If our dataset is represented by a matrix
X ∈ Rn×N with the elements xij representing the expression of feature i ∈ F = {1 . . . n}







where pij(xij) is the probability to observe the value xij for feature i and sample j. For the
sake of simplicity and computational feasibility we will assume rather uniform probability
for all values, sample and feature plus some heuristics to give more weight to the more
relevant data. We call wij := −pij(xij) log ◦pij(xij) the weight of the expression value xij.







where F (S) = {j ∈ F|∀i ∈ S : xij is measured} is the set of all samples, for which all fea-
tures in S are measured. Assuming a completely uniform distribution across all observed
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expression values yields wij = c ∈ R. We want to find a feature set S that maximizes
H(S). Because a constant factor to H(S) does not change the maximum, we can choose
c = 1 without effecting the result. However, not all o the features and samples come
with equal value to the deconvolution algorithm. There are three factors, making a given
expression more or less valuable:
1. The feature is known to carry relevant information about immune cells.
2. Mapping the measured features to a HUGO gene was ambiguous.
3. The sample is the result of an RNAseq or expression array experiment.
We start with ŵij = 1. To decide whether a gene is known to be relevant, we extracted
782 HUGO genes from The Cancer Immunome Atlas (TCIA) [21]. Genes listed by TCIA
were found to be differentially expressed in certain immune cells. If the feature i is the
list of extracted genes, then we increment ŵij by one. To reflect the ambiguity of the
feature mapping, we increment ŵij by another 1, if at least one of the measured features
was mapped to i and none of the mapped features was mapped ambiguously. Finally, if
the measurement experiment was an RNA sequencing experiment, then we double the
value of ŵij. The resulting weights are listed in table 6.2.
feature criteria expression array RNAseq
measured 1 2
listed in TCIA 2 4
unambiguous 2 4
unambiguous & listed in TCIA 4 8
Table 6.2: Values of ŵij based on criteria on the sample (columns) and feature (row).
While our approximation of H(S) is now defined for the complete dataset, optimizing
it directly would not yield the desired result. The issue is that we need to retain samples of
all of the considered cell types. Blindly optimizing S may result in a feature selection that
completely exclude samples of a certain kind. Instead, we calculate the approximation of







where Ft(S) = {j ∈ F (S)|j is of cell type t}. Because an inadequate characterization
of a single cell type could deteriorate the accuracy of the complete deconvolution, we
decided that the goal function of the optimization should mostly be determined by the
cell type with the smallest Ĥ t(S), while other cell types should not be ignored entirely.
We make use of the softmax function to aggregate the approximate entropies of all of the
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cell types. The softmax function is a smooth approximation of the maximum function on
a vector. If a value within the vector approaches its own maximum, then it starts to gain
impact on the result of the function, and hence relevance in the optimization process.
We define our score function to be
G(S) := − log(| exp[−λ(Ht(S))t∈T]|1).
λ scales the absolute differences between values in (Ht(S))t∈T and hence the smoothness
of the function. Setting λ = 1 will keep the impact of values other than the maximum
very small. We chose λ = 110 based on the experience that cell types with small sample
size are protected, while larger datasets are still taken into account.
Because blindly testing all possible S would need n! iterations, we needed to develop
another approach. Due to the unsimplifiable behavior of Ft, we conjecture that finding
the actual optimum is NP-hard. Consequently, we opted for a discrete gradient based
greedy algorithm to find an approximation. As discussed in section 6.1.5, it is not vital
for this step to find the actual optimum, it only needs to perform ”good enough.”
∆sG(S) := G(S ∪ {s}) −G(S) the score difference through adding a feature s can be
calculated quickly for all possible s. The reason for this is that Ft(S ∪ {s}) is a subset of
Ft(S) and so the terms ŵj :=
∑︁
i∈S ŵij only need to be calculate once for all j ∈ Ft(S)
and




Due to time constraints, this leads us to start with S0 = ∅ and we only consider adding
features. This has two additional advantages:
1. We can keep adding features, even when ∆sG(S) becomes negative, and we can
overcome some local minima.
2. When we add the feature s, we can also add all features r with Ft(S ∪ {s}) ⊂
Ft(S ∪ {r}) in the same iteration because this strictly increases the score.
We let f(S) = arg maxs∈F ∆sG(S) and f(S)∗ = {r ∈ F|Ft(S ∪ {f(S)}) ⊂ Ft(S ∪ {r})}
then
Si+1 = Si ∪ f(Si)∗.
We kept iterating until Si = F, plotted the partial and total scores in figure 6.3 and
selected the feature sets with the largest total scores as our final selections. Subplots 6.3a
and 6.3b show how the smallest partial score is almost strictly increasing while especially
larger scores are allowed to deteriorate as long as they do not become critically low. The
total scores in 6.3c and 6.3d exhibit small dips before they assume their global maximum.
Although we cannot exactly quantify the data or how well we approximate an optimal
features selection, we do find a large feature set that is shared in a substantial part of
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(d) Total score and feature count for the fine
grain distinction.
Figure 6.3: Score development during iterations of the feature selection process for the
coarse and fine grain distinction of cell types.
the available samples, especially for the cell type with the fewest representatives. For
the coarse grain distinction, the selected feature set has 12,157 HUGO genes with 668 of
the 782 TCIA genes. In the fine grain distinction, we selected 16747 HUGO genes that
cover 730 TCIA genes. The numbers of samples that were available after the selection
and tagging steps are listed in tables and 6.3 and 6.4. The tables also feature the count
of sane samples that remain after the quality filter, feature selection and an additional
automatic sanitation step.
6.2 Examples of Mixtures with Gold Standard
To rate the quality of deconvolution for the DREAM challenge, the organizers provided
transcriptome expression data of tissue samples for which the composition of the listed
immune cells (A.3 and A.4) is known. The data was released in the course of the three
leaderboard rounds that served as a testing phase for the competitors. While each dataset
is annotated with characteristics such as cancer type, measurement platform, scale and
normalization, it is not entirely clear which datasets were obtained through direct mea-
surement and which are generated in-silico after measuring the expression pattern of
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cell type total good all features sane
B cells 76943 73902 96.0% 16644 21.6% 10323 13.4%
CD4 T cells 12278 11776 95.9% 2075 16.9% 1958 15.9%
CD8 T cells 20388 20388 100.0% 1270 6.2% 1241 6.1%
endothelial cells 19106 19006 99.5% 2416 12.6% 2053 10.7%
fibroblast 11197 7861 70.2% 3142 28.1% 2768 24.7%
monocytic lineage 32822 28661 87.3% 8302 25.3% 4379 13.3%
neutrophils 1156 1137 98.4% 879 76.0% 667 57.7%
NK cells 14172 13049 92.1% 2154 15.2% 366 2.6%
Table 6.3: Absolute count and relative percentage of available samples after different
features selection and filtering for the coarse grain distinction. The column good counts
samples that were not sorted out due to bad quality or other issues. The column all
features contains all of the samples that have all selected features, even if they were not
considered during the feature selection process. The column sane counts good samples
that have all of the features and were not filtered out after the automatic sanitization
6.1.4.3 step.
cell type total good all features sane
endothelial cells 19106 18907 99.0% 1853 9.7% 1741 9.1%
fibroblasts 11197 7861 70.2% 2143 19.1% 1998 17.8%
macrophages 9829 9439 96.0% 1515 15.4% 1278 13.0%
memory B cells 124 124 100.0% 73 58.9% 45 36.3%
memory CD4 T cells 874 844 96.6% 116 13.3% 116 13.3%
memory CD8 T cells 42 42 100.0% 42 100.0% 42 100.0%
monocytes 19814 16296 82.2% 4799 24.2% 4790 24.2%
myeloid dendritic cells 3179 2926 92.0% 894 28.1% 888 27.9%
naive B cells 209 209 100.0% 121 57.9% 97 46.4%
naive CD4 T cells 2502 2502 100.0% 255 10.2% 255 10.2%
naive CD8 T cells 14683 14683 100.0% 44 0.3% 44 0.3%
neutrophils 1156 1137 98.4% 698 60.4% 499 43.2%
NK cells 14172 13049 92.1% 1775 12.5% 1336 9.4%
regulatory T cells 799 785 98.2% 225 28.2% 188 23.5%
Table 6.4: Equivalent to table 6.3 for the fine grain distinction.
the constituent cell types separately. To our disadvantage, most expression data comes
from expression array measurement platforms and all RNA-seq expression data is TPM-
normalized.
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6.2.1 Expression Microarray Data
The mechanics of expression arrays contradict the assumptions that we made about the
uncertainty of the expression data in section 4.3.1. Each spot on an expression array
consists out of a finite number of probes and the experiment o whether an individual
probe is bound by a template is also a Bernoulli experiment. However, in contrast to
the multinomial distribution, we inferred for the RNA-seq measurements that the distri-
bution of feature specific measurements in expression arrays are independent from each
other. Only the spot-wise fluorescence saturation can be deduced to follow a binomial
distribution for finitely many probes or a beta distribution if the number of probes is
assumed to be too large to be assessed individually. To apply our model and the multi-
nomial distribution, the expression array expression vector has to be mapped to Nn with
a guessed sequencing depth that may best approximate the true uncertainty.
Because the final application of the deconvolution algorithm is meant to be RNA-seq
data, we did not analyze the true uncertainty of expression array data. We only shifted
the expression vector to be positive and rescaled it to a simulated sequencing depth of
5 · 107, which produced reasonable results.
6.2.2 Normalized Expression
Another issue with the data is the fact that it is TPM-normalized, which may distort the
expression values in an unaccounted way and occludes the true sequencing depth. This
makes it impossible to accurately infer the measurement uncertainty. It is theoretically
possible to recover the measurement uncertainty if at least the original total read count
is known but upon request this information or the raw RNA-seq counts could not be
supplied by the organizers. We used the normalized expression vectors with an implicitly
assumed sequencing depth of 106 and hence we overestimate the measurement uncertainty
to account for possible unexplained distortion.
Generally, the measurements presented are not in Nn and the multinomial distribution
cannot be applied directly. We experimented with rounding the data but this results in
some loss of information, especially in the weakly expressed genes. Instead, we used the
Dirichlet distribution that is inferred in section 4.3.1 as a potential of the transcriptome
compositions. This can easily be generalized to real numbered expression measurements
and is exactly equivalent to the assumption of multinomially distributed measurements
for integer values.
Expression values for each sample are given for selected Ensembl gene IDs and HUGO
gene symbols. As stated in section 6.1.2, we opted to work with the latter. However, the
feature set for which expression is reported does not usually coincide with the features
selected for training. To use the cell type specific EPDs for the inference in 7.1, we
marginalize the distribution to the subspace spanned by the intersection of features.
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This is done rather trivially by removing the corresponding columns and rows in the
matrix multiplications of the DR computed in 5.4.5.
6.2.3 Composition of the Gold Standard
The gold standard of the composition vector α̃ is provided with unknown units, which
are within the unit interval for some cohorts or attain values up to 400. It is only known
that the coefficient α̃i correlates with the amount of cell type i. Whether this is the
RNA-mass, cell biomass or the cell count is not disclosed. To evaluate the quality of an
estimate α̂, one correlation coefficient for each cell type i within a cohort is calculated.
Because the unit is unknown and given that the values of α cannot be expected to
be normally distributed, we use the Spearman correlation coefficient and the Pearson
correlation coefficient after taking the logarithm. The organizer announced that the
Pearson correlation coefficient will be the primary measure to determine the rank of the
competitors. It is unclear, however, if a logarithm is calculated prior to the correlation.
6.3 Tumor Expression Data
To demonstrate an example application o the deconvolution of expression patterns, we
used RNA-seq data of from human prostate carcinoma tissue samples of multiple cohorts.
We recently published the study “ProstaTrend - A Multivariable Prognostic RNA
Expression Score for Aggressive Prostate Cancer” [65], for which we composed gene ex-
pression data from four RNA-seq and one expression array cohort. Three of the RNA-seq
cohorts are radical prostatectomies samples (UKD1, UKD4 and TCGA-PRAD-US) and
one comes from needle core biopsy (OSR1). UKD1 and TCGA-PRAD-US are fresh frozen
tissue while UKD4 and OSR1 were formalin fixed paraffin embedded. Samples of ques-
tionable quality were excluded and the genomic features were filtered based on minimal
expression. Details can be found in A.5.3.
We also used another exclusive cohort UKDP to assemble enough samples for our
approach. This new cohort has particularly low tumor cell content per sample, and
hence poses an interesting subject for our deconvolution method.
We present an overview of the cohort characteristics in table 6.5.
6.3.1 Tumor Content
Because we have to infer the tumor and non-tumor specific EPDs during the actual de-
convolution, it is essential to use an estimate of the actual tumor content of the sequenced
samples to guide the model.
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cohort tumors TCC source fixation event data events
UKD1 (n=64) 40 77.5 [71.9 - 83.1] % RP fresh frozen DoD (64) 21
UKD4 (n=14) 14 80.0 [72.5 - 90.0] % RP FFPE DoD (14) 7
UKDP (n=285) 185 40.0 [20.0 - 60.0] % biopsy FFPE BCR (183) 79
OSR1 (n=71) 71 55.0 [32.5 - 87.5] % biopsy FFPE DoD (71) 16
OSR2 (n=32) 32 40.0 [30.0 - 70.0] % biopsy FFPE BCR (13) 4
PRAD-US (n=534) 390 70.0 [60.0 - 80.0] % RP fresh frozen BCR (467) 61
Table 6.5: Characteristics of prostate carcinoma cohorts used for the expression pattern
deconvolution application. The column event data indicates the type of the events
and the number of cases for which we have data. Possible events are “death of disease”
(DoD) and “biochemical recurrence” (BCR). RP is radical prostatectomy and FFPE
is formalin-fixed paraffin-embedded tissue. TCC is the median [upper quartile - lower
quartile] tumor cell content within the tumor samples of the cohort.
As discussed in section 4.2, the tumor content estimate coming from the pathologist
gives rise to a probability distribution for the fraction of RNA that originated from the
tumor cells. The PDF will be used in the inference.
6.4 Benchmark Reference Study
To benchmark our deconvolution approach, we want to compare the result to a state-of-
the-art marker discover study that we conducted to identify prostate carcinoma markers
related to the aggressiveness of the carcinoma [65]. The marker study illustrates a well
accepted approach to identify marker genes and establishes a hazard prediction model
form the marker expression levels. This approach employs a stack of software tools to
attain the model through different processing steps.
To evaluate the quality of the Bayesian survival analysis and hazard prediction model
that we will infer in this thesis, we reproduce the method of the paper to the data that
is available now. Then we compare the results of the two methods. We briefly discuss
the methodology in the current context here and list details about the data processing in
the appendix A.5.3.4.
6.4.1 Methodology
Because we do not deviate from the original primary data analysis, which follows a well-
established procedure, and because the data mostly remains the same, we refer the reader
to the appendix A.5.3.4 for details on the used cohorts.
For the marker assessment, we employed a custom reference genome annotation that
combined a current GENCODE [39] annotation with do novo assembled transcripts from
reads of the UKD1 cohort. To mediate the multiple testing problem [47], we removed very
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weak marker candidates and only accessed the 42,809 (20%) genes with the highest aver-
age expression in cohort UKD1 and UKD4. The gene expression counts were transformed
with the DeSeq2 variance stabilization to elevate the variance to mean dependency and
make the data suitable for statistical evaluations that assumes an approximate Gaussian
distribution of the input. However, this stabilization method, as discussed in 4.3.4, is in-
eligible for single samples or multiple cohorts because processing batch effects can distort
the result and was applied cohort-wise. For each cohort, we centered the gene-wise ex-
pression distribution around 0 and rescaled it to a standard deviation of 1 to improve the
comparability between the cohorts. We then applied a gene-wise Cox-regression [31], and
combined the resulting hazard ratios and p-values with the R-package meta [11] across
cohorts. To select an appropriate marker set, we calculated the tail based false discovery
rate for each p-value with the R-package fdrtool [111] and chose a cut-off such that the
fraction of false positives in the resulting marker set does not exceed 5%. The hazard
function of the Cox regression implies a weak expression based predictor for the hazard
per gene. We combined all of the predictors of the maker set with a bagging approach
by using the median of all of the weak predictors to produce the final strong predictor.
In his thesis, Maximilian Joas [54] demonstrated that the prediction quality cannot
easily be improved substantially through the application of other prediction models, so
we consider the result a “best afford without deconvolution.”
Our study conveniently splits up the problem of finding a good predictor into multiple
steps and then applies well-established tools to solve them individually. In this thesis,
we instead describe a direct probabilistic dependency between the raw gene counts, the
phenotypic data, and the parameters of the Cox hazard function to infer the predictor
directly.
6.4.2 Reproduction
The inference in this thesis was done with the cohorts used in the paper [65] but without
the expression microarray cohort (UKD2) and with two additional cohorts (OSR2 and
TCGC PRAD-US) that were used as training data. To compare the performance of
the two methods—paper and thesis—without a bias due to different training data, we
reproduce the study of the paper with the same cohorts that we use in the inference.
Note that the cohort specific Cox regression were conducted with different end points.
For cohorts UKD1, UKD4, we used DoD and for all of the other cohorts BCR defines the
event rate that we regress to.
It may seem concerning to exclude the expression microarray cohort, which contains a
substantial amount of available samples. However, the exclusion of this data did improve
the accuracy of the resulting hazard predictor.
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6.4.3 Reference Hazard Model
To evaluate the quality of the result, we apply the hazard prediction on an independent
testing cohort. While we previously showed that the model performs well for samples of
medium to high tumor cell content, in this these we want to demonstrate the performance
gain through deconvolution; specifically for samples of low tumor content. Thus, we
introduce the cohort UKDP, with samples of medium to low tumor cell content to compare
the prediction quality of our state of the art approach to the hazard prediction of the
model introduced in this thesis.
The appeal of the result is the accuracy when predicting the hazardousness of the
prostate carcinoma. A proxy to assess this accuracy is to compare the hazard score
with the rate of biochemical recurrence (BCR) in the patients after total prostatectomy
because this frequently indicates a persistence of the cancer. If BCR is detected in
the follow-up time after the ectomy, then the date is marked as event. To evaluate the
prediction score, the order of its values among patients is compared to the order of events.
Note that it suffices to known an event date for one patient: as long as the other patient
did not have an event until that date, then we know that his event must come later (even
if the BCR never occurs for him). The percentage of patient pairs for which the two
orders are identical is the concordance index and is one central metric for the accuracy
of the score. The reproduced prediction model of [65] achieves a concordance index of
64.23%. Note that including the array cohort UKD2 into the training data reduces the
prediction accuracy in UKDP down to a concordance index of 60.50%. We conjecture
that this deterioration comes from the different measurement platforms (microarray vs.
RNA-seq) and end points (DoD vs. BCR) between UKD2 and UKDP.
A Cox regression from the prediction score to the event rate in UKDP concludes with
a p-value of 1.49e−5 for the resulting hazard ratio, and hence demonstrates a highly
significant association of the prediction score with the rate of events. To present a visu-
alization of the result, we split the cohort into two equally sized groups with higher and
lower score. We then plot the respective Kaplan-Meier estimators [58] with Greenwood
confidence intervals [103] in figure 6.4.
We want to remind the reader that this is not an evaluation of the original ProsaTrend
score of [65] but instead a reproduction of the method on a different set of training cohorts
as explained in section 6.4.2.
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Figure 6.4: Kaplan-Meier estimators for two halves of the UKDP cohort with the reference
prediction score above the median (High Hazard) and below the median (Low Hazard)
with estimates of the 90% confidence intervals.
Chapter 7
Bayesian Models in Example
Applications
The previous chapters aimed to lay the ground work for the inference process that will
now be discussed. Each individual part of the Bayesian model that we use in the inference
has been explained and now comes together in a Bayesian network, linking assumptions,
prior knowledge and data in a computationally feasible way.
We start with a general abstract model, which we will refine for specific applications
in the following sections. We will then apply different computational inference techniques
and present some results.
All of the probabilistic models that we use for deconvolution are refinements of the
model depicted in figure 7.1. Depending on the application, we use different distributions
or even model the distributions of the coefficients σt if their exact values are unknown.
An exact parametrization of the tissue specific EPDs T is unknown. Therefore, we
resort to the general approximation through a Gaussian mixture model, as discussed in
section 4.4.3. This allows us to approximate any tissue specific EPD.
7.1 Inference of Cell Composition
In this section we will describe the model we used for the DREAM Challenge. The goal
is to infer reliable mixture coefficients α ∈ ∆T −1 for a set of T cell types as in assumption
1, without the need for an exact cell type specific expression pattern.
Recall that computational resources are limited in this application because the chal-
lenge only allows for 4 GB and a total of 2 days computation time on 4 CPUs. For the
whole cohort, this results in 1 GB memory and about 30 CPU-minutes per individually
processed sample.
The model can drastically be simplified from 7.2. We can relax the detail of modeling
expression patterns and focus mostly on the differences in expression between different
cell types. Additionally, the cell type specific EPDs TL(σt) can be trained prior to the
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xt ∼ TL(σt), xt ∈ ∆n−1
λ ∼ D(α), λ ∈ ∆T −1
p = ∑︁t∈T λtxt
x ∼ Multinomial(p, k)
Figure 7.1: The general model for a set of tissue types T = {1, . . . , T} and sequencing
depth k ∈ N. TL is the prior EPD with a Gaussian mixture PDF of L kernels as in (4.17).
The distribution D(α), the prior for the composition vector λ, is usually a Dirichlet
distribution and α = 1.
deconvolution with purified cell samples. This allows us to run the inference for each
sample independently because only sample specific parameters remain to be computed.
7.1.1 The Expression Pattern Distributions (EPDs)
The cell type specific EPDs have been inferred in section 5.4.5, where we concluded that
a transcriptome composition x ∈ ∆n−1 is implied through the distribution
A0B ◦ τ−1 ◦ log(x) ∼ N (A0Bµt, A0BΣtB−1AT0 ). (7.1)
However, this leaves the distribution of τ−1 ◦ log(x) with 0 variance along the co-space
of A0B and restricts possible x to a T − 1 dimensional manifold in ∆n−1. Given that
it is not easy to deduce the implications of this restriction on the inference and we do
not want to make additional assumptions, we relaxed it by sampling from the co-space
independently, as follows:
Let Xt = τ−1 ◦ log(X̂ t), where the k columns of X̂ t ∈ Rn×k are the transcriptome
compositions for samples of the cell type t. Then, Yt := Xt(I − B−1AT0A0B) only varies
along the co-space and we can calculate mean µti and standard deviation σti for all features
i ∈ {1, . . . , n}. This can be used to sample a univariate reminder yti ∼ N (µti, σti) that is
projected to the co-space and added to the sample of (7.1) to produce a random variable
with a full rank covariance matrix. The combined distribution models the cell type
specific EPDs in the full space, while the covariance of genes is only modeled along the
subspace spanned by A0B.
Note that because we chose A0 to be spanned by the cell type specific means, the
univariate means of the co-space µti are 0. We only include the parameter µti in the model
to allow for other choices of projections A0B.
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7.1.2 The Complete Model
The complete model can be described with
x′t ∼ N (A0Bµt, A0BΣtB−1AT0 ), x′t ∈ RT −1, A0B ∈ R(T −1)×n (7.2)
yt ∼ N (µt,σt), yt,µt,σt ∈ Rn (7.3)
xt = yt +B−1AT0 (x′t − A0Byt), xt ∈ Rn (7.4)




αt exp ◦τ(xt) (7.6)
x ∼ Multinomial(p, |x|1), x ∈ Nn,p ∈ ∆n−1 (7.7)
where x is the raw gene count vector for the sample. As already stated in section 6.2,
we had to deal with real valued expression vectors x ∈ Rn instead of integer counts. To
achieve this, we replaced (7.7) with
p ∼ Dirichlet(x + 1).
This is a generalization because the model is equivalent if x ∈ Nn but also defined if
x ∈ Rn.
In another version of the model we do not infer (7.3), which models the divergence
from the set yt = 0 and use





instead of the raw x, which is the reconstruction of x from its dimensionally reduced
Dirichlet expected value. While this trick does not truly eliminate all of the variance
of the cell type specific expression vectors along the co-space, it drastically reduces the
parameter space and computational cost of the inference. The results of both models only
differ slightly but we opted for the trick because the latter often had a slight edge on the
former. Apart from the simplification, the improvement through the reconstruction trick
may also be explained by the fact that it removes potential variations from processing
batch effects that have not been observed in the data and can hence not be explained
well by (7.3).
7.1.3 Start Values
All of the inference algorithms that we used require an initial value for the random
variables that are to be inferred. We chose to initialize the cell type specific transcriptome
composition by the projection of the log-transformed Dirichlet expected value of the raw
expression vector
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and the deviation, if not set to 0, through the projection on the co-space






The composition vector is trivially initiated with α0 = 1/T . This choice of start values
states that each cell type assumes the same expression, which coincides with the expected
value of the Dirichlet distribution from the measurement, and the sample consists of all
cell types in equal parts.
7.1.4 Resource Limits
As stated earlier, CPU-time and memory available for the deconvolution are limited
within the DREAM challenge.
The memory limitation of 1 GB per sample is not an issue. The memory demand for
inference by ADVI (s. section 3.5.2) grows with O(n · T + T 3), where n is the number
of features and T the number of considered cell types. The contributions come from
the dimensional reduction matrix A0B ∈ Rn×(T −1) and the T covariance matrices of the
cell type specific EPDs Σt ∈ R(T −1)×(T −1). With less then 105 features in the training
data, the matrices could consume 10 B per number. Meanwhile, we have still only used
around 10 % of the memory, which leaves enough space for multiple copies in the inference
algorithm. We tested the algorithms in a docker container with the same constraints and
we rarely consumed more than 400 MB per thread.
A more pressing limitation is the time constraint: 2 days on 4 CPUs for up to 500 sam-
ples leaves us with 28.8 minutes per sample. As a comparison, a full sampling inference
for an arbitrary posterior could easily run as long as a week, even for efficient Hamilton
sampling (s. section 3.5.1). We will resort to variational inference to be able to produce
results within the constraint but time is the main limitation to the inference accuracy,
and hence is the resource that we need to exhaust fully. Therefore, we implemented a
mechanism in our algorithm that considers stopping the iterative inference process after
every 100 iterations and then writing the intermediate result. With usually roughly 25
iterations per second, the consideration is done about every fourth second. To decide
whether or not the inference should stop, it reads the number of unfinished samples r
and remaining time minus a 30 minute buffer t at the start. To calculate a time-limit for
the current sample, the given inference runs on four cores: t/⌈r/4⌉ where ⌈·⌉ rounds up.
It then uses the estimate time per iteration from the last 100 iterations to gauge whether
the next 100 iterations can be done within the time-limit for the current sample. If that
is not the case, then the inference is stopped and the results saved to file. Therefore,
the probability for a sample to overshoot its limit is about 50 %, which ensures a rather
fair split of the available time over all samples. Additionally, if an early sample finishes
before reaching its time-limit, then later samples can to run longer.
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7.2 Deconvolution of Expression Patterns
This section discusses a specific application of the model. For this application, we want
to optimize the reconstruction of expression patterns coming from tumor cells when we
only have measurements from a mixture of tissues that also contain non-tumor cells. To
keep it simple, we consider only two types of tissues: T = {tumor, and non-tumor}. The
tissue type specific EPDs TL will be chosen to be as complex as computationally feasible.
All of the possible expression patterns of tumor free cell mixtures have to be explained
with the distribution TL(θnon-tumor) and the heterogeneity of possible tumor cell expression
patterns must be covered with TL(θtumor). We do not simply want to capture what makes
the two tissue types distinct but we also model similarities that cannot be deconvoluted.
Even if the expression patterns are very alike between tumor and non-tumor cells, the
model should still give reasonable estimates of its strength in the respective cell types
and the uncertainty in the result.
The θt cannot be inferred separately or prior to the composition process. To reliably
infer these distributions, we would need a large amount of RNA-expression measurements
of samples that exclusively contain tumor cells or tumor surrounding tissue. Because
such results are not available, we have to make the θt part of the inference. Using the
probabilistic description of the tumor cell content based on the pathological estimate (s.
section 4.2) and all of the available tissue samples in the same inference process, we aim
to conclude a probabilistic description of the θt that is part of the result. Because θt
characterizes an EPD, a distribution of θt is a distribution of EPDs.
7.2.1 The Distribution of Expression Pattern Distribution
This section covers the probabilistic description of distributions θt; or in other words
a probability distribution of EPDs TL(θt). We discussed in section 5.1.4 how we can
reduce the dimensionality of the data down to k dimensions without loosing too much
information. With assumption 12, we can model EPDs by defining TL on the DR space
with 0 variance along the co-space.
Because we assume that TL can be represented with a Gaussian mixture, there is a
parametrization θt = (µt,1, . . . ,µt,L,Σt,1, . . . ,Σt,L,pt) where
x ∼ TL(σt) ⇔ x ∼ N (µt,l,Σt,l), l ∼ Cat(pt).
The probabilistic description of θt requires a prior distribution. Because ϕk used in the
DR is a whitening transformation, we can assume most prior variance to be around 1.
Hence, we chose µt,l ∼ N (0, I), Σt,l ∼ JKLCov(1,σ) as described in section 4.5 and
σ ∼ HN (1), where HN (s) is a normal distribution with standard deviation s and mean
0 from which only positive values are drawn. The probabilistic connection of a tissue
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specific expression vector x and the tissue EPD is depicted in figure 7.2 and the complete
model is depicted in figure 7.3.
The priors for θt are chosen to be minimally informative but not free of information.
To retain computational feasibility while allowing us to approximate a large class of
possible tissue characterizations, we chose L = 10 and hence allow T to be combination
of 10 multivariate normal distribution kernels. To be entirely clear, we make another
assumption:
Assumption 13 (Tissue Characterization). T10(θt) with the prescribed priors on θt can
describe the true tissue specific EPD.
gene expressions vector x











Figure 7.2: Probabilistic connection between the EPD for tissue type t and a gene count
vector x for that tissue.
7.2.2 The Complete Model
The complete model can be described as follows
µt,l ∼ N (0, I), µ,0 ∈ Rk, I ∈ Rk×k (7.8)
σt ∼ HN (1), σt,1 ∈ Rk (7.9)
Σt,l ∼ JKLCov(1,σt), Σt,l ∈ Rk×k (7.10)
pt ∼ Dirichlet(1), pt ∈ ∆9,1 ∈ R10 (7.11)
θt = (µt,1, . . . ,µt,L,Σt,1, . . . ,Σt,L,pt) (7.12)
yst ∼ T10(θt), xst ∈ Rk (7.13)
β ∼ N (0,1), β,1,0 ∈ R550 (7.14)
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e ∼ Cat(pte(β)), (7.15)
xst = exp ◦τ ◦ A(yst ), xst ∈ ∆n−1 (7.16)
psα ∼ B(nsα̂s + 1, ns(1 − α̂s) + 1) psα, α̂s ∈ R+, ns ∈ N (7.17)
αstumor =
psα + pf − 1
pt + pf + 1
(7.18)
x′s = αstumorxstumor + (1 − αstumor)xsnon-tumor, x′s ∈ ∆n−1 (7.19)
xs ∼ Multinomial(x′s), xs ∈ Rn (7.20)
for each sample s, the Gaussian kernels l ∈ {1, . . . , 10}, and events e ∈ E. The dimen-
sionality k ∈ {1, . . . , 275} should be chosen to be as large as possible and is limited by
the computational resources available. Note that n, ns, αs, and xs are data and that all






as in section 4.6 and ys = (ystumor,ysnon-tumor) is optional and is only defined for patients
that had an event. While (7.15) is not required for the deconvolution, it can be beneficial
because it encourages the deconvolution of relevant signals into ystumor and ysnon-tumor.
Additionally, it infers a vector β that defines a multivariate Cox model. While β ∈ R2k
is only defined on the dimensionally reduced space, we can use ϕ−1k (β1,...,k) to calculate a
feature-wise estimate of the Cox-log-hazard-ratio to expression values in the tumor tissue
and ϕ−1k (βk+1,...,2k) to get the same to expressions in the non-tumor tissue. Studying the
inferred β could reveal which part of the hazard can be attributed to the tumor or the
tumor surrounding tissue and the genes involved.
A graphical representation of the model is depicted in figure 7.3.
Note that the inference is degenerate if the used data does not feature very distinctively
distributed psα through greatly varying estimated tumor cell contents across the samples.
The inference can be further enhanced through enrichment of the dataset with purified
tumor or non-tumor samples. The distribution (7.17) is justified in section 4.2.
7.2.3 Single Sample Deconvolution
Please also note that while θt needs to be inferred, all of the available samples have to
be used in the same inference process. However, once a reliable parametrization of the
tissue specific expression distribution has been established, additional samples can be
deconvoluted individually, without the other samples and without any normalization by
selecting the fixed θt and omitting (7.8), (7.9), (7.10) and (7.12). This could be a major
advantage of this approach because many normalization methods only work within a
cohort.
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7.2.4 A Simplification
In an attempt to further simplify the model, we experimented with not making (7.8),
(7.9) and (7.10) tissue specific and only allowing pt in (7.11) to be distinct between the
two tissues EPDs. Consequently, the number of parameters is reduced, while allowing
the T (θt) to remain general. Additionally, investigating the differences of the inferred
EPDs becomes as simple as comparing the vectors ptumor and pnon-tumor. However, this
approach introduces dependencies between the two distributions and a bias towards more
similar ones. This bias is disadvantageous in our pursuit of deconvolution, which works
best with a large statistical distance between T (θtumor) and T (θnon-tumor).
7.2.5 Start Values
All of the inference algorithms that we used require an initial value for the random
variables that are to be inferred. To establish reasonable start values, we select two
subsets of the data with rather pure samples: Xtumor, with samples that have an estimated
tumor content above 80 %; and Xnon-tumor, with samples that are estimated to have less
than 20 % tumor cells. We use the expected values of the sample induced Dirichlet
distribution






This can be used for a preliminary tissue specific EPD by selecting µt,l,0 to be the feature-
wise mean and Σt,l,0 the covariance matrix of X ′t for all l. Consequently, the initial
tissue specific distributions are equivalent to the frequently inferred multivariate normal
distribution in the chosen representation space. The mixing of the 10 equal normals per
tissue type is initialized with pt,0 = 1/n.
The tissue specific expressions xst are initialized with the projected raw sample ex-
pressions xs





for both t ∈ {tumor, non-tumor} and each sample s individually.
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l ∈ {1, . . . , L}
s ∈ Samples
Figure 7.3: Schematic of the Bayesian network for the deconvolution of expression pat-
terns. Random variables are circled and deterministic quantities are in rectangles. This
is a specialization of the general model depicted in figure 7.1.
Chapter 8
Results of Example Applications
The previous chapters revealed two main applications of the model. Firstly, in 8.1 we ap-
ply the sample wise deconvolution model 7.1 on some published datasets of the DREAM
challenge. Secondly, in 8.2 we use the data of multiple prostate carcinoma RNA-seq
samples 6.3 and use a model 7.2 that infers the EPD for tumor and tumor surrounding
tissue, and the sample specific deconvoluted expression of its tumor and non-tumor tis-
sue, respectively. In this section, we describe the inference processes, demonstrate some
characteristics of the results and reveal some implications for bio-marker discovery.
8.1 Inference of Cell Composition
We ran the ADVI inference on model 7.1 with the published example mixture datasets of
the DREAM challenge, as described in section 6.2. The maximal number of iterations was
chosen to be 20,000. Each of the three datasets consists of multiple cohorts. To inspect
the inference, we plotted the ELBO of the ADVI optimization across the iterations.
8.1.1 Single Composition Output
To evaluate the results, we had to use a single estimate of the composition variable α̂ to
compare with the reported gold standard α̃.
The inference produced a parametrized distribution f : ∆n−1 × Ω → R+ for the un-
known composition α ∈ ∆n−1. This distribution is described with a normal distribution
in the stick-breaking transformed space Rn−1. The distribution implied on ∆n−1 is heav-
ily skewed and its mean is far away from a dimension-wise median. In other words, the
mean is strongly influenced by very unlikely but possible values of α that are far from
the mean. To avoid such misrepresentation, we took the mean of the distribution in the
stick-breaking space Rn−1 and applied the reverse stick-breaking transformation to attain
an estimate α̂, which we report as the result of the deconvolution.
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8.1.2 ELBO Convergence in Variational Inference
We recorded the ELBO values for each sample during the inference and plot it in figure
8.1. Note that ELBO trajectories within a cohort can be compared because the measured
expression features and hence the models are the same. The ignored constant in the ELBO
estimation is hence equal and the absolute difference of the ELBO between the samples is
correct. However, the ELBO trajectories cannot be compared between different cohorts.
Because different sets of features are measured, the resulting model for the inference
differs and some constant distorts the difference. We combined trajectories of the same
cohort to a band to make the graphs more readable. It is evident that all of the samples
converge to a similar value.
Because the per iteration estimate of the ELBO is very noisy and stabilized through
averaging in the actual ADVI process (s. section 3.5.2), we average the ELBO estimates
with a Gaussian kernel with a standard deviation of 100. The result is a more stable
estimate of the actual ELBO of a given estimation.
Note that not all trajectories reach iteration 20, 000. The premature stop was triggered
because the sample specific time-limit was reached. We explained this mechanism in
section 7.1.4.
8.1.3 Difficulty - Divergence
The main difficulty of this application is a divergence of the ADVI optimization. Running
the optimizer for too long would not only drastically reduce the ELBO but also change
the resulting α̂ to an extreme. All observations tend to be explained by a single or very
few cell types that assume a rather extreme expression pattern within their class instead
of explaining the observed data with a mixture of all types.
While this could be explained by numerical inaccuracies, experimenting with low-
dimensional examples suggests otherwise. It seems that the distribution of the compo-
sition α implied by the model is very heavy tailed and cannot be explained well with
a normal distribution in the stick-breaking transformed space, which may be a general
problem with mixtures of log-normally distributed vectors. We discussed the issue on a
toy-model with Junpeng Lao from the PyMC3 [102] developer and Tensorflow Probability
[2] development team, which is available at:
https://discourse.pymc.io/t/numerical-issues-with-stickbreaking-in-advi
A workaround for the problem is to use a prior that steers the composition away
from problematic areas. We experimented by using a Dirichlet prior that encourages
compositions involving all types by choosing parameters n · 1 for large n. However, the
divergence could only be delayed and if too large n is chosen, then the accuracy of the
result declines.
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Figure 8.1: The trajectories of the ELBO values, smoothed with a standard deviation
100 Gaussian kernels in one band (upper to lower limit) per cohort for each leaderboard
round dataset of the coarse and fine grain distinction.
The solutions to this problem are to use a more appropriate stick-breaking transfor-
mation that produces a normal distribution of the transformed α in our model or to use
a more general inference technique—we tried both.
8.1.3.1 Implementing an Alternative Stick-Breaking
The original stick-breaking transformation η : ∆n → Rn implemented in PyMC3 was
a generalization of the logit function that maps the uni interval to R. The PyMC3
documentation stated it was ported from STAN [19]. The STAN documentation reveals
the logit inverse is constructed iteratively for the components of the vector, where the
interval size in the inverse logit is adjusted along the way such that the resulting values
sum to one. Hence, the transformation of a later component depends on the value of an
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earlier component and a hierarchical dependency is introduced that treats the individual
values of α differently. It seems that only the domain and range of η were considered for
its design, while unfair numerical conditioning that risks a bias in the values of α seems
to be ignored.
Our transformation τ−1 ◦ log : ∆n → On can easily be modified to match the range
of η. Because one entry of its image vector is the sum of all of the other entries, it can
simply be omitted and then the range becomes Rn. We implemented the diffeomorphism
as an alternative stick-breaking transformation that was accepted as replacement of the
original stick-breaking of PyMC3, see:
https://github.com/pymc-devs/pymc3/pull/4129
As can be read in the pull request, the new transformation improves the numerical
accuracy of the Bayesian inference specifically when the Dirichlet distribution is involved.
We included our own implementation after the end of the DREAM challenge and saw
little improvement in any of our applications. The divergence issue was mediated but not
resolved.
8.1.3.2 Using More General Inference Methods
One natural way to generalize ADVI is to use normalizing flow [97]. This approach trains
parametrized distortions of the inferred distribution to match posteriors that cannot
directly be approximated with normal distributions. However, this requires knowledge
on the combination of distortions that can approximate the specific prior. The PyMC3
implementations allows for an arbitrary combination of shift, scale, reflection, planar-
and radial stretching. However, we were unable to find a combination of distortions
that is capable of adequately modeling the high dimensional tail area without exceeding
computational limits.
We did have some limited success with Stein variational Gradient descent (SVGD)
[72]. This approach models the posterior distribution through a set of points that imply
a kernel density function. We initialized the point set with samples from the ADVI result
and enhance the set with SVGD. However, improvements could only be achieved with
4000 samples or more. This is likely to be due to the size of the tail area in high dimen-
sional space. For point sets of this size, only a few iterations could be computed within
the time constraints. However, exhausting the time limit means that different samples
may complete a different number of iterations before they have to be stopped. This in-
troduces an inter-sample variation that can impair compatibility, and hence impair the
cohort-wise correlation that is used as a quality measure in the challenge. Consequently,
we opted against the post ADVI enhancement and all the complications attached.
Using a sampling based inference method was not an option. Because heavy-tailed
distributions with high dimensionality require a lot of samples to converge, a reasonable
result cannot be produced within the time limit.
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8.1.3.3 Using Better Data
We made the observation that the divergence problem becomes less apparent if the poste-
rior is described more accurately. This is the moment when our assumptions are actually
met and
1. The sample’s expression is measured with an RNA-seq,
2. The all trained features are measured in the sample,
3. The expression vector is not normalized,
4. The sequencing depth is high, and
5. The tissue specific EPDs are trained with better data.
However, the data mostly comes from microarrays, is always normalized and never comes
with all of the features used in training. Therefore, it is possible that the rather heavy
tail of the posterior is an artifact of these shortcomings and will be much less of an issue
if our data had the anticipated format.
8.1.3.4 Restriction of Variance of Cell-Type-Specific EPDs
Assuming that some mislabelled samples are included in the training data, we overesti-
mate the variance of the cell-type-specific EPDs. This can contribute to the uncertainty
of the posterior and may contribute to the divergence behavior of the ADVI. To counter
this, we can scale down the learned variance of the cell-type-specific EPDs through a
scalar factor to the covariance matrix. Experimenting with different factors would also
delay the divergence but not prevent it indefinitely, and would often reduce the accuracy
of the deconvolution result. Given that we have no means to adequately adjust the EPDs
without using heuristics, we can only conclude from the observation that overestimated
EPD variance does indeed contribute to the complication and leave the covariance matrix
untouched for the final model.
8.1.3.5 Doing Fewer Iterations
To resolve the issue for the challenge at hand, we limited the number of iterations to
20,000. This stopped the inference before the results started to diverge. This number
was chosen through empirical testing and due to the time constraints. While the coarse
grain deconvolution usually finished all 20,000 iterations for all samples, the fine grain
deconvolution often reached the time-limit and stopped prematurely. Even though we
attempted to split the available time evenly (s. section 7.1.4), the splitting is not fair
between cohorts. Cohorts that reported more genomic features run with less iterations
per second but require more iterations to achieve good results because the model is more
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complex. This may be improved with an appropriate stopping criterion. However, for
the application in the challenge, we needed to ensure that all samples are run and other
stopping criterion would not guarantee that.
8.1.4 Difficulty - Bias
Another issue seems to be a cohort-specific bias towards individual cell types. Because we
do not known the units of the gold standard, it cannot be assessed directly. However, we
repeatedly observed that some bias across multiple samples towards the same prediction
was produced, even when the expression values were almost unrelated. Because this
bias was sensitive to the chosen stick-breaking algorithm, we conjecture this may be
a numerical artifact. It may therefore be beneficial to investigate the issue in later
applications.
8.1.5 Comparison to Gold Standard
To compare, we plotted the values of our estimates α̂ on the x-axis and the gold standard
values α̃ on the y-axis in figure 8.2 and 8.3. This may reveal any correlation between the
two in any subset. Because the gold standard values are reported in different units per
cohort and cell-type, one cluster for each cohort-cell-type emerges. Given that only the
correlations within these clusters are relevant for the ranking in the DREAM challenge,
the visual separation is appreciated. To guide the viewer, we also plotted a regression
line per cluster and we display the Person correlation in the legend.
Due to the different units used in the gold standard, we cannot evaluate the deconvo-
lution quality within a single sample and we can only assess relative differences between
samples of the same cohort.
8.1.6 Comparison to Competitors
The challenge announced that all of the submissions are ranked by the quality of their
predictions. To deduce a measure of quality, the submitted software was applied on a
dataset of in-scilico RNA-seq admixtures. In other words, a set of expression vectors that
were produced by adding the RNA-seq results of the pure immune cells and an unknown
background in a weighted sum and the weights serve as the gold standard. The resulting
expression vector was TPM-normalized and the same admixtures were used to validate
the coarse and the fine grain deconvolution.
From a total of 41 teams and 275 team-less participants, 22 teams or team-less par-
ticipants made a submission to the final coarse grain validation round and 17 teams or
team-less participants submitted to the final fine grain validation round. Although a final
ranking has not been decided by the challenge committee at the time of writing, the key
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Figure 8.2: The leaderboard-round-wise results and gold standards for the coarse grain
distinction grouped by dataset and cell type with Pearson correlation within each group.
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Figure 8.3: The leaderboard-round-wise results and gold standards for the fine grain
distinction grouped by dataset and cell type with Pearson correlation within each group.
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Table 8.4: fine grain - Spearman
Table 8.5: Top 11 of 22 (coarse grain) and 17 (fine grain) submissions in the final val-
idation round of the Tumor Deconvolution DREAM Challenge and key metrics. The
key metrics are the arithmetic mean of the Person or Spearman correlation coefficients
between the predicted abundance of a cell type in the sample and the gold standard
calculated per cell dataset and per cell type.
As part of the submission, all of the teams had to provide a concise write-up of
their method. At the time of writing, our write-up was made public on https://www.
synapse.org/#!Synapse:syn20547739. Here, we review the write-ups of some of the
top performing teams.
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8.1.6.1 Submission - Aginome-XMU
This team trained a deep neural network with weighted sums of expression profiles from
purified immune cells measured with expression arrays or RNA-seq of non-disclosed origin
to predict the weights of the sum. Predictions of the model were used for the majority of
the cell types but for neutrophils, fibroplasts and endothelial cells the prediction of MCP-
counter [13] was used instead and the content of myeloid dendritic cells was estimated
with xCell [7] because these tools reportedly outperformed the new model for these cell
types.
The write-up was public on https://www.synapse.org/#!Synapse:syn20812270.
8.1.6.2 Submission - Biogem
In this submission, one expression pattern per cell type was learned from a set of publicly
available training data. The team carefully only selected genes to be included in the
expression pattern that showed significant differential expression of a minimal effect size
between at least two of the considered cell types. The expression patterns were then used
in a robust linear regression with the rlm function of the R package MASS.
The write-up was public on https://www.synapse.org/#!Synapse:syn20551146.
8.1.6.3 Submission - DA 505
After careful data treatment, this team applied a random forest based features selection
to prepare the training data. A support vector regression, partial least squares, and a
penalized linear regression was then trained as a prediction model. A test dataset was
then used to find which support vector regression gives the most accurate predictions,
and hence was used as in the submission.
The write-up was public on https://www.synapse.org/#!Synapse:syn20674744.
8.1.6.4 Submission - Aboensis IV
This team focused on finding reliable exclusively expressed marker genes per subtissue.
They used multiple publicly available datasets and results from other publications in-
cluding MCP-counter and CIBERSORT to select genes that are only expressed in one of
the subtissues and they excluded genes that were found to be expressed in tumor cells of
other publicly available datasets. The selected markers were used to calculate an average
score for each subtissue, which serves as the prediction of composition.
The write-up was public on https://www.synapse.org/#!Synapse:syn20688639.
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8.1.6.5 Submission - mitten TDC19
This team generated admixtures of RNA-seq results from samples of non-disclosed origin
and after TPM-normalization as training data. Genes that showed high Pearson corre-
lation with the percentage of a subtissue were chosen as marker genes. The expression
of marker genes for a subtissue is simply added without using weights or a regression
technique to produce a prediction for the respective subtissue.
The write-up was public on https://www.synapse.org/#!Synapse:syn20330693.
8.1.6.6 Submission - Cancer Decon
This team had only one member and seemingly did not provide a write-up, see https:
//www.synapse.org/#!Team:3395690.
8.1.6.7 Submission - CCB
This team extended the published software tool EPIC [94], which uses linear regression to
make composition predictions, to predict new cell types and submitted to the challenge.
The write-up was public on https://www.synapse.org/#!Synapse:syn20505859.
8.1.6.8 Submission - D3Team
The main idea of this submission was to aggregate different prediction methods into
one strong predictor. The prediction methods were support vector regression, con-
strained least squares regression, other regression (e.g., linear, logistic, generalized, pe-
nalized/ridge/lasso/elastic net) and naive-Bayes classifier. This team tested different
bagging and boosting techniques, and chose the best performing method for the final
submission. Other information about the training data or method was not published in
the write-up.
The write-up was public on https://www.synapse.org/#!Synapse:syn19061090.
8.1.6.9 Submission - ICTD
This team published their method in [20]. Because their method involves many steps
and manual refinements, we only give a rough summary here and refer the reader to the
publication for details. This submission uses MRHCA [136] to find co-expression clusters
in the training data and uses them as dimensional reduction by combined expression
within each cluster. The prediction of the cell type composition then comes from a
non-negative matrix factorization.
The write-up was public on https://www.synapse.org/#!Synapse:syn20551227.
8.1. INFERENCE OF CELL COMPOSITION 107
8.1.6.10 Submission - Patrick
This participant only used genes that he found to be expressed primarily by immune
and stroma cells in samples of the Cancer Genome Atlas [128] to obtain subtissue-
specific expression profiles Y . He then fitted a log-normal regression model by minimizing
| log(X) − log(Y β)|2, where X is the data and β the regression parameters.
The write-up was public on https://www.synapse.org/#!Synapse:syn20571310.
8.1.6.11 Conclusion for the Competitor Review
Most of the competing approaches implement linear regression or the aggregation of ex-
clusive marker genes, which are well-known and used by several of the published software
tools that we reviewed in section 1.1. However, as we explained in the same section,
these methods suffer from harsh theoretical limitations. Exclusive marker genes become
scarcer the finer the distinction of cell types becomes and using single expression profiles
per cell type is confounded by biological variability. Because these classical methods out-
performed many other submissions and given that we do not know the features Aboensis
IV’s neural net used for its prediction, we conclude that most gains in prediction accuracy
are still attained through better data selection and sanitization. Hence, the generality
to which these models can be fitted is not exhausted by the extent of available training
data and more general models, such as our own submission, have yet to come into full
effect as more data becomes available.
8.1.7 Implementation
The code that we used for this project is published in the immune-deconv repo [87]. We
included the download shell scripts and the Rlang code to unify the RNA-seq data and
attain the expression microarray data. Additionally, the repo contains the Python code
to select genomic features, as described in section 6.1.5.2; to do the DR, as described in
section 5.4; to learn the cell-type-specific EPDs, as described in section 5.4.5; to do the
immune cell decomposition inference, as described in section 7.1; and it also includes the
code to make the Docker [77] container that was submitted to the Tumor Deconvolution
DREAM Challenge.
The Python [119] packages that we used are NumPy [46], Pandas [76], SciPy [121],
PyCUDA [63], matplotlib [51], plotnine [61], seaborn [125], Theano [113], tqdm [29],
scikit-learn [91], scikit-CUDA [42], Pymanopt [115], and most notably we use PyMC3
[102] for the inference with ADVI.
The R [93] packages that we used are AnnotationDbi [90], ArrayExpress [59], GE-
Ometadb [137], GEOquery [32], bigmemory [56], data.table [35], doMC [5], foreach [78],
ggplot2 [130], and plyr [129].
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8.1.8 Conclusion
We demonstrated promising correlations of the predicted composition vector α̂ to the
supplied gold standards (figure 8.2 and 8.3) for our method, which uses multivariate
normal cell-type-specific EPDs in a DR space. However, we could not outperform all
of the classical methods. We suspect that training data abundance and quality, not the
generality of the prediction method, are the limiting factors of the prediction accuracy.
Notably, α̂ is a simplification of what is actually inferred by our algorithm. The
inference produces a distribution for α that allows us to answer more subtle questions,
such as: With what probability is α within a given range? How certain are we about the
result? And, how much more certain could we become if we sequence deeper?
We should also be able to address such questions for a single sample without the
context of a whole cohort. However, the supplied gold standard cannot be compared
across cohorts, so we can only see that the composition estimates sort similarly to the
gold standard within a cohort. This can be achieved if the estimate tends only slightly
towards the correct result, and even if it has a strong bias in general.
Additionally, we gain information on the cell-type-specific expression patterns xt.
This could help us to detect cell type specific traits that are not directly visible from the
measured bulk expression vector. However, the expression patterns of the constituent cell
types of the in-silico admixtures used in the gold standard data are not published. Hence,
we cannot investigate how well the model performs for such an expression recovery.
Currently, the main difficulty is the divergence of the optimization in the used infer-
ence method. It remains unclear if this is an artifact of inappropriate data or is instead
a hint towards a more profound problem.
Henceforth, the result is only a preliminary indication for the accuracy of the inference
and further studies have to be conducted before the applicability of the method can be
concluded. We could profit from admission to the DRAM challenge community phase to
further assess the underlying mechanisms of competing methods and enhance our model’s
predictions.
8.2 Deconvolution of Expression Patterns
We applied univariate ADVI inference on the model 7.2 with the data described in 6.3
and we ran the model in three configurations with k = 20, k = 100 and k = 275.
We found that only with a very intensive dimensional reduction k = 20 did the ADVI
inference converge within the available time. Even though the resulting deconvoluted
expression values lack information, we could observe improvements in the subsequent
tumor expression based hazard model study.
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The main goal of the inference is a recovery of tumor specific expression patterns in
the sequenced tissue samples but the results are multifarious. Apart from a posterior
distribution of the tumor specific expression xstumor, we infer a posterior of the tissue
specific EPDs σt, a posterior tumor cell content αstumor and the log-hazard-ratios β of a
multivariate cox proportional hazard model featuring all of the included genes.
Before we explain the results of the inference, we illuminate the multimodality of the
posterior distribution and how we responded to this difficulty in the inference process.
We then illustrate and discuss the different results in the respective sections.
8.2.1 Difficulty - Multimodality
There are several multimodalities in the posterior that complicate the inference process.
Multimodality directly contradicts the assumption 2 made for the ADVI inference and
it can also substantially complicate other inference algorithms. Here, we lay out our
observations and how we reacted to issues regarding multimodality.
8.2.1.1 Order of Kernels
One issue is the multimodality of the chosen parametrization of the tissue-specific EPDs
T10(σt). We model T10 with a mixture of 10 normal distributions and σt = (µt,1, . . . ,µt,10,
Σt,1, . . . ,Σt,10,pt) contains the mean and covariance of each normal distribution kernels
and their weights pt. Although the likelihood of the parameters is the same for any
ordering of kernels, the parameter σt is different. In fact there are 10! different σt coding
for the same distribution T10(σt). Assuming that there is an optimal T10(σt), then this
optima corresponds to one of 10! modes in the distribution of σt.
One could fix this problem by selecting the order based on the value of pt ∈ ∆T −1.
However, such a model would not be differentiable around points in which two values of
pt meet and the distribution of pt becomes difficult to model.
This multimodality poses an issue for the inference by sampling. Each chain of samples
could end up in a different mode and combining the chains or testing for convergence of
the resulting distributions would be problematic. Running all chains until they converge
means running them until they have explored all of the possible modes. This would take
a long time and the result would be hard to interpret because the expected value E[µt,i]
would be the same for all i ∈ {1, . . . , 10}.
Note that this is a general issue of some other inference methods; for example, the
Stein variational Gradient descent [72] models the posterior with a set of points.
However, this specific multimodality is not an issue for the chosen inference algorithm
ADVI with univariate parametrization. A mode switch for the order of kernels is so
unlikely that the univariate posterior parameter distribution seems to be unaffected.
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8.2.1.2 Posterior EPD Complexity
A more problematic multimodality of the posterior comes from the different complexities
that the Gaussian mixture for tissue specific EPDs T10 can assume. By choosing a sparse
weight pt, the resulting distribution T10(σt) becomes simpler because fewer Gaussian
kernels are utilized. Switching from a very simple distribution that uses only one kernel
to describe the whole dataset to a more complicated one that uses two or more kernels
is a mode switch that ADVI is reluctant to do.
While the switch would be done eventually if we run ADVI for long enough, this can
substantially prolongate the inference process. To circumvent this issue, we will start the
inference with a strong prior towards a non-sparse weight vector pt ∼ Dirichlet(100 · 1)
and initial covariance matrices Σt,i with very large variances. After ∼ 1,000,000 iterations,
we can relax the posterior the non-informative pt ∼ Dirichlet(1).
8.2.1.3 Tumor Cell Content Estimate
One result of the inference is a posterior distribution for the sample-specific tumor cell
content estimate αstumor, which is used to mix the tumor and non-tumor specific expres-
sion. We allow the model to diverge from the pathological estimate through equation
(7.17). This correction is based on the consistency of the tumor specific expression pat-
tern with the inferred T10(σtumor). However, in the early stages of the ADVI inference, the
posterior of σtumor has not yet converged to a reasonable distribution. Hence, any correc-
tion of the tumor cell content is unsubstantiated, only diverts the result and prolongates
the inference.
To avoid this divergence, we fixate the posterior of αstumor to the pathological estimate
by increasing the ns in 7.17 with a factor 100 for the first ∼ 1,000,000 iterations of the
inference.
8.2.2 Difficulty - Time
Inferring the subtissue specific EPDs with the chosen detail simultaneously with the
expression pattern deconvolution makes the convergence of the variational inference very
slow. The parameter space is very large and the parameters have complex dependencies.
These circumstances put a strain on the tractability.
We ran the model with a DR of k = 275, k = 100, and k = 20 for multiple months
and, judging by the development of the ELBO value, only the smallest model with k = 20
converged in the ADVI process. Due to the long runtime, the process had to be continued
after maintenance restarts and crashes of the processing machines. This further extended
the runtime because only the last model parameters but not the state of the stochastic
optimizer could be passed on to the continuation process.
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To allow us to work with this time requirement, our implementation updates the
current parameter set and the history of ELBO values of the ADVI process onto the
hard drive approximately every 10 minutes. This allows for manual inspection and early
stopping.
We suggest that the latest tumor and non-tumor-specific EPDs can be used for quick
single sample deconvolution, while a long running process continuously integrates new
data to further enhance the EPDs. It is also possible to increase the dimensionality k
and thereby to further enrich the detail of the EPDs once ADVI has converged for the
currently available data.
8.2.3 The Inference Process
To aid the convergence of the ADVI optimization, we started the process with more
informative priors and relaxed them after 1,009,900 iterations. More specifically, we
raised the pathological tumor contents estimate resolution ns by a factor 100 to force the
inferred tumor cell content αstumor to stay closer to its prior expected value. Additionally,
we set the Dirichlet distribution parameter of pt to 100 · 1 instead of 1. This forces the
Gaussian mixtures that represent the tissue specific expression pattern distribution to
use all off its kernels.
After the burn in, we made the prior uninformative again by setting pt = 1 and
removing the factor of ns. Furthermore, we adjusted the model by reducing the dimension
of all pte for all events e. Specifically, we removed all entries for samples that are not in
the same cohort as e. This avoids the need to compare the time of DoD with the time of
BCR in the Cox hazard ratio model.
The GPU-supported inference with 64 bit floating point precision took ∼ 5 seconds
per iterations. Hence, the informative prior burn-in ran for ∼ 60 days. The refinement
with less informative priors ran for 413,300 iterations and ∼ 24 days. As a statistical
optimizer for ADVI, we used adam [62] during the burn-in and the refinement phase
because it carefully avoids bias and converges quickly. In the refinement phase we reduced
the learning rate of adam from the default 1e−3 down to 1e−5. While the optimal choice
of learning rate is unknown a reduction over time improves convergence in practical
applications, e.g. [18].
8.2.3.1 ELBO Convergence in Variational Inference
The trajectories of the ELBO during the burn-in and the refinement phase are depicted
in 8.4. Because the iteration-wise ELBO values are single samples of the integral that
is optimized with ADVI, they are subject to strong noise. To show a more accurate
estimation of the integral, we use a Gaussian filter with a standard deviation of 100
iterations to calculate a moving average which is drawn in a more solid red color. This
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(a) Burn-in iterations. (b) Refinement iterations.
Figure 8.4: Recording of the ELBO values that serve as loss function in the ADVI
stochastic optimization. The light shades are the sampled values per iteration and the
dark shade is a moving average using a Gaussian filter with a standard deviation of 100.
estimate is decreasing in both optimization runs and shows deceleration that suggests
convergence. However, the ELBO loss has not yet come to a complete halt and further
improvements can be expected through more iterations.
8.2.4 Posterior of Tumor Cell Content
One result of the inference is the posterior distribution of the sample specific tumor
cell content αstumor ∈ [0, 1]. The posterior distribution of αstumor is modeled by ADVI
with a normal distribution on R that is mapped to the interval [0, 1] through the logit
transformation. To represent αstumor with a single point estimate, we map the mean of the
normal distribution with the same logit transformation to the unit interval. The result
compared to the pathological estimate is depicted in figure 8.5.
8.2.5 Posterior of Tissue Specific Expression
A central result of the inference is the posterior for the tumor specific expression xstumor of
each sample s. To draw a visual representation of E[xstumor] and E[xsnon-tumor], we plotted
their values in the first and second component of the DR representation in figure 8.6.
We also show a representation of the tissue specific EPDs T10(E[σt]) in the same
plot. To visualize the Gaussian mixtures, we first calculated the expected values of their
parameters from the posterior inferred by ADVI. The resulting parameter set defines
a single EPD per tissue. We marginalized the 20-dimensional EPDs down to the two
dimensions that we selected for a visualization and drew a 95% confidence ellipse for each
kernel. The opacity of each eclipse is scaled with the respective weights pt in the mixture.
The result is a very rough estimate of the marginal distributions in two dimensions.
Due to the extensive marginalization from 20 down to 2 dimensions, all kernels overlap
spaciously. To better illustrate the difference between the two tissue EPDs, we selected
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Figure 8.5: We plot the TCC of each sample with the pathological estimate tumor
content on the x-axis and the logit-mean of the tcc estimated by the inference model
corrected tumor content on the y-axis. Tumor or non-tumor samples without patho-
logical estimate have a tumor content 0 or 1, respectively, with a very low resolution
ns = 1 as described in section 4.2.
the two components in which the marginalized Gaussian mixtures have maximal stochas-
tic distance in figure 8.6b. As a stochastic distance, we chose ”A Wasserstein-type distance
in the space of Gaussian Mixture Models” [33] and used the implementation published
on https://github.com/judelo/gmmot. Note that the depicted marginalization is only
an optimal selection of components and is not an optimal projection. For an efficient
optimization of the projections as in section 5.4.4.2, we would require a differentiable
stochastic distance.
To inspect the non-marginalized variance of tissue-specific EPDs T10(E[σt]), we plot-
ted the weights pt against the det(Σt,i), which is proportional to the volume of the 20
dimensional 95% confidence ellipsoid in figure 8.7. The plot reveals a dominant central
region in each EPD with a high weight and small volume.
8.2.6 Posterior Hazard Model
The included Cox hazard model induces a log-hazard-ratio vector E[β] ∈ R20 with one
entry per component of the DR space and per tissue. This component specific log-
hazard-ratio vector can be embedded in the space of gene expressions with the inverse
DR for the tumor specific expression by ϕ−11 (E[β1,...,10]) ∈ Rn and the non-tumor-specific
expression by ϕ−11 (E[β11,...,20]) ∈ Rn, as explained in section 7.2.2. We plot both the
component-specific log-hazard-ratios and the gene specific log-hazard-ratios in figure 8.8.
However, the p-values indicated in this plot should be interpretedc carefully because
ADVI can underestimate the standard deviation of the posterior if inferred variables are
not statistically independent.
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(a) Components 1 and 2. (b) Components 15 and 18.
Figure 8.6: Projections of the posterior tumor-specific and non-tumor-specific expression
patterns per sample and the respective tissue-specific EPDs. Date is projected down from
a 20-dimensional space to two components of the DR space. The expression values and
parameter of the EPDs are the mean values of their respective posterior distribution.
More details are explained in section 8.2.5.










Figure 8.7: The two tissue specific EPDs T10(E[σt]) are Gaussian mixtures with 10 nor-
mal distributions as kernels. The axis volume corresponds to the determinant of the
covariance matrix det(Σt,i) and weight to the respective value in pt in the mixture.
As a measure for the quality of the expression deconvolution, we compare the perfor-
mance of the implied Cox model with the benchmark model explained in section 6.4.3.
We used the coefficients E[β] and the deconvoluted expression values of the cohort UKDP
from which no event data was included in the inference process. We utilized the sample
specific log-hazard
hs = E[β1,...,10] · yst + E[β11,...,20] · ysf
to calculate the concordance index and and Cox p-value identically to the study referenced
in section 6.4.3. The inferred model reached a concordance index of 67.49%, which is a
3.26% improvement over the original model, and a p-value of for the Cox regression with
hs of 4.51e−7.






































(a) Per component of the DR. (b) Per gene.
Figure 8.8: Posterior mean cox log-hazard-ratios for the tumor-specific expression values
in the y-axis and the non-tumor-specific expression values in the x-axis. Indicated p-
values are according to the 0-hypothesis that it is normally distributed around 0 with the
standard variance of the marginalized ADVI posterior.
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Figure 8.9: Kaplan-Meier estimators for two halves of the UKDP cohort with the reference
prediction score above the median (High Hazard) and below the median (Low Hazard)
with an estimate of the 90% confidence intervals.
8.2.7 Gene Marker Study with Deconvoluted Tumor Expression
Because the improvement in section 8.2.6 of the hazard prediction model could come
from the expression deconvolution or the fact that we use a Bayesian-Cox model that
also uses non-tumor-specific expression value, we constructed another hazard prediction
model. Instead of using the Bayesian-Cox model, we used the tumor-specific deconvoluted
expression patterns E[xst ] in the original benchmark study (s. section 6.4) instead of the
vst-normalized counts for all cohorts. This means that any improvements can only be
attributed to the inferred tumor-specific expression values. Please note that this also
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replaces the cohort specific vst-normalization. The resulting concordance index is 66.32%.
Hence, an improvement of 2.09% can be attributed to the deconvolution alone.
8.2.8 Hazard Model Comparison Overview
To give an overview for the performance of all hazard prediction models in the indepen-
dent test cohort UKDP, we list the concordance index and Cox p-value as core metrics
in table 8.6.
Model Cox p-value Concordance Index
Benchmark study (s. section 6.4) 1.49e−5 64.23%
Benchmark study with deconvolution 2.15e−6 66.32%
Deconvoluted expression and Bayesian Cox 7.96e−7 67.37%
Table 8.6: A performance comparison of the considered hazard prediction models.
This results demonstrates a measurable improvement of the gene marker study (Bench-
mark study) when we apply the gene expression deconvolution to extract tumor-specific
expression patterns per sample prior to the study (Benchmark study with deconvolution).
Additionally, when we include the Bayesian survival analysis model into the inference
process (Deconvoluted expression and Bayesian Cox) we further improved the prediction
accuracy. Note that the latter replaces the gene-wise Cox-Regression, Meta-analysis to
combine cohort-specific results, and bagging to combine the gene-wise predictors.
8.2.9 Implementation
The implementation is published in the tumor-deconv Github repo [86]. The Python
[119] packages that we used are NumPy [46], Pandas [76], SciPy [121], PyCUDA [63],
matplotlib [51], plotnine [61], Theano [113], tqdm [29], scikit-learn [91], scikit-CUDA [42],
and most notably we use PyMC3 [102] for the inference with ADVI.
Chapter 9
Discussion
In this final chapter we will give our concluding remarks in three sections. After going
through some noteworthy limitations, we point out potential follow-up work and we close
with our conclusions.
9.1 Limitations
The reader should be aware of the following major limitations of the presented approach.
9.1.1 Simplifying Assumptions
Only if our assumptions are true can the conclusions be accepted. While we tried to
make very few rather subtle assumptions, they are certainly not guaranteed to be true.
Specifically, assumptions 2 and 11 that are implied through the choice of software tools
could be subject to improvement.
Furthermore, assumptions 9, 12, and 13 that imply a certain parametrization of the
model are rather crude simplifications that are obviously not entirely true and have only
be shown empirically to produce useful results. However, less simplification requires more
computational resources and may also require much more data to be beneficial.
Assumption 8 states a prior for the transcriptome composition p ∼ Dirichlet(λ · 1)
with λ = 1. However, in most samples a large set of genes is not expressed at all. Hence,
finding a much smaller λ ≪ 1 could be beneficial.
We want to highlight the potential improvement through other parameterizations of
the subtissue specific EPDs. The accuracy by which they model the true EPDs and
the computational ease to sample from them is most essential to our inference method.
The thinkable alternatives range from using normalizing flows as parametrization [64] to
latent space representation through neural networks.
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9.1.2 Computation Resources
All deconvolution approaches aim to recover hidden quantities from the observed data.
Many solutions supply a single point estimate for the hidden quantity but our approach
infers a probability density distribution for such quantities instead. This inference is
always more costly and our data had to be compressed in chapter 5 to enable feasibility,
thereby losing some information.
Nevertheless, our compute times are still rather long before the inferred model starts
to make good predictions. Some calculations can be accelerated by incorporating graph-
ics processing units (GPUs) into the calculation but significant gains in compute speed
can only be achieved for 32 bit floating point numbers instead of 64 bit on a lot of the
current hardware. Experiments demonstrated diminishing accuracy when lower floating
point precision was used in the inference. This not only increases the compute time but
also raises the question as to what degree numerical errors may already confound the
computation. The divergence observed in section 8.1.3 further supports doubt about the
numerical accuracy. If these doubts are justified, then a more complicated parametriza-
tion will most likely not yield an improvement.
9.1.3 Limited Data and Suboptimal Format
The deconvolution applications demonstrated in the thesis hinge on the correctness of the
tissue-specific EPDs. Specifically, for the inference of cell composition, we learned these
distributions with a large set of public datasets that do not all ideally fit our criteria.
Although we assume to use raw read counts from RNA-seq experiments only, some of
the datasets were normalized or we used expression array experiments. Furthermore, to
include sufficient data, we also included slightly modified cell samples in the training data
and we expect to also include mislabeled samples.
Data from other RNA-expression measurements or formats can be used in the model
because some deviations from a respective RNA-seq can be covered by the tissue-specific
EPD. However, a specialized and more accurate interpretation of such expression data,
as in 4.3.1, would be beneficial. Less data would be needed to learn a tissue-specific dis-
tribution of expression patterns that is valid for all inputs and measurement uncertainty
would also be modeled more adequately.
It became apparent from the Dream Deconvolution Challenge, that the inference
potential with very simple EPDs, which do not model gene specific variances or co-
expression, is not yet exhausted. Improving very simple parametrization, likely through
better training data, yields strong improvements of prediction accuracy. More detailed
EPDs, such as in our proposed method, have yet to become beneficial as more RNA-seq
data becomes available.
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For the tumor expression deconvolution example application, more data could further
improve the tissue-specific EPDs. Specifically, samples of very pure tumor or non-tumor
tissue could elevate the EPD quality, and hence the deconvolution accuracy.
9.1.4 It Is Just Consistency
Specifically, the expression pattern recovery for tumor cells that we performed as an
example application is conducted without any prior or expert knowledge. The decon-
volution is solely achieved by pursuing consistency among the samples. Recovering the
tumor-specific expression pattern of one sample is enabled by the tumor EPD and the tu-
mor EPD is determined by the tumor-specific expression patterns of all samples. Hence,
deconvoluting one sample means finding an interpretation of the observed read counts
that is consistent with the interpretation of all other observations. Consequently, only
tumors that are sufficiently represented in the cohorts can be deconvoluted adequately.
9.1.5 ADVI Uncertainty Estimation
One major advantage of the process is the propagation of uncertainty from the measure-
ment down to the result. Instead of a single point estimate, this method infers a proba-
bility density distribution of the latent variables that encodes the uncertainty about the
true value and can be used to supply credible intervals to the user. However, we applied
the ADVI algorithm without modeling covariance between the latent variables to retain
feasibility. Given that ADVI minimizes the Kullback-Leibler divergence to the true pos-
terior distribution, the univariate approximation inherently underestimates the variance
of correlated variables [67]. Hence, the size of some credible intervals is underestimated.
9.2 Outlook
An improvement of the measurement interpretation could significantly enhance the pre-
diction accuracy of the model. In particular, a more thorough investigation of variation
of technical origin would be beneficial because modeling the effect of different RNA-seq
protocols and sample treatments correctly would reduce the variance in the cell or tissue
type specific EPDs, and hence delimit predictions of possible subtissue expression pat-
terns. Additionally, more measurement platforms could be supported through dedicated
sub-models.
The dimensional reductions that we presented are specific for the example applica-
tions. For the inference of cell type composition, we optimized statistical distances with-
out knowing which distance measure would be most appropriate. While the difference
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of means of the EPDs is retained, a more educated choice of statistical distance to opti-
mize for may retain more co-expression information that is beneficial for the composition
inference.
For the deconvolution of expression patterns, the chosen DR is even less specific.
Instead of retaining information that is specifically relevant for the deconvolution, we
aimed to keep as much biological information as feasible. Using experience from the first
deconvolution runs may reveal a more appropriate selection of dimensions. Establishing
a more detailed measure for the internal distortion could result in a more educated choice
of dimensionality (e.g. by examining differential expression between more subgroups of
the considered cohorts). Additionally, it may be possible to retain feasibility for higher di-
mensions by using sparse covariance matrices for the EPDs that only model dependencies
between the first few components.
The largest potential for improvement of the presented methods likely resides in the
formulation of the cell type or tissue-specific EPDs. We have mentioned the issues of the
current parametrization in multiple contexts, ranging from the non-unique parametriza-
tion of Gaussian mixtures in section 8.2.1.1 to the non-Gaussianity of cell type specific
EPDs in section 5.4.5. However, our exploration of alternative parameterizations has not
been exhaustive and some progress can already be achieved by simply choosing a DR
or data transformation that increases the Gaussianity of the data. Even more impor-
tant than the parametrization is the actual choice of parameters. The displayed solutions
are capable of modeling detailed description of gene-specific variability, co-expression and
even non-linear dependencies of the expressions. Research has not yet settled on the mean
representative cell-type-specific expression profiles, let alone on cell-type-specific EPDs in
the available detail. We believe that a lot of progress can be achieved through encoding
the understanding of the transcriptional behaviors through residency probabilities in the
respective EPDs.
If the parameters of the EPDs are inferred as in the presented tumor expression
deconvolution and not or only partially known before the inference, then the outcome
may reveal new insights into the respective subtissue. However, an investigation of our
results has not yet been undertaken.
An economically beneficial follow-up of this thesis would be a single sample tumor
expression deconvolution. Once reliable tissue-specific EPDs have been established, they
can be used to infer tumor-specific expression patterns from raw RNA-seq gene counts of
individual samples within less than one hour compute time per sample.
Finally, of course, the amount and quality of the training data can always be improved.
Specifically, extending under-represented cell types could enhence overall composition
accuracy in the proposed applications.
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9.3 Conclusion
We applied a methodology to turn subject matter knowledge into a computational appli-
cation for gene expression deconvolution by laying out traceable assumptions, from which
we concluded building blocks for a Bayesian inference approach. By pursuing mathemati-
cal rigor, we produced intermediate results that may find use in general applications; such
as, a parameter free density approximation utilizing the characteristic function, a model
for transcriptome composition uncertainty through the Dirichlet distribution, the τ−1◦log
transformation to improve computational investigation of compositions in general, and
multiple dimensional reduction schemes.
The resulting model achieved accurate immune cell composition predictions from bulk
RNA-seq samples, despite theoretically suboptimal circumstances. Our participation in
the Tumor Deconvolution DREAM Challenge, which has not concluded at the time of
writing, resulted in a consortium authorship of the summarizing paper. Interest in our
contribution was sparked in particular through its novelty because using multivariate
gene co-expression or ADVI for variational inference had not previously found its way
into a deconvolution software.
Through the probabilistic reconstruction of tumor specific expression patterns, we
measurable improved the hazard prediction accuracy for biochemical recurrence of the
prostate carcinoma. We integrated RNA-seq results from multiple cohorts of multiple
tissue sources and distinct phenotypical data into one comprehensive uncertainty distri-
bution over the parameters of interest. Without learning tissue type specific characteris-
tics before the deconvolution or the necessity for purified samples, we were able to infer
EPDs for tumor and non-tumor tissue across all cohorts and the concluded EPDs can
potentially be used for a quick single sample deconvolution of new samples.
Our example applications can replace a stack of tools to produce equivalent or better
results. Expression normalization and batch effect removal preprocessing can be omitted
because we extract measurement uncertainty from the raw gene counts and model batch
effects as part of the EPD variability. Hence, samples of different cohorts can be combined
in a single study and no meta analysis is required to combine results from multiple isolated
datasets. Gene marker selection or univariate differential expression investigations are su-
perseded by multivariate probability density distributions examinations and dimensional
reduction techniques that explicitly retain the relevant information. A prior tissue type
characterization is not necessary, as we demonstrated in the expression pattern decon-
volution. Instead, we simultaneously learned the deconvoluted expression patterns and
the respective characterization. Additionally, we demonstrated how subsequent investi-
gations can be appended to the model through a survival analysis that further enhanced
the resulting hazard prediction model.
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Notable novelties of the this thesis are (i) the explicit description and application of
EPDs and inclusion of gene co-expression information, (ii) a method for single sample
expression pattern recovery of tumor samples, and (iii) the application of ADVI in compu-
tational gene expression deconvolution. All novelties are justified by explicitly formulated




The parameter α of the distribution (4.6) is defined to minimize
E(|α̂− α|2) =E(α̂2) − 2αE(α̂) + α2
= (α− E(α̂))2 + V(α̂).
The expected value of the binomial distribution fd(α̂|α) is pα and V(α̂) is given by (4.7).
Hence,




By substituting (4.8) and setting d
dα
E(|α̂− α|2) = 0 we get
α = n(n− 1)(pf + pt − 1)
α̂ + 2pfn− 2pf + 12(n− 1)(pf + pt − 1)
.
Because α represents the tumor cell content relative to the total cell mass, it is restricted
to lie within [0, 1]:
α̃ = max {0,min {1, α}}
A.2 Digamma Function and Logarithm
As discussed in section 4.3.1, we propose the digamma function ψ, depicted in figure A.1,
as an alternative to the logarithm as a transformation method to analyse transcript dis-
tributions in log scale. We demonstrate the minor difference between the two approaches
here.
The functions are only applied on integer values equal or above 1. So we consider
ϵ(k) := log(k) − ψ(k), k ≥ 1.
Known from [81] log(k + 1) − 1
x
≥ ψ(k) ≥ log(k) − 1
x








≤ ϵ(k) ≤ 1
k
.
Hence, ϵ(k) is positive and quickly converges to 0 as k → ∞.
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(a) Comparing the digamma function ψ to the
natural logarithm. Some values of ψ close to
n = 1 are missing because they are negative
and have no representation in the logarithmic
scale. The absolute error stays below 1 and













(b) The digamma function and the logarithm
with linear scale of the y-axis.
Figure A.1: Characteristics of the digamma function.
A.3 Common Normalization
As a reference and to avoid ambiguity, we shortly elaborate on some common normaliza-
tion methods and the definitions that we assume throughout this thesis.
A.3.1 CPM Normalization
The Counts Per Million (CPM) normalization (also Reads Per Million (RPM) normal-
ization) ηCPM : Rn → Rn divides the RNA-seq count vector of a sample by a scalar such





This eliminates the effects of sequencing depth on the expected value of each gene expres-
sion if the set of considered genes remains the same. However, because RNA-seq counts
are whole numbers, weakly expressed genes tend to only produce a positive value when
the sequencing depth is large enough. Hence, some variability due to sequencing depth
is not eliminated by the normalization.
A.3.2 TPM Normalization
We calculate the Transcripts Per kilobase Million (TPM) normalization ηTPM : Rn → Rn
utilizing effective feature length ιi = L− li as suggested by [89]. L is the average length
of reads in the RNA-seq experiment and li is the length of genomic feature i in kilobase:
ηTPM(x) =
106 · x
(ι − L) · Σ
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where Σ = ∑︁ni=1 xiιi−L . The average read length L can differ between experiments but for
the sake of simplicity we assume a constant L = 300 for the samples that we applied
the normalization on. To ensure positivity, we exclude features that are shorter than the
average read length L from the normalization result.
Thereby, the normalization aims to remove effects of sequencing depth, RNA-seq read
length and length of the respectively quantified feature to produce an abundance estimate
that can be compared between samples and between different features of the same sample.
A.3.3 VST Normalization
We explain the objective of the Variance Stabilizing Transformation (VST) in section
4.3.4 and we refer the reader to DESeq2 [73], voom [68] and, EdgeR [98] for the respective
definitions. For the visualizations in this thesis, we used the vst assay of DESeq2.
A.3.4 PCA After Different Normalizations
We visualize the effects of different normalizations of the principal components in figure
A.2. Note that only after applying a logarithm expression does the data become somewhat
more normally distributed and the first principal components can capture some interesting
structures of the data. Normalizations that do not apply any logarithmization, such as
CPM or TPM normalization, do not work well in PCA and cannot be well approximated
by the normal distributions that we pursue in this theses. However, this does not make
these normalizations less viable in other applications.
A.4 Mixture Prior Per Tissue Source
We assume the mixture coefficient α in assumption 1 to be Dirichlet distributed α ∼
Dirichlet(a). In this section, we list the chosen coefficients a for all tissue and cell types
that we inferred. Unfortunately, due to a lack of data, we choose a = 1 for all tissue
types and did not apply the inference described in section 4.1.
A.5 Data
In this section we will list some complementary information for the used datasets.
A.5.1 DREAM Challenge Cell Type Tables
Figures A.3 and A.4 show the images provided by the Tumor Deconvolution DREAM
challenge, which define the cell type groups that ought to be differentiated for the decon-
volution. Any classification of publicly available data was sorted into the cell type sets
according to table A.1.
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(a) PCA of CPM normalized counts 106x/x̄. (b) PCA of TPM normalized counts.
(c) PCA of log(x + 1). (d) PCA of VST normalized counts.
Figure A.2: The first two components of PCA transformed expression data after different
normalizations. The cohorts are described in section A.5.3.
Table A.1: Mapping of cell types to the groups defined by figure A.3 and A.4.
original cell type coarse grain fine grain
Activated B cells B cells too unspecific
Activated T cells too unspecific too unspecific
Basophils others others
B cells B cells too unspecific
CD4 T cells CD4 T cells too unspecific
CD8 T cells CD8 T cells too unspecific
Central Memory too unspecific too unspecific
Central Memory CD4 T cells CD4 T cells memory CD4 T cells
continued on the next page...
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Table A.1: Continuation of the table.
original cell type coarse grain fine grain
Central Memory CD8 T cells CD8 T cells memory CD8 T cells
Central Memory T cells too unspecific too unspecific
Dendritic cells monocytic lineage myeloid dendritic cells
Effector CD4 T cells CD4 T cells too unspecific
Effector Memory too unspecific too unspecific
Effector Memory CD8 T cells CD8 T cells regulatory T cells
Effector Memory T cells too unspecific too unspecific
endothelial endothelial cells endothelial cells
Eosinophils others others
fibroblast fibroblasts fibroblasts
Follicular helper T cells CD4 T cells too unspecific
gamma delta T cells others others
GC B cells B cells too unspecific
Granulocytes neutrophils neutrophils
Macrophage monocytic lineage macrophages
Memory B cells B cells memory B cells
Memory CD4 T cells CD4 T cells memory CD4 T cells
Memory CD8 T cells CD8 T cells memory CD8 T cells
Memory T cells too unspecific too unspecific
Monocytes monocytic lineage monocytes
Myeloid Dendritic cells monocytic lineage myeloid dendritic cells
Naive B cells B cells naive B cells
Naive CD4 T cells CD4 T cells naive CD4 T cells
Naive CD8 T cells CD8 T cells naive CD8 T cells
Naive T cells too unspecific too unspecific
Naive T effector cells too unspecific too unspecific
Neutrophils neutrophils neutrophils
NK cells NK cells NK cells
NKT cells others others
PBMC too unspecific too unspecific
Plasma cells B cells others
Plasmablast B cells others
Plasmacytoid Dendritic Cells others others
T cells too unspecific too unspecific
Th1 cells CD4 T cells others
Th2 cells CD4 T cells others
Th17 cells CD4 T cells others
continued on the next page...
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Table A.1: Continuation of the table.
original cell type coarse grain fine grain
Tregs CD4 T cells regulatory T cells
White blood cells others too unspecific
End of the table.
A.5.2 Immune Cell Data t-SNE
We applied t-SNE after whitening (s. 5.4.3) the immune cell expression data and using
only the first 20 components of the whitening PCA. We used the Python implementation
from Scikit-Learn [91] v0.21.3. To achieve optimal results, we set the learning rate to
10, its minimal value and increased the maximal number of iterations to 10,000. For
the perplexity value, we used the heuristic
√
N ≈ 156. The result is depicted in figure
A.5. Notably, the result is underwhelming. In the two component DR, many clusters
contain more than one cell type and most cell types have representatives in multiple
clusters. Additionally, a large circular cluster of mixed cell types has formed despite the
low learning rate. Testing different values of perplexity between 50 and 200 also did not
yield visually notable improvements. We conjecture that the poor performance is caused
by the high heterogeneity of the dataset because multiple measurement techniques from
multiple labs are included.
A.5.3 Prostate Carcinoma Expression Data
We used the data from our paper “ProstaTrend - A Multivariable Prognostic RNA Ex-
pression Score for Aggressive Prostate Cancer” [65] for the example application of decon-
volution of expression patterns.
To ensure comparability of the paper’s results and the results of this thesis, we adopt
the cohort composition and preprocessing. An overview over the cohort characteristics
can be found in table A.2 on page 134.
A.5.3.1 Sequencing of UKD1
We depleted 1 µg of total RNA of ribosomal RNA using the Ribo-Zero rRNA Removal Kit
(Epicentre, Madison, WI) and processed 50 ng of rRNA-depleted RNA with ScriptSeq
v2 RNA-seq Library Preparation Kit (Epicentre). After 10 cycles of PCR, to incor-
porate index barcodes for sample multiplexing and to amplify the cDNA libraries, we
determined the quality and concentration of the amplified libraries using the Bioanalyzer
2100. Meanwhile, 4 ng each of eight samples were pooled and size-selected on 2% agarose
gels using agarose gel electrophoresis. We gel-excised the sample ranging between 150 bp
and 600 bp, and purified it with the MinElute Gel Extraction Kit (Qiagen), according to
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Figure A.3: The coarse grain schematics provided by the Tumor Deconvolution DREAM
Challenge [101].
the manufacturer’s instructions. To quantify the purified libraries, we used the Bioana-
lyzer 2100. We then loaded every purified and size-selected library pool onto an Illumina
HiSeq2000 flow cell, distributing it across all lanes. Finally, we performed sequencing
with 2 x 101-bp paired-end reads using SBS V3 chemistry on a HiSeq2000 (Illumina, Inc,
San Diego, CA). In total, we sequenced five flow cells with eight pooled libraries each (40
in total).
A.5.3.2 Sequencing of UKD4, UT1, OSR1, OSR2, UKDP, and ELSA
For the RNA-seq of FFPE specimens, we used 200 ng RNA per sample. We prepared
RNA libraries using TruSeq-Stranded Total RNA Sample Prep kit (Illumina), including
an rRNA depletion step according to manufacturers protocol (i.e. Ribo-Zero Gold rRNA
Removal Kit). Following Illumina’s recommendation, we skipped the fragmentation step
for all samples. We analyzed the quality and quantity of each prepared library with
the Qubit 2.0 instrument (Qubit DNA-Kit). We calculated the molarity of each library
with the Bioanalyzer 2100 and we pooled equal amounts, which were used for subsequent
sequencing (12 pM). We sequenced 2 x 126-bp paired-end reads using SBS V4 chemistry
with a HiSeq 2500 (Illumina). For UKD4, we sequenced on two eight-lane flow cells: one
with six and the other with eight libraries (14 in total). For OSR1, we sequenced 13 and
12 libraries on two flow cells (25 in total). For OSR2, we sequenced 32 libraries on one
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Figure A.4: The fine grain schematics provided by the Tumor Deconvolution DREAM
Challenge [101].
Figure A.5: A 2 component t-SNE DR of the immune cell data after whitening. Details
can be read in A.5.2.
flow cell. For UKDP, we sequenced on four flow cells: one with 32 libraries and the other
three with 51 (185 total). For UT1, we sequenced 32 libraries in two flow cells (64 in
total). Finally, for ELSA we sequenced three libraries on one flow cell.
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A.5.3.3 Quality Control of Total RNA Sequencing
We excluded all of the tissue specimens from quality control and all downstream anal-
yses if either clinical follow-up data were not available (n=2 for OSR1) or a critical
low sequencing depth was observed; that is, less than 10 million raw reads (n=1 for
UKD4, n=7 for OSR1). We assessed the overall quality of all of the remaining tis-
sue specimens using a subsample of 1 million raw paired-end reads randomly chosen
by fastq-sample v0.0.14 with default parameters (https://homes.cs.washington.edu/
˜dcjones/fastq-tools/). We clipped adapters utilizing AdapterRemoval v2.2.1 [105]
with parameters minquality 20, minlength 20, and used FastQC v0.11.5 (https://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) to assess base call accuracy,
as well as FastQ Screen v0.11.1a [131] and bowtie v2.3.2 [118] to assess RNA library
composition. We evaluated each sample according to the following criteria: (i) minimal
Illumina Phred Quality Score of 30 reflecting minimal base call accuracy of 99.9%, (ii)
no adapter sequence remnants after adapter clipping, and (iii) a negligible number of
reads mapped to reference genomes other than human. All samples of all sequencing
cohorts (n=40 for UKD1, n=13 for UKD4, and n=16 for OSR1) passed all of the de-
scribed quality criteria. The noteworthy fraction of reads mapping to bacterial genomes
of the UKD4 cohort represent bacterial 16S rRNA. We observed reads mapping to bac-
terial 16S rRNA with RNA libraries prepared from water as negative controls, as well as
from other RNA libraries of low complexity. These reads may thus represent remnants
of 16S rRNA included in the chemical kits used for library preparation and which are
preferentially sequenced in case of low complexity libraries. Because the number of reads
uniquely mapping to the human genome did not decrease critically for UKD4, all of the
samples were kept for downstream analysis. In addition, we used a manually assorted list
of human rRNA sequences to calculate the fraction of reads mapping to human rRNA
transcripts to assess rRNA depletion efficacy during RNA library preparation. For all
cohorts, the fraction of rRNA sense or antisense reads was not critical for assessing the
expression of genes other than rRNAs because remaining reads were over-represented.
We did not exclude the outlier sample of the cohort OSR1 with more than 50% of rRNA
antisense reads because we did not observe a noteworthy difference in the number of reads
uniquely mapping to the human genome for that sample compared to other samples. The
observed overall differences in fractions of rRNA reads between fresh-frozen and FFPE
samples resulted from different rRNA depletion protocols because older versions as used
for UKD1 did not deplete mitochondrial rRNA. Principal component analysis of all o the
samples did not reveal any critical outliers.
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A.5.3.4 Gene expression quantification and quality filtering
To facilitate the multi-step analysis of the RNA sequencing datasets, we applied the
workflow-manager uap [55].
Primary Analysis of Total RNA-sequencing Data: We demultiplexed the Illu-
mina sequencing output FASTQ files allowing for one mismatch with Illumina CASAVA
1.8.2 (UKD1) and with Illumina bcl2fastq v1.84 (all other cohorts). We clipped adapter
sequences from the reads by utilizing AdapterRemoval v2.2.0 [105] with parameters
minquality 20 and minlength 20, respectively.
De novo transcript assembly: For de novo transcript assembly, we mapped all
reads of the cohort UKD1 to the human genome version GRCh37/hg19 with TopHat
v.2.0.8 [116] setting RNA library type to fr-secondstrand and all other parameters
to default values, and used Cufflinks v.2.2.1 [117] with default parameters and library
type specification fr-secondstrand to assemble transcripts. We compared all of the
assembled transcripts to Gencode v27 lifted to the human genome reference assembly
GRCh37/hg19 (https://www.gencodegenes.org/human/release_27lift37.html) uti-
lizing cuffmerge [117] and cuffcompare [117] with default parameters to identify novel
transcripts. We received a comprehensive transcriptome annotation for prostate tissue
for all subsequent analyses by extending the Gencode annotation v27lift37 by all novel
transcripts classified as unknown intergenic.
Expression quantification for total RNA sequencing: We mapped the reads
of all three cohorts UKD1, UKD4, OSR1, OSR2 and UKDP to the human genome
version GRCh37/hg19, excluding unannotated chromosomes and chromosome 6 MHC
haplotypes using segemehl v.0.2.0 [50]. We utilized segemehl in split read mode (option
-S) with additional parameters -H 1 -D 0 to report all alignments with no indels or
mutations in the initial seed and passed the default minimal alignment accuracy. We
used segemehl for expression quantification because it outperforms TopHat in terms of
sensitivity and specificity [49]. Read counts for known (Gencode v27lift37) and novel
transcripts contained in the comprehensive transcript assembly were determined using
HTSeqCount v0.6.1 [6] with parameters mode intersection-strict, stranded yes,
idattr gene_id, and type exon. For all RNA sequencing datasets, raw read counts
were analyzed using the R-package DESeq2 [73]. Reads were normalized, and variance
stabilized (VST) for each cohort individually.
Gene expression quality filtering: For all subsequent analyses, we considered
only genes expressed within the upper 20% quantile in the UKD1 and UKD4 cohort.
Additionally, we filtered genes according to the availability of both RNA-seq and array
data; that is, we discarded all genes not represented on the custom expression microarray
by at least one probe. Subsequently, we standardized all variance stabilized read counts
per dataset.
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A.5.3.5 The TCGA-PRAD-US Cohort
We used the RNA sequencing datasets of the Prostate Adenocarcinoma (PRAD-US [1])
cohort from the Cancer Genome Atlas. We downloaded the sequencing reads for all 552
samples (fresh frozen tissue specimens from radical prostatectomies) included in TCGA
PRAD-US in BAM format through the NCI’s Genomic Data Commons (GDC) Data
Portal via the GDC Data Transfer Tool. We accessed corresponding clinical data via the
R package TCGAbiolinks (data downloaded on 11/22/2017) and matched clinical data to
tissue specimens via a GDC-API query (data downloaded on 01/15/2018). The evaluation
of the provided clinical and specimen data of all 552 samples revealed 390 tumor samples
with more than 50% tumor cells, of which 332 had information on biochemical recurrence
(BCR) and event time. For 42 of these samples, BCR was observed within follow-up
time.
A.6 Cell Type Characterization without Whitening
We applied the optimization of section 5.4.4.2 without pre-whitening. We used A0 as
the starting point and chose B = B0 as the pre-transformation without rescaling. The
results for the Wasserstein metric are depicted in figure A.6 and for the Bhattacharyya
in figure A.7. While the Wasserstein distance is sensitive to rescaling (e.g. through mul-
tiplication of the data with a diagonal matrix), the Bhattacharyya is not; as explained in
section 5.4.4.2. This also manifests in the similar discrimination after the Bhattacharyya
distance based optimization with and without pre-whitening the data, and the deteri-
orated accuracy after the optimization for Wasserstein distance without pre-whitening.
Nevertheless, while the classification with ABhattacharyya is fairly accurate, visually judg-
ing by the projections in figure A.7 reveals that the cell type specific samples are not
distributed very normally after the dimensional reduction. Hence, the resulting cell type
specific EPD would not generalize well and would predict expressional patterns that are
unlike those that we observed in the data. Therefore, we concluded to continue with the
result of section 5.4.
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UKD1 (n=40) UKD4 (n=13) UT1 (n=62) OSR1 (n=16) OSR2 (n=13) PRAD (n=332)
Age 62.0 (60.0-67.2) 63 (60-70) 65.0 (61.0-67.8) 68.0 (62.8-70.2) 62 (56-66) 62 (56-66)
Tumor cell
content




40 (30-70) 70 (60-80)
Stroma cell
content
20.0 (14.4-25.0) 11.2 (10.0-24.4)
missing:3
missing missing missing missing
Presurgery
total PSA
10.6 (6.9-18.4) 12.8 (9.9-24.9) 6.40 (4.98-8.85)
missing:3
5.12 (4.82-17.30) 6.20 (5.70-7.59) 7.6 (5.2-12.1)
missing:26






































































































































Follow-up time 12.2 (10.3-15.3) 10.1 (8.6-10.5) 3.24 (2.44-4.25) 4.4 (3.3-5.0) missing 1.5 (0.7-2.8)
Table A.2: Some characteristics of the included cohorts. Numeric values are in the format
mean (25% quartile-75% quartile) and categorical quantities with category:count.
Age indicate the age of the patients at the time of radical prostatectomy (RP) or at
initial pathological diagnosis in the TCGA PRAD cohort. Tumor cell content de-
scribes the mean tumor cell content of flanking sections on either side of the sections
used for RNA isolation as evaluated by pathologists after HE-staining for the UKD1,
and UKD4 cohorts. For the cohort OSR1, OSR2, and UKDP, the Tumor cell content
was evaluated for each analyzed biopsy and for the TCGA PRAD cohort it is defined by
the TCGA research network [1]. Stroma cell content was assessed accordingly for all
cohorts. Gleason score denotes the RP GS score. In addition, RP Gleason Grad-
ing Groups are presented. The clinical endpoint Biochemical Recurrence for OSR1,
OSR2, and UKDP is defined as two consecutive prostate-specific antigen (PSA) values ≥
0.2 ng/mL after intervention and for TCGA PRAD as in [1]. Patients without BCR were
censored at last follow-up. The Pathological stage classification is made according to
the TNM staging, the Organ confinement of the tumor within the prostate (i.e. pT2)
and the Resection Status, respectively. Lymph node metastases are divided into
the category of regional lymph node metastases (pN1), or if the patient was free of lymph
node metastases (pN0).
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(a) Confusion matrix between labels and maximum likelihood estimate based
on resulting cell type characterizations.
(b) Components 1 and 2. (c) Components 3 and 4.
(d) Components 5 and 6. (e) Components 6 and 7.
Figure A.6: Projections after the Wasserstein distance optimized DR without pre-
whitening (AWassersteinB0 ◦ τ−1 ◦ log, exp ◦τ ◦ B−10 ATWasserstein).
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(a) Confusion matrix between labels and maximum likelihood estimate based
on resulting cell type characterizations.
(b) Components 1 and 2. (c) Components 3 and 4.
(d) Components 5 and 6. (e) Components 6 and 7.
Figure A.7: Projections after the Bhattacharyya distance optimized DR without pre-




Proof. We note that z̄ = 0 for z ∈ On−1 and




hence | exp ◦τ(z)|1 = 1. Furthermore 0 ≤ exp ◦τ(z) ≤ 1.
B.2 Lemma 2
Proof. Let τ−1(y) := y−1 (ȳ/n+ | exp(y)|1 − 1). Using the fact that z̄ = 0 for z ∈ On−1
and | exp(y)|1 = 1 for y ∈ log(∆n−1), we can reduce
τ(z) = z − 1 log (| exp(z)|1)
τ−1(y) = y − 1ȳ/n
and show that τ and τ−1 are inverse to one another and bijective:
τ−1 ◦ τ(z) = z − 1 log (| exp(z)|1) − 1
(︂
z − 1 log (| exp(z)|1)
)︂
/n
= z − 1 log (| exp(z)|1) − 0 + 1 log (| exp(z)|1)
= z
τ ◦ τ−1(y) = y − 1ȳ/n− 1 log (| exp(y − 1ȳ/n)|1)







138 APPENDIX B. PROOFS
Since log and exp are known to be inverse to one another, it is left to show that exp ◦τ
is a group morphism.






= exp ◦τ(a) exp ◦τ(b)
| exp ◦τ(a) exp ◦τ(b)|1
This is an element-wise vector product within ∆n−1. Because τ−1 ◦ log is the inverse
bijection, it maps this multiplication back to + in On−1.
B.3 Lemma 3
This lemma is never applied and a proof is omitted.
B.4 Lemma 4
Proof. The theorem states
|D exp ◦τ ′(z′)| = n(exp (−z′) + | exp(z′)|1)n
which is equivalent to
|Dτ−1 ◦ log′(y′)| = 1
n
∏︁n−1
k=1 yk(1 − y′)
by the inverse function theorem. Note that the prime ·′ indicates that only the first n− 1
dimensions of the vector are used. Consequently yn = 1 − y′ for y ∈ ∆n−1 and






Note that yn is a function of y′ and hence depends on yi for i ∈ {1, . . . , n − 1} with




= y−1i + ri
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Hence, the Jacobian matrix has the form
Dτ−1 ◦ log′(y′) =
⎛⎜⎜⎜⎜⎜⎜⎝
y−11 + r1 r2 · · · rn−1
r1
. . . . . . ...
... . . . . . . rn−1
r1 · · · rn−2 y−1n−1 + rn−1
⎞⎟⎟⎟⎟⎟⎟⎠ = A ·B
A =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
1 0 · · · 0 0
1 1 . . . ... ...
1 0 . . . 0 ...
... ... . . . 1 0




y−11 + r1 r2 · · · · · · rn−1
−y−11 y−12 0 · · · 0
... 0 . . . . . . ...
... ... . . . . . . 0
−y−11 0 · · · 0 y−1n−1
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
Because |Dτ−1 ◦ log′(y′)| = det(A) · det(B) and the determinant of the triangular A is
trivially 1, we only have to show that det(B) has the claimed value. The determinant
of B can be calculated with the Laplace expansion along the first column. We note that






1 + y1 − yn
nyn
)︄




and the other terms of the expansion












The alternating sign in the sum of the expansion cancels out because the minor M1,k
requires line permutation to become an upper triangular matrix M ′1,k and these permu-
tations alternate between odd and even. The first minor considered M1,2 is diagonal and
requires no permutations. Other minors are permutated such that
diag(M ′1,k) = (y−12 , . . . , y−1k−1, rk, y−1k+1, . . . , y−1n−1)





= |Dτ−1 ◦ log′(y′)|
which concludes the proof.
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